US5428123A - Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range - Google Patents
Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range Download PDFInfo
- Publication number
- US5428123A US5428123A US08/052,361 US5236193A US5428123A US 5428123 A US5428123 A US 5428123A US 5236193 A US5236193 A US 5236193A US 5428123 A US5428123 A US 5428123A
- Authority
- US
- United States
- Prior art keywords
- copolymer
- polyethyleneoxide
- polymer
- molecular weight
- soft segment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229920001577 copolymer Polymers 0.000 title claims abstract description 91
- 239000012528 membrane Substances 0.000 title claims description 187
- 229920000642 polymer Polymers 0.000 claims abstract description 192
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 118
- 239000004814 polyurethane Substances 0.000 claims abstract description 88
- 229920002635 polyurethane Polymers 0.000 claims abstract description 83
- 238000000034 method Methods 0.000 claims abstract description 48
- 238000010521 absorption reaction Methods 0.000 claims abstract description 25
- 229920001400 block copolymer Polymers 0.000 claims abstract description 21
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 13
- 239000012530 fluid Substances 0.000 claims abstract description 10
- 239000013618 particulate matter Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 64
- -1 aliphatic polyols Chemical class 0.000 claims description 54
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 51
- 229920005862 polyol Polymers 0.000 claims description 50
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 claims description 39
- 150000003077 polyols Chemical class 0.000 claims description 39
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 34
- 125000005442 diisocyanate group Chemical group 0.000 claims description 31
- 229920000768 polyamine Polymers 0.000 claims description 20
- 229920001519 homopolymer Polymers 0.000 claims description 19
- 239000000758 substrate Substances 0.000 claims description 18
- 238000000576 coating method Methods 0.000 claims description 16
- 150000001412 amines Chemical class 0.000 claims description 14
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 14
- 229920001451 polypropylene glycol Polymers 0.000 claims description 13
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 10
- 229920001296 polysiloxane Polymers 0.000 claims description 10
- 229920005604 random copolymer Polymers 0.000 claims description 9
- 125000001931 aliphatic group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 239000004417 polycarbonate Substances 0.000 claims description 8
- 229920000515 polycarbonate Polymers 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 150000004982 aromatic amines Chemical class 0.000 claims description 5
- 239000007795 chemical reaction product Substances 0.000 claims description 5
- 150000004072 triols Chemical class 0.000 claims description 5
- 229920002367 Polyisobutene Polymers 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 229920002857 polybutadiene Polymers 0.000 claims description 4
- 239000005062 Polybutadiene Substances 0.000 claims description 3
- 125000005265 dialkylamine group Chemical group 0.000 claims description 3
- 229920001281 polyalkylene Polymers 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000005263 alkylenediamine group Chemical group 0.000 claims 3
- HIFVAOIJYDXIJG-UHFFFAOYSA-N benzylbenzene;isocyanic acid Chemical class N=C=O.N=C=O.C=1C=CC=CC=1CC1=CC=CC=C1 HIFVAOIJYDXIJG-UHFFFAOYSA-N 0.000 claims 2
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical class C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 claims 1
- 125000003916 ethylene diamine group Chemical group 0.000 claims 1
- 229920000578 graft copolymer Polymers 0.000 claims 1
- 229920000412 polyarylene Polymers 0.000 claims 1
- 229920006294 polydialkylsiloxane Polymers 0.000 claims 1
- 239000012510 hollow fiber Substances 0.000 abstract description 29
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 239000002699 waste material Substances 0.000 abstract description 2
- 230000035699 permeability Effects 0.000 description 85
- 239000010408 film Substances 0.000 description 59
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
- 238000006243 chemical reaction Methods 0.000 description 45
- 239000002904 solvent Substances 0.000 description 41
- 239000000243 solution Substances 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 34
- 230000015572 biosynthetic process Effects 0.000 description 29
- 230000001965 increasing effect Effects 0.000 description 29
- 238000003786 synthesis reaction Methods 0.000 description 26
- 239000012071 phase Substances 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 229920003226 polyurethane urea Polymers 0.000 description 21
- 229920000570 polyether Polymers 0.000 description 19
- 239000004721 Polyphenylene oxide Substances 0.000 description 18
- 238000009792 diffusion process Methods 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 239000000376 reactant Substances 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 17
- 239000008103 glucose Substances 0.000 description 17
- 239000007787 solid Substances 0.000 description 16
- 239000012948 isocyanate Substances 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 230000007423 decrease Effects 0.000 description 14
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 14
- 239000000499 gel Substances 0.000 description 14
- 238000005266 casting Methods 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 150000002513 isocyanates Chemical class 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 11
- 229920001971 elastomer Polymers 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 238000004132 cross linking Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000000806 elastomer Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 229920005597 polymer membrane Polymers 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 9
- 239000000017 hydrogel Substances 0.000 description 9
- 229920002521 macromolecule Polymers 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000004970 Chain extender Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 230000009477 glass transition Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000007789 gas Substances 0.000 description 7
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 7
- CWEFIMQKSZFZNY-UHFFFAOYSA-N pentyl 2-[4-[[4-[4-[[4-[[4-(pentoxycarbonylamino)phenyl]methyl]phenyl]carbamoyloxy]butoxycarbonylamino]phenyl]methyl]phenyl]acetate Chemical compound C1=CC(CC(=O)OCCCCC)=CC=C1CC(C=C1)=CC=C1NC(=O)OCCCCOC(=O)NC(C=C1)=CC=C1CC1=CC=C(NC(=O)OCCCCC)C=C1 CWEFIMQKSZFZNY-UHFFFAOYSA-N 0.000 description 7
- 238000005191 phase separation Methods 0.000 description 7
- 125000006850 spacer group Chemical group 0.000 description 7
- 229910001220 stainless steel Inorganic materials 0.000 description 7
- 239000010935 stainless steel Substances 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000004744 fabric Substances 0.000 description 6
- 235000019420 glucose oxidase Nutrition 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 230000000704 physical effect Effects 0.000 description 6
- 239000004014 plasticizer Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 239000005056 polyisocyanate Substances 0.000 description 6
- 229920001228 polyisocyanate Polymers 0.000 description 6
- 229920001155 polypropylene Polymers 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 238000004448 titration Methods 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 229920001730 Moisture cure polyurethane Polymers 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 229920001169 thermoplastic Polymers 0.000 description 5
- 239000004416 thermosoftening plastic Substances 0.000 description 5
- RYECOJGRJDOGPP-UHFFFAOYSA-N Ethylurea Chemical compound CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 description 4
- 239000004366 Glucose oxidase Substances 0.000 description 4
- 108010015776 Glucose oxidase Proteins 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- XITRBUPOXXBIJN-UHFFFAOYSA-N bis(2,2,6,6-tetramethylpiperidin-4-yl) decanedioate Chemical compound C1C(C)(C)NC(C)(C)CC1OC(=O)CCCCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1 XITRBUPOXXBIJN-UHFFFAOYSA-N 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 4
- 150000004985 diamines Chemical class 0.000 description 4
- 150000002009 diols Chemical group 0.000 description 4
- 238000007598 dipping method Methods 0.000 description 4
- 239000012632 extractable Substances 0.000 description 4
- 229940116332 glucose oxidase Drugs 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 150000002605 large molecules Chemical class 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012982 microporous membrane Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920006254 polymer film Polymers 0.000 description 4
- 229920003225 polyurethane elastomer Polymers 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000013557 residual solvent Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 238000007086 side reaction Methods 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 4
- 229920004934 Dacron® Polymers 0.000 description 3
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 3
- 229920002396 Polyurea Polymers 0.000 description 3
- 229920002334 Spandex Polymers 0.000 description 3
- KXBFLNPZHXDQLV-UHFFFAOYSA-N [cyclohexyl(diisocyanato)methyl]cyclohexane Chemical compound C1CCCCC1C(N=C=O)(N=C=O)C1CCCCC1 KXBFLNPZHXDQLV-UHFFFAOYSA-N 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229920000049 Carbon (fiber) Polymers 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000004917 carbon fiber Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- KORSJDCBLAPZEQ-UHFFFAOYSA-N dicyclohexylmethane-4,4'-diisocyanate Chemical class C1CC(N=C=O)CCC1CC1CCC(N=C=O)CC1 KORSJDCBLAPZEQ-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 230000000887 hydrating effect Effects 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000005470 impregnation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000004611 light stabiliser Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000013178 mathematical model Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- INHDSJSGMCZSHA-UHFFFAOYSA-N n,n-bis(5-methyl-2-propan-2-ylcyclohexyl)formamide Chemical compound CC(C)C1CCC(C)CC1N(C=O)C1C(C(C)C)CCC(C)C1 INHDSJSGMCZSHA-UHFFFAOYSA-N 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920000909 polytetrahydrofuran Polymers 0.000 description 2
- 229920006264 polyurethane film Polymers 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000004759 spandex Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 150000003512 tertiary amines Chemical group 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 230000010512 thermal transition Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 150000003673 urethanes Chemical class 0.000 description 2
- FKTHNVSLHLHISI-UHFFFAOYSA-N 1,2-bis(isocyanatomethyl)benzene Chemical compound O=C=NCC1=CC=CC=C1CN=C=O FKTHNVSLHLHISI-UHFFFAOYSA-N 0.000 description 1
- VGHSXKTVMPXHNG-UHFFFAOYSA-N 1,3-diisocyanatobenzene Chemical compound O=C=NC1=CC=CC(N=C=O)=C1 VGHSXKTVMPXHNG-UHFFFAOYSA-N 0.000 description 1
- WZCQRUWWHSTZEM-UHFFFAOYSA-N 1,3-phenylenediamine Chemical compound NC1=CC=CC(N)=C1 WZCQRUWWHSTZEM-UHFFFAOYSA-N 0.000 description 1
- ALQLPWJFHRMHIU-UHFFFAOYSA-N 1,4-diisocyanatobenzene Chemical compound O=C=NC1=CC=C(N=C=O)C=C1 ALQLPWJFHRMHIU-UHFFFAOYSA-N 0.000 description 1
- CDMDQYCEEKCBGR-UHFFFAOYSA-N 1,4-diisocyanatocyclohexane Chemical compound O=C=NC1CCC(N=C=O)CC1 CDMDQYCEEKCBGR-UHFFFAOYSA-N 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- SBJCUZQNHOLYMD-UHFFFAOYSA-N 1,5-Naphthalene diisocyanate Chemical compound C1=CC=C2C(N=C=O)=CC=CC2=C1N=C=O SBJCUZQNHOLYMD-UHFFFAOYSA-N 0.000 description 1
- VOZKAJLKRJDJLL-UHFFFAOYSA-N 2,4-diaminotoluene Chemical compound CC1=CC=C(N)C=C1N VOZKAJLKRJDJLL-UHFFFAOYSA-N 0.000 description 1
- RLYCRLGLCUXUPO-UHFFFAOYSA-N 2,6-diaminotoluene Chemical compound CC1=C(N)C=CC=C1N RLYCRLGLCUXUPO-UHFFFAOYSA-N 0.000 description 1
- OJPDDQSCZGTACX-UHFFFAOYSA-N 2-[n-(2-hydroxyethyl)anilino]ethanol Chemical compound OCCN(CCO)C1=CC=CC=C1 OJPDDQSCZGTACX-UHFFFAOYSA-N 0.000 description 1
- BSESQBBHCKBEIW-UHFFFAOYSA-N 2-amino-4-[(3-amino-4-carboxyphenyl)methyl]benzoic acid Chemical compound C1=C(C(O)=O)C(N)=CC(CC=2C=C(N)C(C(O)=O)=CC=2)=C1 BSESQBBHCKBEIW-UHFFFAOYSA-N 0.000 description 1
- JOMNTHCQHJPVAZ-UHFFFAOYSA-N 2-methylpiperazine Chemical compound CC1CNCCN1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 description 1
- NUIURNJTPRWVAP-UHFFFAOYSA-N 3,3'-Dimethylbenzidine Chemical compound C1=C(N)C(C)=CC(C=2C=C(C)C(N)=CC=2)=C1 NUIURNJTPRWVAP-UHFFFAOYSA-N 0.000 description 1
- YPACMOORZSDQDQ-UHFFFAOYSA-N 3-(4-aminobenzoyl)oxypropyl 4-aminobenzoate Chemical compound C1=CC(N)=CC=C1C(=O)OCCCOC(=O)C1=CC=C(N)C=C1 YPACMOORZSDQDQ-UHFFFAOYSA-N 0.000 description 1
- RNLHGQLZWXBQNY-UHFFFAOYSA-N 3-(aminomethyl)-3,5,5-trimethylcyclohexan-1-amine Chemical compound CC1(C)CC(N)CC(C)(CN)C1 RNLHGQLZWXBQNY-UHFFFAOYSA-N 0.000 description 1
- YBRVSVVVWCFQMG-UHFFFAOYSA-N 4,4'-diaminodiphenylmethane Chemical compound C1=CC(N)=CC=C1CC1=CC=C(N)C=C1 YBRVSVVVWCFQMG-UHFFFAOYSA-N 0.000 description 1
- IBOFVQJTBBUKMU-UHFFFAOYSA-N 4,4'-methylene-bis-(2-chloroaniline) Chemical compound C1=C(Cl)C(N)=CC=C1CC1=CC=C(N)C(Cl)=C1 IBOFVQJTBBUKMU-UHFFFAOYSA-N 0.000 description 1
- LPDSNGAFAJYVKH-UHFFFAOYSA-N 4-(4-aminophenyl)-2,3-dichloroaniline Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C(Cl)=C1Cl LPDSNGAFAJYVKH-UHFFFAOYSA-N 0.000 description 1
- HLBLWEWZXPIGSM-UHFFFAOYSA-N 4-Aminophenyl ether Chemical compound C1=CC(N)=CC=C1OC1=CC=C(N)C=C1 HLBLWEWZXPIGSM-UHFFFAOYSA-N 0.000 description 1
- LKHVCEWNPKEPBT-UHFFFAOYSA-N 4-[(4-amino-3-methoxyphenyl)methyl]-2-methoxyaniline Chemical compound C1=C(N)C(OC)=CC(CC=2C=C(OC)C(N)=CC=2)=C1 LKHVCEWNPKEPBT-UHFFFAOYSA-N 0.000 description 1
- DZIHTWJGPDVSGE-UHFFFAOYSA-N 4-[(4-aminocyclohexyl)methyl]cyclohexan-1-amine Chemical compound C1CC(N)CCC1CC1CCC(N)CC1 DZIHTWJGPDVSGE-UHFFFAOYSA-N 0.000 description 1
- DSUFPYCILZXJFF-UHFFFAOYSA-N 4-[[4-[[4-(pentoxycarbonylamino)cyclohexyl]methyl]cyclohexyl]carbamoyloxy]butyl n-[4-[[4-(butoxycarbonylamino)cyclohexyl]methyl]cyclohexyl]carbamate Chemical compound C1CC(NC(=O)OCCCCC)CCC1CC1CCC(NC(=O)OCCCCOC(=O)NC2CCC(CC3CCC(CC3)NC(=O)OCCCC)CC2)CC1 DSUFPYCILZXJFF-UHFFFAOYSA-N 0.000 description 1
- ZCILGMFPJBRCNO-UHFFFAOYSA-N 4-phenyl-2H-benzotriazol-5-ol Chemical compound OC1=CC=C2NN=NC2=C1C1=CC=CC=C1 ZCILGMFPJBRCNO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 239000005058 Isophorone diisocyanate Substances 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 101150108015 STR6 gene Proteins 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004433 Thermoplastic polyurethane Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- 229920001938 Vegetable gum Polymers 0.000 description 1
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 1
- GKXVJHDEWHKBFH-UHFFFAOYSA-N [2-(aminomethyl)phenyl]methanamine Chemical compound NCC1=CC=CC=C1CN GKXVJHDEWHKBFH-UHFFFAOYSA-N 0.000 description 1
- YIMQCDZDWXUDCA-UHFFFAOYSA-N [4-(hydroxymethyl)cyclohexyl]methanol Chemical compound OCC1CCC(CO)CC1 YIMQCDZDWXUDCA-UHFFFAOYSA-N 0.000 description 1
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229910001514 alkali metal chloride Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229920006125 amorphous polymer Polymers 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- 150000001565 benzotriazoles Chemical class 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- UEDCISSWIRDTRC-UHFFFAOYSA-N bis[2,2,6,6-tetrakis(5-methyl-2-propan-2-ylcyclohexyl)piperidin-4-yl] decanedioate Chemical compound CC(C)C1CCC(C)CC1C1(C2C(CCC(C)C2)C(C)C)NC(C2C(CCC(C)C2)C(C)C)(C2C(CCC(C)C2)C(C)C)CC(OC(=O)CCCCCCCCC(=O)OC2CC(NC(C2)(C2C(CCC(C)C2)C(C)C)C2C(CCC(C)C2)C(C)C)(C2C(CCC(C)C2)C(C)C)C2C(CCC(C)C2)C(C)C)C1 UEDCISSWIRDTRC-UHFFFAOYSA-N 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical group NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000003490 calendering Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000005493 condensed matter Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000004427 diamine group Chemical group 0.000 description 1
- 239000012975 dibutyltin dilaurate Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004070 electrodeposition Methods 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 1
- 239000006066 glass batch Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 108010046301 glucose peroxidase Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 150000002483 hydrogen compounds Chemical class 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine group Chemical group NO AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229940018564 m-phenylenediamine Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- ZMVMYBGDGJLCHV-UHFFFAOYSA-N n-methyl-4-[[4-(methylamino)phenyl]methyl]aniline Chemical compound C1=CC(NC)=CC=C1CC1=CC=C(NC)C=C1 ZMVMYBGDGJLCHV-UHFFFAOYSA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920006389 polyphenyl polymer Polymers 0.000 description 1
- 229920003009 polyurethane dispersion Polymers 0.000 description 1
- 229920005749 polyurethane resin Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 239000011546 protein dye Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229920006126 semicrystalline polymer Polymers 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000003017 thermal stabilizer Substances 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 1
- RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- AVWRKZWQTYIKIY-UHFFFAOYSA-N urea-1-carboxylic acid Chemical compound NC(=O)NC(O)=O AVWRKZWQTYIKIY-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000004017 vitrification Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000004078 waterproofing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/068—Use of macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/08—Hollow fibre membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/38—Polyalkenylalcohols; Polyalkenylesters; Polyalkenylethers; Polyalkenylaldehydes; Polyalkenylketones; Polyalkenylacetals; Polyalkenylketals
- B01D71/381—Polyvinylalcohol
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/54—Polyureas; Polyurethanes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/58—Other polymers having nitrogen in the main chain, with or without oxygen or carbon only
- B01D71/60—Polyamines
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/76—Macromolecular material not specifically provided for in a single one of groups B01D71/08 - B01D71/74
- B01D71/80—Block polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/10—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
- C08G18/12—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step using two or more compounds having active hydrogen in the first polymerisation step
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/2805—Compounds having only one group containing active hydrogen
- C08G18/2815—Monohydroxy compounds
- C08G18/283—Compounds containing ether groups, e.g. oxyalkylated monohydroxy compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/2805—Compounds having only one group containing active hydrogen
- C08G18/285—Nitrogen containing compounds
- C08G18/2865—Compounds having only one primary or secondary amino group; Ammonia
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/2805—Compounds having only one group containing active hydrogen
- C08G18/288—Compounds containing at least one heteroatom other than oxygen or nitrogen
- C08G18/2885—Compounds containing at least one heteroatom other than oxygen or nitrogen containing halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/2805—Compounds having only one group containing active hydrogen
- C08G18/288—Compounds containing at least one heteroatom other than oxygen or nitrogen
- C08G18/289—Compounds containing at least one heteroatom other than oxygen or nitrogen containing silicon
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/42—Polycondensates having carboxylic or carbonic ester groups in the main chain
- C08G18/44—Polycarbonates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4804—Two or more polyethers of different physical or chemical nature
- C08G18/4808—Mixtures of two or more polyetherdiols
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4833—Polyethers containing oxyethylene units
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4854—Polyethers containing oxyalkylene groups having four carbon atoms in the alkylene group
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/65—Low-molecular-weight compounds having active hydrogen with high-molecular-weight compounds having active hydrogen
- C08G18/66—Compounds of groups C08G18/42, C08G18/48, or C08G18/52
- C08G18/6666—Compounds of group C08G18/48 or C08G18/52
- C08G18/667—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/32 or polyamines of C08G18/38
- C08G18/6674—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/32 or polyamines of C08G18/38 with compounds of group C08G18/3203
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/65—Low-molecular-weight compounds having active hydrogen with high-molecular-weight compounds having active hydrogen
- C08G18/66—Compounds of groups C08G18/42, C08G18/48, or C08G18/52
- C08G18/6666—Compounds of group C08G18/48 or C08G18/52
- C08G18/667—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/32 or polyamines of C08G18/38
- C08G18/6681—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/32 or polyamines of C08G18/38 with compounds of group C08G18/32 or C08G18/3271 and/or polyamines of C08G18/38
- C08G18/6685—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/32 or polyamines of C08G18/38 with compounds of group C08G18/32 or C08G18/3271 and/or polyamines of C08G18/38 with compounds of group C08G18/3225 or polyamines of C08G18/38
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- C12N11/093—Polyurethanes
Definitions
- This invention relates to a biocompatible, hydrophilic, segmented block copolymer that comprises hard and soft segments in a predefined proportion.
- the copolymers have hydrophilic or amphipathic soft segments that provide permeability to films and membranes prepared therefrom due to their lyophilicity, hydrophilicity and molecular weight, and hard segments that provide high cohesive energy reinforcement.
- the polymers of the invention may be cast into flexible sheets and/or hollow membrane shapes.
- the copolymers of this invention form strong, optically-clear, dense membranes which are selectively permeable to gases, ions, proteins and other macromolecules.
- the molecular weight cut-off of the membrane is controlled by varying the soft segment content, soft segment polarity/hydrophilicity and soft segment molecular weight.
- polyetherurethane block or segmented copolymers exhibit good biocompatibility along with high strength and elastomeric properties. This unique combination of properties is due in part to the two-phase morphology of the polyurethane molecule.
- aggregated aromatic or aliphatic urethane or urea segments constitute a hard glassy or semicrystalline phase, while low glass transition temperature (Tg) oligomeric segments comprise the liquid-like, rubbery soft phase or segment.
- Tg glass transition temperature
- the morphology of a polyurethane depends on many factors, including hard and soft segment chemistry, segment polarity differences, hard segment content, and hard and soft segment molecular weights.
- Okkema, et al. discloses a series of polyether polyurethanes based on polyethylene oxide (PEO), polytetramethylene oxide (PTMO) and mixed PEO/PTMO soft segments suitable as blood contacting surfaces, but with a hard segment content of 55 wt %, too high to be useful in the present invention.
- PEO polyethylene oxide
- PTMO polytetramethylene oxide
- mixed PEO/PTMO soft segments suitable as blood contacting surfaces, but with a hard segment content of 55 wt %, too high to be useful in the present invention.
- Takahara, et al. discloses the preparation of Segmented Poly (etherurethaneureas) (SPUU) with hydrophilic and hydrophobic polyether components.
- SPUU Segmented Poly (etherurethaneureas)
- Platelet adhesion and dynamic contact angle measured after adsorption of bovine serum albumin revealed that the SPUUs with hydrophilic soft segments had a non-adhesive surface.
- Chen, et al. examines the relationship between structure and properties of polyether based polyurethanes. (Chen et al., "Synthesis, Characterization and Permeation Properties of Polyether Based Polyurethanes", J. Appl. Polym. Sci. 16: 2105-2114 (1972)). Of particular interest is the testing of the transport of water and low molecular weight salt through polymeric membranes made of elastomers that are block copolymers consisting of hard and soft segments, with the former acting as physical crosslinks.
- U.S. Pat. No. 3,804,786 to Sekmakas discloses water-dispersible cationic resins, particularly polyurethane resins prepared by reaction of a resinous polyepoxide with a polyisocyanate to provide an hydroxy-functional polyurethane with tertiary amine functionality. These resins are useful for electrode position at the cathode.
- U.S. Pat. No. 3,826,768 to Suzuki and Osonol discloses a process for preparing polyurethane compositions by dispersion of polyurethane-containing isocyanates made from polyols and organic isocyanates in water under specified conditions.
- U.S. Pat. No. 3,852,090 to Leonard et al. discloses the utilization of a urethane film for waterproofing a breathable textile substrate.
- U.S. Pat. No. 4,124,572 to Mao relates to thermoplastic polyurethanes prepared by a specified method.
- the thus produced elastomers are useful for automotive products, applications such as cattle ear tags, coatings and coated fabrics.
- U.S. Pat. No. 4,183,836 to Wolfe, Jr. discloses a water-based polyurethane dispersion and its preparation by reacting an aliphatic diisocyanate with three critical active hydrogen compounds to form a pre-polymer containing carboxyl and free isocyanate groups, and then dispersing the pre-polymer in an aqueous medium with a tertiary amine and a diamine. These dispersions are useful in coating applications such as textile materials.
- U.S. Pat. No. 4,190,566 to Noll et al. relates to non-ionic, water dispersible polyurethanes with substantially linear molecular structure and lateral polyalkylene oxide polyether chains containing ethylene oxide units of specified content.
- U.S. Pat. No. 4,202,880 to Fildes et al. discloses sustained release delivery means comprising a biologically active agent, i.e., a drug, a linear hydrophilic block polyoxyalkylene-polyurethane copolymer, and optionally a buffer.
- a biologically active agent i.e., a drug
- a linear hydrophilic block polyoxyalkylene-polyurethane copolymer i.e., a drug
- a linear hydrophilic block polyoxyalkylene-polyurethane copolymer optionally a buffer.
- a single hydrophilic soft segment is used. Only the hard segment is hydrophobic.
- U.S. Pat. No. 4,202,957 to Bunk, et al. discloses polyurethane polyether-based elastomers which are thermoplastic and recyclable, and have increased high temperature resistance that makes them suitable for injection molding.
- U.S. Pat. No. 4,224,432 to Pechhold et al. discloses a polyurethane comprising a reaction product of a polymerizate of tetrahydrofuran and an alkylene oxide, an organic polyisocyanate and a chain extender which is an aliphatic polyol or a polyamine. 2001.
- U.S. Pat. No. 4,367,327 to Holker et al. relates to a breathable polyurethane film for coating fabrics to make them waterproof.
- the polyurethane film comprises in stoichiometric amounts a hard segment made of a low molecular weight diisocyanate with a difunctional compound, and a soft segment comprising polyethylene glycol.
- the mechanical properties of the film are improved by crosslinking with a triisocyanate.
- U.S. Pat. No. 4,849,458 to Reed et al. discloses a hydrophilic, segmented polyether polyurethane-urea exhibiting increased tensile strength and elongation when wet with water.
- the polymers form clear films that are permeable to water vapor.
- AVCOTHANE-51® resulted from the combination of two commercially available polymers, a silicone and a polyurethane, both of which are widely used as fabric coatings.
- AVCOTHANE-51® is utilized in biomedical devices such as an intra-aortic balloon.
- the sole improvements introduced for its biomedical applications were the use of highly purified starting materials, the filtration of the product solution and clean conditions for the fabrication of blood-contacting surfaces.
- Another biomedical polyurethane, AVCOTHANE-610®, also called CARDIOMAT-610®, and ANGIOFLEX® are presently being used in blood pumps and trileaflet heart valves.
- thermoplastic material PELLETHANE® was first applied to the manufacture of cannulae for blood vessels, and later of catheters. This material had originally been developed as an extrusion molding resin exhibiting superior hydrolytic stability than their polyester-based counterparts. Table 1 below lists some of the biomedical polyurethanes available in the U.S. market.
- Table 1 The known materials listed in Table 1 below may be essentially divided into two groups, where for each group one material is derived from the previous one, and so on.
- polyesterurethanes which exhibit low hydrolytic stability
- polyetherurethanes which exhibit low hydrolytic stability
- polyurethanes containing solely urethane groups and polyurethaneureas, which also contain urea groups.
- polyether glycols The majority of useful biomedical elastomers are those prepared from polyether glycols.
- a most commonly-used polyether glycol is a product of the ring-opening polymerization of tetrahydrofuran (THF).
- THF tetrahydrofuran
- This polyether is known mostly as polytetramethylenetherglycol (PTMEG), polytetramethyleneoxide (PTMO) and polytetrahydrofuran (poly(THF)).
- PTMEG polytetramethylenetherglycol
- PTMO polytetramethyleneoxide
- poly(THF) poly(THF)
- MDI-based polyurethane elastomers generally have physical and mechanical properties that are superior to polymers prepared from tolylene diisocyanate (TDI), or the aliphatic diisocyanates such as hexamethylene diisocyanate (HDI) and dicyclohexanediisocyanate (HMDI), a hydrogenated MDI analogue.
- TDI tolylene diisocyanate
- HDI hexamethylene diisocyanate
- HMDI dicyclohexanediisocyanate
- HMDI hard segments are often too miscible with the polyether segments to provide the degree of phase separation required to achieve optimal mechanical properties. This is particularly true at elevated temperatures, such as 37° C., which significantly decrease the physical strength of a polymer. Phase separation is, therefore, important for attaining good physical properties in polyurethane elastomers. This relationship is discussed further below.
- the chemical composition of the permeable, rubbery phase of a block copolymer may be varied in this invention without resulting in a significant variation in its total volume fraction or glass transition temperature.
- Polyurethanes like the PELLETHANE 2363® series are moderately phase-separated thermoplastics generally having a shore hardness of 70A or higher. These polymers are reasonably tough and resistant to fatigue, but exhibit a high level of hysteresis or creep under load. These polyurethanes are usually unable to withstand autoclaving without distortion and molecular weight reduction.
- BIOMER® Polyurethaneureas like BIOMER® are more highly phase-separated elastomers which are generally manufactured in solution unless the diamine chain extender is completely replaced by water, as it is in the extrudable BIOMER® polymer. When the total content of hard segment is lowered, useful urea-containing urethanes are obtained. These are elastomers approaching natural rubber characteristics. Both BIOMER® and the polyether PELLETHANES® have pure PTMO soft segments and are unsuitable for use in the present invention.
- polyurethaneureas A combination of high elongation at break and high ultimate tensile strength make the polyurethaneureas tougher than the corresponding polyurethanes. Their low hysteresis or creep properties, however, are probably their most outstanding feature. Polyurethaneureas exhibit excellent flex life when subjected to biaxial strain, such as in a blood pump. Finally, polyurethaneureas can withstand one or two autoclave cycles without evidencing a significant decrease in molecular weight or physical properties. This is indicative of a superior ability to retain their properties at elevated temperatures relative to their polyurethane analogues.
- This invention relates to a biocompatible, hydrophilic, segmented block polyurethane copolymer, comprising
- At least one soft segment comprising at least one hydrophilic, hydrophobic or amphipathic oligomer selected from the group consisting of aliphatic polyols, aliphatic or aromatic polyamines and mixtures thereof; the copolymer being capable of forming a substantially non-porous, semi-permeable film having a tensile strength greater than about 350 psi and up to about 10,000 psi, an ultimate elongation greater than about 300% and up to about 1,500% and a water absorption such that the sum of the hydrophilic volume fraction of the soft segment and the absorbed water volume fraction is greater than about 100% and up to about 2,000% of the dry polymer volume and greater than about 50% and up to about 95% of the wet polymer volume and being permeable to molecules of molecular weight up to about 6,000 to 600,000 daltons and substantially impermeable to cells and particulate matter.
- This invention also relates to a non-porous, semi-permeable, biocompatible film formed from the block copolymer described above.
- Also encompassed herein is a method of permeating molecules of a predetermined molecular weight range while substantially preventing the passage of cells and particulate matter between two fluids, the method comprising interposing between the two fluids a non-porous, semi-permeable, biocompatible film formed from the copolymer of the invention.
- FIG. 1 depicts the variation in glucose permeability vs. time through dense membranes of the inventor with varying hydrophilicity.
- the wt % hydrophilic content or hydrophilicity is as follows: A (85%); B (66%); C (50%); D (40%); E (30%); F (20%); G (10%); H (0%).
- FIG. 2 shows the correlation of membrane tensile strength vs. hydrophilic content of the polymers of the present invention. In every case the tensile strength of the hydrated membrane is lower than that of the dry membrane. The difference is small, however, and useful polymers may be obtained even at high hydrophilic contents.
- FIG. 3 is a representation of the variation of the capacity for water absorption of the membrane of this invention with increasing hydrophilicity.
- This invention arose from a desire by the inventors to improve on existing polymer technology to regulate, by varying certain parameters of the polymer composition, the permeability of the membranes obtained therefrom.
- the inventors have provided a co-polymer composition where they can vary the soft segment compostition, soft segment molecular weight and proportion thereof to the hard segment. The variation of these parameters provides a plurality of membranes of specifically tailored permeabilities.
- This invention provides strong, biocompatible, hydrophilic segmented block polyurethane copolymers comprising a minor volume fraction of short hard segments and amphipathic or hydrophilic soft segments.
- Soft segment molecular weight, soft segment chemistry, and soft segment concentration may be chosen so that the resulting block copolymer absorbs sufficient water and the sum of the volume fraction of water and the volume fraction of hydrophilic soft segment exceed about 50% of the total volume of the water-swollen polymer. More preferable, the volume of absorbed water alone equals or exceeds about 50% of the total volume of the water-swollen polymer.
- the water-swollen polymer has an apparent continuous phase of hydrated soft segment and/or water which permits the permeation of macromolecules into, and through, the copolymer. This is particularly true when the copolymer is prepared in the form of a membrane, film or coating.
- the nature of the hard segment is a relatively unimportant determinant of the permeability of the resulting copolymers. Since the hard segments are essentially impermeable, their major function is to provide physical strength to the copolymer while existing as a separate molecular phase from the soft segment(s). In all cases maximum permeability to proteins and other macromolecules is achieved at minimum hard segment content. Therefore, when maximum permeability is required of the copolymer, its total hard segment is chosen to be no higher than required to provide sufficient strength for use in the intended application. Since hard segments other than polyurethanes and polyureas can often provide the required strength, it is within the scope of the present invention to employ copolymers with hard segments other than polyurethanes or polyureas.
- suitable hard segments include those which when prepared as homopolymers have melting points (Tm) or glass transition temperatures (Tg) above 37° C. and preferably above about 60° C. in the dry state and which have melting points or glass transition temperatures above 37° C. in the fully hydrated state when initially hydrated at 20° to about 37° C.
- Suitable hard segments have the optional requirement that, if present at sufficiently-high molecular weight and total concentration in the copolymer, they form a separate molecular phase from the soft segment(s) such that a distinct Tg or Tm is measurable in the copolymer, which must be within the above-specified range and which is also greater than the major Tg or Tm of the soft segments when the copolymer is fully hydrated. It should be noted that if the hard segment content is low and/or if the hard segment molecular weight is low, available instruments may be unable to detect the dominant thermal transition of the hard segment, hence the statement that detectability of Tg or Tm is an optional requirement.
- hard segments with the specified thermal transitions and water resistance which can be used in the present invention include a wide variety of chemical compositions. This is further illustrated by the following list of examples which is not intended to be all-inclusive or to limit the scope of the invention: aromatic and cycloaliphatic polyethers, polyesters, preferably aromatic polyesters, polyamides, polyimides, polycarbonates, polyolefins, polyacrylates, polydienes, polyacetals and other homopolymers, copolymers or multipolymers which have Tg or Tm greater than 37° C. in the hydrated state and preferably greater than about 60° C. in the hydrated state.
- Suitable crosslinks may be obtained through the use of multi-functional reagents employed in the synthesis or membrane casting steps and/or crosslinking may be achieved by a variety of methods known in the art which involve the use of various kinds of radiation to crosslink the polymer during or after it is converted to a configured shape, often through the inclusion of suitable reagents which become reactive when exposed to radiation.
- suitable reagents which become reactive when exposed to radiation.
- essentially linear polyurethane(urea) copolymers are presented as exemplary copolymers, it is possible to achieve the required permeability and strength by incorporating branching or grafting along the backbone of the polymers of the present invention.
- One method of introducing branch points is through a combination of reactants having functionality greater than two together with monofunctional reactants. For example, a monofunctional polyalkyleneoxide may be reacted with a trifunctional isocyanate to produce a difunctional isocyanate with a pendant polyalkyleneoxide chain. The modified diisocyanate may then be used in the synthesis of a copolymer with branched or graft structure.
- Other methods of achieving branching and grafting are well known to those skilled in the art and are considered to be within the scope of the current invention.
- the resulting polymer must retain sufficient water absorptivity and molecular weight between crosslinks (or molecular weight between hard segments defined later as "spacer length") to possess an apparent continuous aqueous phase in the fully-hydrated state.
- spacer length molecular weight between crosslinks
- the exact hard segment content or crosslink density that is required to maintain a water-rich phase greater than about 50 vol % will vary for each specific polymer, but is easily measured gravimetrically by hydrating essentially dry polymer and noting the weight change if polymer density is known, or volume change upon hydration by displacement of a fluid of known specific gravity or direct measurement with, e.g., calipers.
- Polymers suitable for the practice of this invention will absorb sufficient water such that the total of the volume fraction of absorbed water and the volume fraction of the water-absorbing hydrophilic soft segments, which may be calculated from the density and weight fraction of hydrophilic soft segment present, exceeds about 50 vol % of the total volume of the fully-hydrated polymer. More preferable are copolymers which absorb sufficient water so that the volume fraction of absorbed water alone exceeds about 50 vol % and up to about 95 vol % of the total volume of the fully-hydrated polymer.
- the hard segment can also include a linkage between polyols or polyamines formed by a single diisocyanate without the use of chain-extending reagents.
- Suitable substrates may be woven or knitted fabrics, microporous polymer structures, including integral microporous structures made of the polymers of the present invention, glass or carbon fiber mats and the like. These are known in the art and need not be further described herein.
- Particularly desirable substrates are expanded polytetrafluoroethylene, expanded polypropylene, expanded polyethylene, sintered ultra-high molecular weight polyolefins, carbon fiber fabrics, sintered carbon, woven dacron, knitted dacron, dacron velour and the polymers of this invention either as a separate substrate or as an integral part of the membrane.
- others are suitable as well.
- non-porous, semi-permeable, optically-clear biocompatible film, membrane or coating formed from the block copolymer of this invention is also provided herein.
- optically-clear, non-porous, semi-permeable, film, membrane or coating formed from the block copolymer of this invention allows direct visual observation through the film or membrane.
- a method of permeating molecules of molecular weights of up to about 6,000 to 600,000 daltons, and sometimes higher, while preventing the passage of condensed matter, and cells between two fluids the method comprising interposing between the two fluids the non-porous polymer membrane, film or coating of this invention.
- Macroscopic structure affects the permeability and selectivity of a polymer membrane. Macroscopic structure, particularly the presence or absence of permanent pores, also determines the mechanism by which permeation will occur.
- microporous membrane In a microporous membrane, the passage of gases, vapors and solutes occurs through small capillary-like pores that inhibit the passage of larger molecules and cells, but which may eventually become clogged with oversized permeants restricting the passage of desirable permeants. Since microporous membranes have pores that are larger than the wavelength of visible light, they are invariably opaque or translucent in color, precluding the possibility of direct or microscopic observation of the contents of membrane containers.
- a non-porous or dense membrane acts in general as an absolute barrier to cells and other condensed phases of matter, but may be made selectively permeable to predetermined gases, vapors and/or solutes. Since dense membranes have no permanent pores that are larger than the wavelength of visible light, they can be water-clear or transparent in color. This is a very significant improvement over opaque microporous membranes, particularly in in vitro cell culture applications.
- c is the concentration of permeant in the polymer film
- p is the concentration of permeant in equilibrium with the film
- S is the solubility coefficient for the polymer.
- q is the amount of permeant diffusing through a unit area of the film per unit time
- dc/dx is the concentration gradient across a thickness dx
- D is the diffusion constant for the specific polymer/permeant system.
- c 1 and c 2 are the concentrations in the two surfaces of the film.
- equation (IV) is equivalent to equation (V) below.
- equation (IV) A simple inspection of equation (IV) reveals that the permeation rate of a specific non-porous film is directly proportional to the concentration difference and film area, and is inversely proportional to the film thickness.
- the permeability coefficient, p may be maximized through changes in polymer chemistry or structure which maximize D and S for the desired permeant. These changes will increase both the water uptake and the segmental mobility of the polymer.
- a membrane polymer with high water content may be permeable to high molecular weight, water-soluble permeants by presenting a water-like continuous phase through which the permeant may easily pass (diffusivity enhancement) and an aqueous environment in which the permeant may easily dissolve (solubility enhancement).
- Crystalline polymers are generally considered to be completely impermeable. In semicrystalline polymers, an increase in crystallinity produces a decrease in permeability. This effect can be quite significant at the phase inversion point when the continuous phase, which is usually the phase present at >50% volume fraction, changes from amorphous to crystalline. Certain membrane polymers of the present invention may also form impermeable crystalline regions within the soft segments when the membrane polymer is in the dry state. On hydrating, however, we have found that these crystalline regions become amorphous and readily permit the passage of relatively high molecular weight permeants.
- An amorphous polymer will be more permeable as a rubbery material at a temperature above its glass transition temperature (Tg) than in its glassy state below Tg.
- Silicone rubber for example, has a Tg of -120° C. When at room temperature, it is 140° C. above its Tg, and it is, therefore, extremely permeable to a number of gases and vapors. Silicone is virtually impermeable to water-soluble permeants of high MW, however, since its hydrophobicity results in very low solubilites of permeant in the polymer, which absorbs little or no water.
- segmented polymers such as polyurethaneureas
- the hard segment is glassy or crystalline and the soft segment is rubbery
- permeation occurs primarily through the rubbery phase. If the content of hard segment is increased to a point where it becomes the continuous phase, the permeability coefficient, p, drops significantly.
- An important aspect of the polymers of the present invention is that the soft segment Tg is relatively low due to the choice of reactants and due to the placticizing effect of absorbed water and that the impermeable hard segments comprise a minor volume fraction of the water-swollen polymer.
- the difference between the solubility parameters of the permeant and the polymer is one way of expressing this property.
- specific interactions normally exist between the polymer and the permeant which make any predictions based solely on the solubility parameter less than accurate.
- One such specific interaction involves hydrogen bonding between (water-swollen) polymer and permeant. More specifically, reversible hydrogen bonding among water molecules, chemical groups on the polymer, and chemical groups on the permeant molecules may play an important role in facilitating permeability of proteins through dense membranes of the present invention.
- the chemical structure of a polymer may be varied, and this variation may be used to maximize the permeability of a dense film made from that polymer to a specific permeant.
- this variation may be used to maximize the permeability of a dense film made from that polymer to a specific permeant.
- an understanding of the exact relationship between the structure of the polymer and the permeant selectivity obtained by a membrane during solute separation is lacking. Any a priori prediction of permeability, thus, remains difficult.
- Crosslinking generally decreases the permeability of a membrane, particularly to large molecules, such as proteins. At low crosslink density, however, the permeability of low molecular weight solutes may be only slightly affected.
- the crosslinking of polyurethanes may be the result of certain side reactions during polymer synthesis which form allophanate and/or biuret groups, the reaction of polyfunctional reagents to form urethane or urea groups, or because of exposure to radiation.
- high levels of crosslinking may have a significant negative effect on the permeation coefficient of proteins and other macromolecules, although low to medium levels may be useful in enhancing the strength of the membranes, particularly in the hydrated state. It is an important feature of the present invention that the amount of crosslinking in membranes, films and coatings be kept low enough so that the previously-stated water absorption requirements are met.
- Stretching and orienting a film generally reduces its permeability constant p, primarily because of denser molecular packing or increased crystallinity, which occur as a result of the orientation.
- a substantial sorption of water by a polymer film increases the diffusion constant D due to swelling and plasticization.
- water absorption by the membrane polymers of the present invention can increase permeability by both Tg-lowering plasticization, and by a reduction in crystallinity of the hydrophilic domains relative to their crystallinity in the dry state.
- the affinity, or solubility, S, of the water-swollen polymer to water-soluble permeants such as proteins is also related to polymer water absorption, since a water-swollen soft segment capable of hydrogen bonding with sorbed water, will appear to the permeant to be more water-like than the dry polymer.
- the present inventors have found that by carefully choosing the soft segment chemistry to enhance water absorption, and by limiting the (impermeable) hard segment content such that it comprises a minor volume fraction of the water-swollen polymer membrane, protein permeability may be achieved.
- the present inventors have also found that an additional structural variable is important in determining the upper molecular weight of solutes which will permeate through the polymer membrane (i.e. selectivity): segment molecular weight or, more precisely, segment molecular length.
- the soft segment comprises the permeable, but weak phase of the membrane polymer.
- the hard segment comprises the strong, impermeable phase of the membrane polymer.
- the much higher cohesive energy density of the hard segment gives it the ability to add strength to the overall polymer, but contributes essentially no permeability to the polymer (membrane).
- the soft segment may be assumed that all permeation occurs through the soft segment.
- the most effective hard segments are those with the best phase separation from the soft segment. That is, on a molecular scale, the most desirable hard segments are those that separate into domains containing like hard segments on adjacent polymer chains, while the soft segments comprise a separate phase. In an aqueous environment, the soft segment will also contain an amount of absorbed water which can vary from nearly zero to very high levels, depending on the inherent hydrophilicity of the soft segment oligomers.
- the soft segment oligomers are, on average, covalently bonded at each end to a hard segment, it is clear that the maximum spacing possible between the impermeable hard segments is related to the length of the soft segment oligomer.
- a critical molecular dimension for permeation of large molecules is set by the average soft segment molecular length.
- molecular length is directly proportional to molecular weight. It follows then that increasing soft segment oligomer molecular weight should increase the maximum molecular weight of solutes which may permeate through the polymer. This effect may be applied to tailoring membrane permeability by choosing soft segment oligomer molecular weight.
- a typical commercially-available polyether oligomer may be obtained in molecular weights ranging from a few hundred to a few thousand daltons. To achieve molecular weight cutoffs higher than those obtainable with commercially-available soft segment oligomers, another approach is possible. Available soft segment oligomers may be coupled together prior to the reaction used to synthesize the final membrane polymer.
- a so-called three-step reaction in which the first step involves covalently bonding two or more oligomers together while optionally retaining the oligomer's original end-groups by appropriate control of the stoichiometry of the coupling reaction.
- the first step involves covalently bonding two or more oligomers together while optionally retaining the oligomer's original end-groups by appropriate control of the stoichiometry of the coupling reaction.
- three moles of hydroxyl-terminated polyether oligomer might be reacted with two moles of a diisocyanate chosen to be different from the isocyanate used in the hard segment of the final polymer.
- a diisocyanate to couple soft segment oligomers is optional but preferable since it minimizes the association of the coupling segment with the hard segment of the polymer. This is the desired situation for maximum permeability.
- the coupled oligomer would have an average molecular of 6,000 plus the molecular weight of the two diisocyanates used in the urethane-forming coupling reaction.
- the maximum end-to-end distance between hard segments would be increased more than three times, relative to the original 2,000 molecular weight oligomer before coupling.
- the maximum end-to-end distance of the optionally-coupled soft segment oligomer is referred to herein as a "spacer length".
- the spacer length is a determinant of the upper molecular weight cut-off of the membrane polymer.
- the relationship between the maximum permeant molecular weight which can pass through a membrane may not be a linear function of the spacer length.
- a permeant which assumes a roughly spherical conformation might increase its spherical diameter in proportion to the cube root of its molecular weight.
- a rod-like permeant on the other hand, might increase its major dimension in direct proportion to its molecular weight.
- An additional effect of increased soft segment molecular length may be that longer chain length between hard segments permits the formation of a smaller number of hard segment domains, albeit of larger size. This effect could be caused by increased mobility of hard segments tethered through covalent bonds to very long soft segment spacers.
- domain volume increases with the cube of the diameter. A small increase in domain diameter may result in a large decrease in the number of hard segment domains impeding the transport of high molecular weight solutes, resulting in an increase in permeability to high MW permeants.
- Short hard segment length enhances permeation of high MW solutes for the same reason that long soft segment length does. It is therefore desirable to minimize hard segment length. This must be done without decreasing total hard segment content, e.g., weight fraction of hard segment, below a critical minimum, since the strength of the polymer decreases with total hard segment content. For a given hard segment content and soft segment molecular weight, the hard segment length is minimized at maximum membrane polymer molecular weight. Too high a molecular weight, however, causes fabrication difficulties due to excessively-high melt or solution viscosities.
- membrane polymer molecular weight is controlled by chain-stopping through the addition of monofunctional reagents to the reaction mixture, or through the use of a stoichiometric imbalance of one of the reactants. Furthermore, by selecting certain hydrophilic monofunctional chain-stoppers the permeability of the polymers of the present invention can be enhanced. This may be attained by adding to the total hydrophilic content of the polymer while also limiting molecular weight to a desired range.
- the polymers of the present invention may be synthesized to have a specific permeability to a given permeant and/or to have a specific molecular weight cutoff, by implementing an empirical, yet systematic approach.
- the empirical nature of the method is mandated by the nature of the phenomenon of permeability through dense membranes, the properties of specific permeants or non-permeants, including their solubility properties, molecular size and conformation.
- the inventors provide herein a systematic approach to the production of membrane polymers in accordance with the present invention, which may be used to tailor membrane properties for specific applications. This is described briefly in the following paragraphs.
- the permeation of solutes through dense polymeric membranes is determined for the most part by the diffusivity and solubility of the permeants in the membrane polymer. If the membrane polymer absorbs a significant amount of the solvent, then the permeation of the solutes will be determined by the diffusivity and solubility of the permeants in the solvent-swollen membrane polymer.
- the absorption of a solvent e.g., water
- the solvent must be capable of dissolving the solute/permeant. It follows, thus, that the absorption of the solvent by the membrane may increase contribution of the solubility factor to the permeability coefficient by making the environment within the membrane polymer more like the pure solvent than it was in the dry state.
- plasticizer In general, in addition to enhancing the solubility of the permeant in the membrane polymer, a low molecular weight solvent will often act as a plasticizer for the membrane polymer. Plasticization involves a degree of dissolution of the polymer by the plasticizer. Furthermore, as the level of plasticizer/solvent increases, the glass transition temperature of the mixture will generally decrease. A decreased glass transition temperature suggests that the plasticizer may facilitate the relative movement of macromolecular chains by inserting themselves between adjacent chains to increase the intermolecular spacing there between. In addition to the above, plasticizer/solvents may reduce the degree of possible polymer-polymer interactions through specific interactions between the polymer and the plasticizer/solvent. A reduction in the soft segment crystallinity upon hydration, which occurs with certain membrane polymers of the present invention, is an example of the latter mechanism.
- the absorption of a solvent by a membrane polymer may enhance the membranes permeability by increasing both the diffusivity and the solubility of a particular permeant.
- One method of tailoring the membrane of the present invention to obtain a specific permeability rate and/or molecular weight cutoff, is to vary the composition and morphology of the membrane. This will effect an enhancement of the amount of solvent absorbed, and of the extent of solubility and diffusivity that results from greater solvent absorption.
- the inventors have found that certain qualitative and quantitative relationships exist which guide the process.
- the permeability of candidate membranes may be performed with the methods described by the inventors herein.
- the structure vs. property relationships provided herein may be used to adjust the permeability properties of the membrane through an iterative process of synthesis, membrane casting and permeability measurement, until the desired values for the intended use are attained.
- the permeant is a water-soluble macromolecule and that the solvent is water or an aqueous fluid.
- the solvent is water or an aqueous fluid.
- the transmission rate through a microporous membrane is generally directly proportional to the film area and the concentration driving force. However, the transmission rate is affected far less by the thickness of the film than it is in monolithic films.
- the porosity of a microporous membrane is a major determinant of the permeability rate.
- a microporous membrane made from polyethylene, polycarbonate, polyvinylchloride or other polymers and copolymers which are glassy or crystalline at the use temperature, e.g., 37° C., will transport polar permeants primarily through its pores. For that type of membrane, therefore, permeability increases and strength decreases with total porosity or void volume fraction.
- microporous membranes to the concentration-driven transport of large molecules, such as proteins present in a medium, poses several problems. Since only the pores of the membrane are available for the mass transfer of large molecules, the fraction of the total area of the membrane available for permeation is limited. This slows the rate of transfer of molecules across the membrane. Porous membranes which work well in pressure-driven separation such as ultrafiltration, exhibit much lower permeation rates when used in concentration-driven processes in which pressure is not or can not be applied to the upstream side of the membrane. Usually, highly porous membranes also lack strength and present a rough surface to blood and tissue alike.
- the hydrophilicity increases as concentration of ether oxygens in the soft segment increases.
- Ether oxygens are the preferred hydrophilic group for the practice of the present invention, especially the ether oxygens present on the polyethyleneoxide (PEO) and PEO-containing copolymers, multipolymers and blends.
- PEO homopolymers When PEO homopolymers are used as the sole soft segment, it is particularly preferred to use high molecular weight oligomers, preferably above about 1,000 daltons, and most preferably above 3,000 daltons, for the reasons already stated. PEO ether oxygens readily absorb and hydrogen bond with water, without giving rise to a permanent adsorption of the permeants, which would otherwise retard or prevent permeation through the membranes of the present invention. On the other hand, it is possible to utilize other hydrophilic groups in the soft-segment for practicing of the present invention, including hydroxyl, carboxyl and/or other ionic groups alone, or in various combinations, to achieve a desired water absortivity.
- copolymers of the invention may be prepared by one-step, two-step or three-step synthetic methods depending on the complexity of the chemical structure desired. Examples of polymers prepared by all three methods are provided below.
- the one-step method is exemplified in Table 6 below.
- the end groups on the polymer may vary depending upon which polyol reacts with the isocyanate e.g., (MDI) and the exact stoichiometry of the reaction mixture.
- the end group could be butanediol (--OH), polyethylene oxide (--OH), or isocyanate (--NCO) residues.
- the two-step method is exemplified in Table 7 below.
- the three-step method is exemplified in Table 8 below.
- the exemplified prepolymer may be made using a combination of different polyols or polyamines or mixtures thereof.
- the DBA, PTMO and the MDI may be first reacted to form an isocyanate-terminated prepolymer.
- Preferred conditions for this step are as follows.
- the prepolymer may then be chain extended with ethylene diamine (ED) at low temperatures, such as about 0° to 70° C., and preferably about 5° to 10° C., to give a high molecular weight, segmented polymer.
- ED ethylene diamine
- ED ethylene diamine
- enough water may be present as an impurity to consume a significant portion of the isocyanate groups present.
- This reaction will generate carbon dioxide and a urea group, that will couple two MDI residues with no methylene groups there between. These structures will be present in proportion to the amount of water present in the reactants and solvent.
- the hard segments produced in each reaction may be expected to contribute differently to the properties of the polymer, e.g., by changing the degree of phase separation from the soft segment.
- Many other reactions, such as side reactions further complicate the structure of the polymer of the invention, thus making any simple representation of the copolymer approximate.
- the side reactions may create difficulties for any prediction of structure vs. property relationships as well as increase the likelihood of batch-to-batch variations in the characteristics of the copolymer of the invention.
- the use of pure, dry reactants and anhydrous reaction conditions, and the use of chain-terminating reagents aids in the control of the overall polymer molecular weight minimizes side reactions and gives polymer structures more closely approximating the ideal or theoretical structure.
- the elastomers are designed to have excellent physical characteristics, such as toughness and elongation.
- the copolymers of this invention are designed as a family of materials with a broad range of modulus and hardness that may be tailored for many particular applications. Although tailoring of permeability properties of the copolymer of this invention is often of primary importance, within the structural constraints of the required permeability, it is also possible to tailor physical properties as well. In most cases the polymers of the present invention will have the desired protein and/or macromolecular permeability and also possess excellent physical properties as well.
- the hard segment content is defined herein as the weight of diisocyanate plus chain extender, and hydrophobic chain terminator, if present, divided by total polymer weight.
- a linear proportion is found between initial, i.e., measured at less than 10% strain, modulus and hard segment over a range of about 9 to 30% hard segment content.
- Linear, not crosslinked, elastomers of about 9% hard segment and below have properties similar to unvulcanized rubber and are, therefore, not of particular interest for the present use as unsupported films or membranes. They may be used, however, as coatings or impregnations on porous reinforcing substrates.
- the pure soft segment may undergo reversible crystallization, giving an increased modulus and a somewhat reduced ultimate elongation.
- the thus resulting polymer also possesses excellent strength and certain other desirable properties.
- the diisocyanate and all reactants which contribute an active hydrogen i.e., polyols, diamine, amines, may be added in a proportion of about 0.9 to 1.2 and more preferably about 0.95 to 1.1.
- the reactants may be added to a solvent of the following characteristics.
- Suitable solvents are organic solvents that partially or completely stabilize or suspend the various reagents utilized in the preparation of the polymer.
- Preferred solvents are generally polar liquids and may include, but are not limited to, dimethylacetamide, dimethylformamide, dimethylsulfoxide, 2-methyoxyethanol, n-methylpyrrolidone, pyridine, and tetrahydrofuran. Combinations of these solvents may also be used.
- the solution of diisocyanate and polyalkylene oxide in a solvent is preferably about 40 to 85 wt % solids, more preferably about 50 to 80 wt % solids, and still more preferably about 75 wt % solids. However, it may be varied within a broader range.
- the polyalkylene oxide reagent typically has a molecular weight of about 200 to 9,000, although other ones may be utilized.
- the diisocyanate may be an aromatic or an aliphatic polyisocyanate.
- the diisocyanates may be selected from the group consisting of alkyl diisocyanates, arylalkyl diisocyanates, cycloalkylalkyl diisocyanates, alkylaryl diisocyanates, cycloalkyl diisocyanates, aryl diisocyanates, and cycloalkylaryl diisocyanates, which may be further substituted with oxygen, and mixtures thereof. However, others are also suitable.
- the reaction may be conducted at a temperature of about 50° to 130° C., and more preferably about 55° to 60° C. for aromatic isocyanates and about 100° to 110° C. for aliphatic isocyanates, and a pressure of about 0.1 to 100 atm, and more preferably about 0.1 to 10 atm. Preferred are atmospheric pressure and an atmosphere free of moisture and oxygen.
- the reaction will in general go to completion in about 3 hours, and it may be conducted with agitation.
- the thus obtained polymer or prepolymer will, in general, have a molecular weight of about 300 to 1,000,000, and more preferably, about 5,000 to 60,000.
- the reagents and solvents should preferably be of high purity if the best results are desired. However, other grade reagents and solvents may also be utilized.
- the synthesis of polyurethanes is affected by moisture. Accordingly, all equipment utilized for synthesizing the copolymers of the invention should be thoroughly dried before use. All steps of the preparation thus should, in general, be maintained substantially water-free. Caution, in addition, should be exercised not to expose any reactants or solvents to atmospheric moisture. Moreover, some of the substances utilized for the synthesis of the copolymers of the invention, such as diphenyl methane diisocyanate (MDI), are highly toxic. Accordingly, the use of a respirator and gloves and adequate mechanical ventilation is recommended when handling them. Combustible solvents, such as dimethylformamide, which are suitable for use herein, are absorbed through the skin. Accordingly, any vapor breathing and skin contact with these compounds must be avoided.
- MDI diphenyl methane diisocyanate
- One general procedure for preparing the copolymer of the invention is as follows.
- the polyols may be blended together under essentially anhydrous conditions, preferably under vacuum and a nitrogen atmosphere at a temperature of about 100°-110 ° C. until their water content is, e.g., less or equal to about 250 ppm. This value is usually attained in about 1 to 1.5 hours.
- a clean, dry nitrogen-purged reactor may then be filled with the dry polyol blend.
- a polyol or polyamine such as dibutyl amine may then be accurately weighed and added to the reactor, and a solvent, such as dimethylformamide (DMF), may be added to a concentration of about 40 to 85% solids, and more preferably about 75% solids to form a pre-polymer, and the mixture may then be stirred, e.g., at about 30 to 40 rpm.
- a diisocyanate such as 4,4'-diphenylmethane diisocyanate (MDI) may be added at this point.
- the content of the reactor may then be heated to about 60° C. with a variation of about 2° C. The reaction is then allowed to continue for, generally, about 3 hours at this temperature, noting the temperature at regular intervals throughout.
- the reaction is stopped by cooling, e.g., in an ice bath.
- the temperature of the solution at this point should be about 15° C. with a margin of 2° C. for starting the chain extension reaction.
- the thus obtained pre-polymer may be diluted to about 25% in an organic solvent, such as DMF, with a margin of error of about 2%.
- Samples may be removed from the reactor at different times for titration to determine the amount of isocyanate in order to assess readiness for ethylene diamine addition according to the following protocol.
- the figures provided are exemplary, but similar calculations may be conducted for different volumes and amounts of substrate to be titrated.
- a derivatizing solution may be prepared by adding 7.5 grams of dibutylamine to a dry 250 ml volumetric flask and diluting to the mark on the flask with the same organic solvent used in the synthesis. Three 5 gram (nominal) samples of the prepolymer may be accurately weighed, and each placed into a separate Erlenmeyer flask with a dry magnetic stir bar. 20 ml of the derivatizing solution may be added to each sample using a 20 ml volumetric pipet. The flask may then be covered with aluminum foil and stirred for 20 minutes at room temperature.
- IPA isopropyl alcohol
- bromophenol blue indicator 50 ml of isopropyl alcohol (IPA) and six drops of bromophenol blue indicator may be added.
- a buret may be filled with 1.0N aqueous HCl.
- the solution may then be stirred and titrated with 1.0N aqueous HCl to a yellow end point, and the amount of titrant used recorded.
- Two blanks may then be prepared by repeating the previously described procedure without adding the prepolymer sample to the flask.
- the amount of ethylene diamine (ED) required for chain extension may then be calculated by using the equations shown below. ##EQU1##
- Chain extension may be attained by adding a solution containing about 40 to 60 wt %, and preferably about 50 wt %, of the theoretical amount of ethylene diamine (ED) in a solvent such as dimethyl formamide (DMF), in a proportion of ED:DMF of about 1:5.
- ED ethylene diamine
- DMF dimethyl formamide
- the ED solution may be added to the mixture over a period of, e.g., about 30-45 minutes. In general, about 20 minutes is sufficient to permit complete reaction. Half the remaining ED, as calculated below, may be added at this point.
- the reaction may go to completion in about 20 minutes.
- the above-described titration/calculation may then be repeated until the presence of isocyanate is no longer detected by titration. If isocyanate is still present after all the ED/DMF solution is added and reacted, the reaction may be aborted and discarded. If no isocyanate is detected, the mixture may be further stirred for, e.g., about 30 minutes, at about 15° C. with a variance of about 2° C.
- the polymer may then be stabilized by the addition of about 0.5% to 5% Tinuvin 328 and 0.5% to 5% Tinuvin 770, and preferably 0.5 to 1% of each, based on total solids of the polyurethane polymer formed. This may be attained with about 25 wt % solution of Tinuvin 328 and Tinuvin 770 in THF.
- Tinuvin 770 is a commercially available product comprising bis(2,2,6,6-tetramenthyl-4 -piperidyl)sebacate or bis(2,2,6,6-tetramethyl-4-piperidinyl)decanedioate.
- Tinuvin 328 is one of a family of substituted benzotriazoles. Other families of compounds may also be used in their stead.
- stabilizers are antioxidants, thermal stabilizers and ultraviolet (UV) light absorbers include, but are not limited to, hindered amine light stabilizers, sterically hindered phenol compounds, compounds with sterically hindered phenolic hydroxyl groups, compounds from the hydroxyphenyl-benzotriazole family, and light stabilizers of the benzophenone-type. Combinations of any or all of the compounds listed above may also be used as well as other stabilizers known in the field.
- UV light absorbers include, but are not limited to, hindered amine light stabilizers, sterically hindered phenol compounds, compounds with sterically hindered phenolic hydroxyl groups, compounds from the hydroxyphenyl-benzotriazole family, and light stabilizers of the benzophenone-type. Combinations of any or all of the compounds listed above may also be used as well as other stabilizers known in the field.
- the reaction mixture may then be further stirred for, e.g., about 30 minutes at about 15° C. with a variance of about 2° C., and the thus attained polyurethane filtered through, e.g., a woven stainless steel 10 micron filter into, e.g., clean, dry glass containers.
- the optimal reaction temperature for the reaction of aromatic diisocyanates with polyols is about 50° to 60° C.
- the optimal reaction temperature for the reaction of aliphatic diisocyanates with polyols is about 100° to 110° C.
- the optimal reaction temperature for amine terminated reactants is about 0° C. and 25° C. This reaction temperature applies to amines used as chain extenders and amines used in the soft segment.
- the diisocyanate and all reactants which contribute an active hydrogen, i.e., polyols, diamines, amines may be added in a proportion of about 0.9 to 1.2 and more preferably about 0.95 to 1.1.
- the reactants may be added to a solvent as described above.
- the copolymer of the invention may be prepared in a wide range of molecular weights, for some applications preferred is a molecular weight of about 5,000 to 1,000,000, and more preferable about 6,000 to 60,000. Still another range of preferred copolymer molecular weight is about 2,000 to 10,000, and more preferable about 3,000 to 6,000. Some of these may be used as pre-polymers capable of further reaction during fabrication, whereas higher molecular weight homologues are utilized as the final polymers for preparation of the films such as membranes, sheets or hollow fibers.
- the soft segment used in the preparation of the polyurethane of the invention may be a polyfunctional aliphatic polyol, or a polyfunctional aliphatic or aromatic amine such as are commonly used for the preparation of polyurethanes or mixtures thereof.
- the molecular weight of the soft segment is typically about 200 to 1,000,000, and preferably about 400 to 9,000.
- the aliphatic polyols of the soft segment may be selected from the group consisting of linear and branched polyalkylene and polyalkenyl oxides, random and block copolymers thereof, polycarbonate polyols, hydroxyl-terminated silicones, random and block copolymers thereof with polyalkylene oxides, linear and branched polyalkenyl and polyalkylene polyols, and mixtures thereof.
- other polyols may also be utilized if the resultant polymer posses the required water absorptivity.
- polyols that are suitable for use in the present invention are polyethylene oxides, polypropyleneoxides, polytetramethylene oxides, random or block polypropylene oxide-polyethylene oxide copolymers, various ethyleneoxide-terminated polyols, random or block polytetramethylene oxide-polyethylene oxide copolymers, polycarbonate diols and triols, multifunctional hydroxyalkyl- or amine-terminated silicones, random or block silicone-polyethyleneoxide copolymers, polybutadiene diols and triols, polyisobutylene diols and triols, and mixtures thereof.
- the amines of the soft segment may be selected from the group consisting of amine-terminated homologues of the exemplary polyols, including but not limited to polyamine-terminated alkylene oxides and random and block copolymers thereof, polyamine-terminated silicones, random and block copolymers thereof with polyalkylene oxides and mixtures thereof.
- Examples of the amines that are suitable for use in the present invention are multifunctional amine-terminated polytetramethylene oxides, multifunctional amine terminated polyethylene oxides, random or block multifunctional amine terminated polypropylene oxide-polyethylene oxide copolymers, random or block multifunctional amine-terminated polytetramethylene oxide-polyethylene oxide copolymers, multifunctional amine-terminated silicones, random or block amine-terminated silicon polyethylene oxide copolymers and mixtures thereof.
- Suitable polyisocyanates for the preparation of the hard segment of the copolymer of the invention are aromatic or aliphatic polyisocyanates.
- the organic diisocyanates may be selected from the group consisting of alkyl diisocyanates, arylalkyl diisocyanates, cycloalkylalkyl diisocyanates, alkylaryl diisocyanates, cycloalkyl diisocyanates, aryl diisocyanates, cycloalkylaryl diisocyanates, all of which may be further substituted with oxygen, and mixtures thereof.
- polyisocyanates examples include 4,4'-diphenylmethane diisocyanate, hexamethylene diisocyanate, dicyclohexylmethane diisocyanate, 2,4-toluene diisocyanate, 2,6-toluene diisocyanate, hexamethylene-1,6-diisocyanate, tetramethylene-1,4-diisocyanate, cyclohexane-1,4-diisocyanate, naphthalene-1,5-diisocyanate, diphenylmethane-4,4'-diisocyanate, xylylene diisocyanate, dicyclohexylmethane-4,4'-diisocyanate, 1,4-benzene diisocyanate, 3,3'-dimethoxy-4,4'-diphenyl diisocyanate, m-phenylene diisocyanate, isophorone diisocyan
- the chain extender of the hard segment used in the preparation of the copolymers of the invention may be an aliphatic polyol or an aliphatic or aromatic polyamine such as those known for preparing polyurethanes.
- the polyol for the hard segment may be preferably selected from the group consisting of alkylene, cycloalkylene and arylene diols, triols, tetraalcohols, and pentaalcohols, and mixtures thereof.
- polyols suitable for the preparation of the hard segment are 1,4-butanediol, ethylene glycol, 1,6-hexanediol, glycerine, trimethylolpropane, pentaerythritol, 1,4-cyclohexane dimethanol, phenyl diethanolamine, and mixtures thereof, among others.
- polyols are also suitable.
- the polyamine of the hard segment may be selected from the group consisting of alkyl, cycloalkyl and aryl amines which may be further substituted with N, O, or halogen, complexes thereof with alkali metal salts, and mixtures thereof.
- Suitable polyamines for preparing the hard segment are p,p'-methylene dianiline and complexes thereof with alkali metal chlorides, bromides, iodides, nitrites and nitrates, 4,4'-methylene-bis(2-chloroaniline), piperazine, 2-methylpiperazine, oxydianiline, hydrazine, ethylenediamine, hexamethylenediamine, xylylenediamine, bis(p-aminocyclohexyl)methane, dimethyl ester of 4,4'-methylenedianthranilic acid, p-phenylenediamine, m-phenylenediamine, 4,4'-methylene bis(2-methoxyaniline), 4,4'-methylene bis(N-methylaniline), 2,4-toluenediamine, 2,6-toluenediamine, benzidine, dichlorobenzidine, 3,3'-dimethylbenzidine, 3,3'-dimethoxy
- the hard segment of the copolymer may further comprise an end group selected from the group consisting of monofunctional aliphatic alcohols, polyols, aliphatic or aromatic amines and mixtures thereof.
- Preferred monofunctional aliphatic polyols for the end group are monofunctional polyalkylene oxides, siloxanes, and mixtures or copolymers thereof.
- Examples of aliphatic polyols are monofunctional polyethylene oxides, monofunctional polytetramethylene oxides, monofunctional polypropylene oxides, monofunctional siloxanes, and mixtures and/or copolymers thereof. However, others are also suitable.
- the monofunctional amines of the end group may be selected from the group consisting of dialkylamines, amine-functional siloxanes, amine-terminated polyalkylene oxides and mixtures and copolymers thereof.
- the hard segment of the copolymer of the invention may preferably have a molecular weight of about 160 to 10,000, and more preferably about 200 to 2,000. Its components also have preferred molecular weights as shown in Table 11 below.
- the content of hard segment of the copolymer is typically about 5 to 45 wt %, the remainder of the polymer consisting of soft segment, which may be a combination of hydrophilic, hydrophobic and amphipathic oligomers.
- the copolymer comprises about 9 to 30 wt % of the hard segment, and more preferably 10 to 28 wt % thereof.
- a typical content of the soft segment is about 91 to 70 wt %, and more preferably about 90 to 72 wt %.
- other proportions of hard and soft segments are also suitable for practicing this invention.
- a polymer made from this composition will have the properties described in Table 13 below.
- This invention also provides a non-porous, semi-permeable, biocompatible film that comprises the block copolymer of the invention.
- the film is formed from the copolymer of this invention.
- the film is coated onto a support.
- the film is an integrated part of the substrate and is made of the same or similar polymer.
- the non-porous film of the invention is provided in the form of a flexible sheet and a hollow membrane or fiber.
- the flexible sheet may be prepared as a long rollable sheet of about 10 to 15 inches width and 1 to 6 feet length. However, other dimensions may also be selected. Of particular importance is the thickness of the sheet which may be about 5 to 100 microns, and more preferably about 19 to 25 microns when it is to be used without support or reinforcement.
- the flexible sheet is prepared from the block copolymer of the invention by methods known in the art, typically, by casting, and more preferably by casting on a web or release liner.
- the composition may be coated as a film onto a substrate.
- a reinforcing web e.g., a fabric
- the film or membrane may be thinner, e.g., as thin as about 1 micron, whereas when used unsupported the thickness may only be as low as about 5 to 10 microns.
- membranes When membranes are fabricated from the polymer of the invention by knife-over-roll casting onto a release paper, web or liner in the form of dry films, they may have an about 1 to 100 micron nominal thicknesses on a continuous coating line.
- a 20-foot-long continuous web coater may be utilized having, e.g., a maximum web width of 15 inches equipped with two forced-air ovens.
- the coater may be modified for clean operation by fitting the air inlet ducts with High Efficiency Particulate Air (HEPA) filters.
- HEPA High Efficiency Particulate Air
- a nitrogen-purged coater box may be used to hold and dispense filtered polymer solutions or reactive prepolymer liquids.
- other set-ups are also suitable.
- a casting solvent e.g., dimenthylformamide
- a coating solvent e.g., dimenthylformamide
- HEPA filters After membrane casting, membrane and substrate may be further dried to reduce residual solvent content to less than about 100 ppm, as determined by liquid chromatography.
- the thickness of the fully-dried cast films may be measured by, e.g., using a spring micrometer sensitive to 0.0001 inch (2.5 ⁇ M) or visually by using a microscope.
- the membrane of this invention may have any shape resulting from a process utilizing a liquid which is subsequently converted to a solid during or after fabrication, e.g., solutions, dispersions, 100% solids prepolymer liquids, polymer melts, etc. Converted shapes may also be further modified using methods such as die cutting, heat sealing, solvent or adhesive bonding or any of a variety of other commonly-used fabrication methods.
- the membrane when in the form of a hollow tube, the membrane is generally prepared with a diameter of about 0.5 to 10 mm , and more preferably about 1 to 3 mm, and a thickness of about 1 to 100 microns, and more preferably about 19 to 25 microns.
- the hollow membrane may easily be prepared in long rollable form, and be cut to a length of about 0.75 to 31 inches, and more preferably about 0.5 to 6 inches.
- Hollow fibers may be fabricated from the polymer solutions by dipping clean, dry, mandrels, e.g., a 1 mm diameter stainless steel mandrel into the polymer solution.
- the mandrel may be suspended in a baffled chamber maintained at above normal room temperature, e.g., about 27° to 50° C., in a Class 1,000 Cleanroom.
- the mandrel may be attached to a motor driven cable and dipped into the polymer solution and withdrawn at an even speed and the solvent may be allowed to evaporate.
- the mandrel may then be inverted, hung and dipped again. This procedure may be repeated, e.g., three times, to yield a tube with a single wall thickness of, e.g., 19 microns.
- the mandrels may then be left in the heated chamber for at least 16 hours to allow the solvent to evaporate.
- the coated mandrel may be soaked in distilled water for, e.g., one hour.
- the removal of any remaining residual solvent may be achieved by water extracting the hollow fibers in distilled water for, e.g., 24 hours.
- the hollow fibers may then be flushed three times with distilled water and packaged in distilled water in clean glass tubes. Prior to filling the hollow fibers they may be leak-tested. One end of the hollow fiber may be heat-sealed, the fiber filled with distilled water and the remaining end heat-sealed.
- the filled hollow fiber may then be pressurized and the tube examined for water leakage under pressure.
- the fabrication methods just described employ liquid solutions or reactive liquid prepolymers of the membrane polymers.
- thermoplastic fabrication methods may also be employed.
- Membrane polymers made by the bulk or solvent-free polymerization method described above may be cast into, e.g., a teflon-lined pan during the polymerization reaction. As the reaction proceeds and the polymerizing liquid becomes a rubbery solid, the pan may be postcured in an oven at, e.g., 100°-120° C. for about 1 hour. Upon cooling, the rubbery mass may be chopped into pellets and dried in a dehumidifying hopper dryer for, e.g., about 16 hours.
- the dry pellets may then be compression molded, e.g., at about 175° C. to form a flat membrane which, when cool, will leave a thickness of about 50 ⁇ M.
- Extrusion, injection molding, calendering and other conversion methods that are well-known in the art may also be used to form membranes, films and coatings of the polymers of the present invention, including hollow fibers.
- the non-porous film of the invention is substantially permeable to molecules of molecular weight of up to about 6,000 to 600,000, and more preferably of up to about 6,000 to 60,000, and is substantially impermeable to molecules of molecular weight greater than about 6,000 to 600,000 daltons, and more preferably greater than about 100,000.
- the utility of a specific membrane is based on its ability to allow the permeation of desired permeants while preventing the permeation of other permeants, including all condensed phases of matter. It is within the scope of the present invention to provide membranes with permeability to permeants of up to about 600,000 daltons and higher, while simultaneously excluding permeants of higher molecular weight and/or lower solubility.
- the soft segment composition, content and molecular weight may be varied during polymer synthesis.
- polyether oligomer for example, may be obtained in molecular weights ranging from a few hundred to a few thousand. To achieve molecular weight cutoffs higher than those obtainable with commercially-available soft segment oligomers, available soft segment oligomers may be coupled together prior to the synthetic reaction to obtain the final membrane polymer.
- a so-called three-step reaction in which the first step involves covalently bonding two or more oligomers together, while optionally retaining the oligomer's original end-groups by appropriate control of the stoichiometry of the coupling reaction.
- the first step involves covalently bonding two or more oligomers together, while optionally retaining the oligomer's original end-groups by appropriate control of the stoichiometry of the coupling reaction.
- three moles of hydroxyl-terminated polyether oligomer might be reacted with two moles of a diisocyanate optionally chosen to be different from the isocyanate used in the hard segment of the final polymer.
- a diisocyanate to couple soft segment oligomers minimizes the association of the coupling segment with the hard segment of the polymer, which is desireable for maximum permeability.
- the coupled oligomer would have an average molecular weight of about 6,000 plus the molecular weight of the two diisocyanates used in the urethane-forming coupling reaction.
- the maximum end-to-end distance between hard segments is increased more than three times, relative to the original 2,000 molecular weight oligomer before coupling.
- an organic diisocyanate is used to couple soft segments, and that diisocyante is chosen to be different from the diisocyanate used in the hard segment, the coupling diisocyanate is considered to be part of the soft segment.
- low hard segment lengths of molecular weights e.g., about 160 to 1,000, and a proportion of hard to soft segment of about 1 to 11, and more preferably about 1 to 6.
- the purity, molecular weight and water content of the starting materials were determined by titration.
- the polyurethanes were synthesized in glass batch reactors with glass-distilled solvents using a two-step prepolymer/chain extension method as described in Example 2.
- the film forming polymer used was a polyurethaneurea with a diphenylmethanediisocyanate/ethylene diamine hard segment and a hydrophobic and hydrophilic mixed polyalkyleneoxides soft segment.
- a series of five elastomers with nominal hydrophilic contents of 0, 10, 20, 30, 40 and 50 wt % were synthesized by the two step, prepolymer/chain extension method described in Example 2 in dimethylformamide (DMF) solvent.
- the optimum molecular weight of each polyol was determined to be about 1,400 and 2,000 and then fixed for the whole series of polymers, subject to availability from commercial suppliers.
- Infrared spectrophotometry and/or titration were used to monitor the disappearance of isocyanate to assure the completion of the reaction.
- the content of the hard segment was held constant at about 20 wt % for a series of polymers.
- the membrane casting solution of each polymer was filtered through a 10 micron 316 woven stainless steel filter and outgassed under mild vacuum prior to film casting.
- Membranes were fabricated from the polymers of the above examples by knife-over-roll casting onto a release paper, web or liner in the form of dry films of 1 to 100 micron nominal thicknesses on a coating line.
- a 20-foot-long continuous web coater was utilized, that had a maximum web width of 15 inches and was equipped with two forced-air ovens.
- a nitrogen-purged coater box was used to hold and dispense filtered polyurethane solutions.
- a casting solvent such as dimenthylformamide
- HEPA filters HEPA filters
- membrane and substrate were further dried to reduce residual solvent content to about 100 ppm, as determined by liquid chromatography. The thickness of the fully-dried cast films were measured using either a spring micrometer sensitive to 2.5 microns or visually using a microscope.
- a 1 wt % glucose solution was prepared in phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- eight permeation chambers with similar membranes were used. The experiment was repeated utilizing membranes of increasing hydrophilicity, between 0% and 85%. As the hydrophilicity is increased, the permeability of the membrane increases while the permeation time decreases.
- the glucose concentration on the downstream side of each chamber was determined using a quantitative glucose oxidase enzymatic assay.
- the test sample was added to a mixture containing glucose oxidase, peroxidase and o-dianisidine. The reaction was allowed to proceed to completion, for approximately 45 minutes at 23° C.
- the final color intensity was measured at 450 nm on a Milton Roy Visible Spectrophotometer, Model Spectronic 20D, and found to be proportional to the glucose concentration.
- a calibration curve was generated by plotting the glucose concentrations from 0 to 3000 ⁇ g/ml (0 to 3 mg/ml) vs. the absorbance at 450 nm. The data were analyzed using linear regression to generate the line with the best fit. This correlation was used to calculate the glucose concentration in the unknown samples.
- FIG. 1 of this patent contains these data for membranes of increasing hydrophilicity.
- the curves of FIG. 1 were generated using the averaged data from two chambers for each point.
- the first seven polymers in this series i.e., 0 to 66% hydrophilicity inclusive
- the polymer with 85% hydrophilicity had an 8,000 dalton soft segment molecular weight and a glucose permeability of 29,000.
- the mechanical properties in tension of the polymers prepared in Example 4 were determined according to ASTM procedure D1708.
- a Lloyd Universal Testing Machine, Model 500N, and a 112 pound load cell was used to evaluate the polymers.
- the initial modulus, tensile strength at break, and the ultimate elongation were calculated for water-extracted, solvent-cast films.
- the films were equilibrated at 23° C. and 50% relative humidity for 24 hours prior to testing.
- Microdogbone samples of both dry and hydrated films were used to determine the tensile properties at 23° C. for each polyurethaneurea.
- the hydrated samples were prepared by placing the films in water for 24 hours, die cutting the samples and returning them to the water.
- the permeability coefficient P may be expressed in different units by applying suitable conversion factors. Data obtained for various proteins are shown in Table 21 below.
- the oxygen permeability was determined for various membranes prepared with the polymers of this invention using a Createch 201 T Permeometer and a Rehder flat polargraphic cell in a 100% humidity chamber at 35° ⁇ 0.2° C. For each material reading four 13 mm circles of material were stacked together on the electrode. All materials were fully hydrated in 0.9% saline and incubated at 35° C. prior to readings being taken. The readings for three different samples of each material were averaged to produce the average reading in micro amps. The central thickness of each sample was measured with a micrometer. The central thickness of each material were averaged to produce the average thickness in cm. The results of the experiment are shown in Table 22 below.
- Example A is a polymer made from the reaction of MDI with and amine-terminated siloxane.
- Examples B through F are polymers made from reacting MDI with a hydrophilic/hydrophobic soft segment and then chain extending with ED. The ratio of hydrophilic to hydrophobic content in the soft segment was varied, with Example B being the most hydrophobic and Example F the most hydrophilic.
- Example G has a MDI/ED hard segment, a mixed hydrophobic/hydrophilic soft segment and was chain terminated with dibutylamine.
- Hollow fibers of 1 mm nominal diameter and 19 micron thickness assessed by diffusion studies were dip cast on stainless steel mandrels, dried and water extracted from a 8% solids solution of the copolymer in dimethylformamide prepared as described in Example 2.
- Hollow fibers were fabricated from the polymer solutions by dipping clean, dry 1 mm diameter stainless steel mandrels into the polymer solution.
- the mandrels were suspended in a baffled chamber maintained at 37° C. in a Class 1000 Cleanroom.
- the mandrel was attached to a motor driven cable and dipped into the polymer solution and withdrawn at an even speed. Time was allowed for the solvent to evaporate.
- the mandrel was inverted, hung and dipped again. This procedure was repeated three times to yield a tube with a single wall thickness of 0.75 mil. Multiple dippings were performed to reduce the chances of pinholes in the polymer hollow fibers.
- the mandrels were left in the heated chamber for at least 16 hours to allow the solvent to evaporate.
- the coated mandrel was soaked in distilled water for one hour. The removal of any remaining residual solvent was achieved by water extracting the hollow fibers in distilled water for 24 hours. The hollow fibers were then flushed three times with distilled water and packaged in distilled water in clean glass tubes. Prior to filling the hollow fiber with islet cells the hollow fibers were leak tested. One end of the hollow fibers was heat-sealed, the tube was filled with distilled water and the remaining end was heat-sealed. The filled hollow fiber was pressurized and the tube was examined for water leakage.
- the extracted hollow fibers were then sterilized by "liquid cycle” autoclave sterilization and stored in a sterile environment until they are used.
- Optimal diffusion of intracellular products out of a membrane implant is achieved, in part, by maintaining an even distribution of the cells within the membrane.
- hydrophilic natural polymers to encapsulate mammalian cells.
- mammalian cells have been microencapsulated through crosslinking using, for example, alginate and polylysine.
- One drawback to microencapsulation using certain crosslinked hydrophilic polymers is the tendency of crosslinked polymers to biodegrade.
- alginates and some vegetable gums are capable of forming high water content gels suitable as encapsulating agents. Gels where the water content is higher than 99.5% have been produced. The high water content of these gels provides these gels with high permeability to the various permeants important to hybrid artificial organs. Even at very high water contents, these gels are very viscous and thus capable of immobilizing cells dispersed within the gel.
- one drawback to the use of some of these acrylic hydrogels is their biodegradability, particularly when the gels are implanted as microcapsules directly into tissue.
- a preferred embodiment of the instant invention is the use of a hydrophilic gel with a water content ⁇ of about 35% water but preferably ⁇ 90% water inside of a dense, semi-permeable polymer membrane.
- the dense membranes of the instant invention provide immunoisolation and necessary selective permeability while also providing an absolute barrier to cells.
- the water swollen gel fixes the position of the cells within the dense membrane (e.g. in the shape of a hollow fiber) to prevent bunching.
- the high water content of the water swollen gel provides low resistance to the permeability of species leaving or arriving at the contained cells.
- the dense membrane may also provide a biostable protective layer to the water-swollen gel, thus preventing or reducing biodegradation of the gel.
- Suitable dense membranes include but are not limited to hydrophilic or amphipathic polyurethanes having ⁇ about 20% water but preferably ⁇ 50% water but less equilibrium water content than the water-swollen gel. Water content is measured in water @ 37° C. and expressed as a percentage of the wet weight of the sample after maximum weight gain has occurred. This value is determined by weighing the polymer wet and again after the polymer has been dried to equilibration at standard laboratory conditions, e.g. ⁇ 23° C. and 50% relative humidity.
- Suitable hydrogels are alginates (e.g. sodium alginate, ammonia alginates, potassium alginates, propylene glycol alginates, algins), guar gum, gum tragacanth, locust bean gum, methocel, xanthan gum, polyethylene oxide, polypropylene oxide, dextrans, acrylates, methacrylates, polyvinyl alcohol, polyvinyl pyrolidone and combinations of the above.
- alginates e.g. sodium alginate, ammonia alginates, potassium alginates, propylene glycol alginates, algins
- guar gum e.g. sodium alginate, ammonia alginates, potassium alginates, propylene glycol alginates, algins
- guar gum e.g. sodium alginate, ammonia alginates, potassium alginates, propylene glycol alginates, algins
- gum tragacanth e.g. sodium alginate, ammonia al
- Those gums or resins capable of "crosslinking” may be used crosslinked or linear.
- sodium alginate may be used "as is” or converted to its insoluble calcium form.
- the most preferred hydrogel is calcium alginate wherein the water content is greater than about 90%.
- the devices further comprise a hydrogel, that comprises greater than about 35% water, within the cavity of the device.
- the hydrogel serves to immobilize the cells within the device, thus insuring an even cell distribution within the device.
- the most preferred embodiment of the instant invention comprises the implantation of a dense membrane in the form of hollow fibers where the hollow fiber is filled with calcium alginate with a water content greater than about 90%.
- the geometry of the dense membrane can be in any form including sheets, larger diameter tubes, etc.
- MVTR moisture vapor transmission rates
- E-96-80 Procedure B Two variations of the ASTM E96-80 method are presently popular.
- the first, called the Upright-Cup method, is known as E-96-80 Procedure B.
- E-96-80 Procedure B standard cups are filled with water to a prescribed depth and sealed with the sample.
- the cups are accurately weighed and placed upright in an environment maintained at 23° C. and 50% relative humidity (RH) with an air velocity of 500 to 600 ft/minute parallel to the sample.
- the sample is in contact with the vapor space within the cup, which is also at 23° C. and 100% RH.
- weight loss versus time at steady state is measured and used to calculate MVTR from the area of the sample.
- the vapor pressure driving force ( ⁇ V.P.) in the ASTM E-96 Procedure B is a constant 10.5 mm Hg.
- the other is the Inverted-Cup method, Procedure BW.
- the conditions for this procedure are in general similar to those used in the upright cup method, except that the cup is inverted so that water contacts the sample.
- MVTR values there are few published tabulations of polymer MVTR values available.
- One mil film values may be calculated from their published water vapor permeability constants as described above.
- the MVTR value as determined by the Upright Cup method, may vary over nearly four orders of magnitude, from ⁇ 0.1 for polyvinylidenechloride to >800 g/M 2 /day for the present hydrophilic polyurethanes. Although part of the variation is due to the varying levels of crystallinity within the range of polymers cited, the wide range of values illustrates that very significant changes in permeability may be obtained through changes in membrane chemistry.
- the inventors developed an analytical model for the non-steady-state diffusion of solutes in a closed diffusion cell, which is well suited for conducting protein permeability studies utilizing two-chamber dialysis/diffusion cells.
- the use of these simple cells allows several experiments to proceed in parallel due to the small size and simplicity of the apparatus.
- the membranes are hydrated and the diffusion cells are assembled and leak-tested, then completely filled with, e.g., solute-free phosphate-buffered saline (PBS) in one chamber, chamber 2, and solute-containing PBS in a second chamber, chamber 1. No air interface is allowed between the two chambers.
- PBS solute-free phosphate-buffered saline
- the cells may be placed on a gentle mechanical shaker, e.g., in an incubator with temperature control for maintaining the temperature at, e.g., 37° C.
- the permeant concentration in chamber 2 may be measured by sensitive calorimetric methods using a visible light spectrophotometer and appropriate reagent kits.
- the flux of permeant through a membrane is proportional to the concentration driving force across the membrane, c1-c2, and the membrane area, a, and inversely proportional to the membrane thickness, 1.
- the permeability coefficient, p is the proportionality constant linking the solubility and diffusivity coefficients and the liquid film resistance together.
- ceq is the equilibrium concentration in both chambers.
- the driving force in membrane permeation is the difference between the upstream concentration, c1, and the downstream concentration, c2, of the permeant.
- p permeability coefficient (ugcm/daycm 2 g/mL).
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Water Supply & Treatment (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Polyurethanes Or Polyureas (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Manufacture Of Macromolecular Shaped Articles (AREA)
Abstract
A biocompatible, hydrophilic, segmented block polyurethane copolymer which comprises 5 to 45 wt % of a hard segment and 95 to 55 wt % of a soft segment selected from a hydrophilic, hydrophobic and amphipathic oligomer is disclosed. The copolymer is capable of forming a non-porous, semi-permeable film of a tensile strength greater than 300 and up to 10,000 psi, and has an ultimate elongation greater than 300% and up to 1,500% and a water absorption such that the sum of the volume fraction of absorbed water and the hydrophilic volume fraction of the soft segment exceeds about 100% and is up to about 2,000% of the dry polymer volume. The film is permeable to cell nutrients and waste molecules of up to about 6,000 to 600,000 molecular weight and is substantially impermeable to cells and particulate matter. A non-porous, semi-permeable, biocompatible film is formed from the block copolymer of the invention in the form of a flexible sheet or a hollow fiber. Also disclosed is a method of permeating molecules of a predetermined molecular weight range while preventing the passage of larger molecular weight molecules, cells, and condensed phases of matter between two fluids comprising interposing between the two fluids the non-porous film of the invention.
Description
This application is a CIP of Ser. No. 07/874,336, now abandoned filed Apr. 24, 1992.
1. Field of the Invention
This invention relates to a biocompatible, hydrophilic, segmented block copolymer that comprises hard and soft segments in a predefined proportion. The copolymers have hydrophilic or amphipathic soft segments that provide permeability to films and membranes prepared therefrom due to their lyophilicity, hydrophilicity and molecular weight, and hard segments that provide high cohesive energy reinforcement. The polymers of the invention may be cast into flexible sheets and/or hollow membrane shapes. The copolymers of this invention form strong, optically-clear, dense membranes which are selectively permeable to gases, ions, proteins and other macromolecules. The molecular weight cut-off of the membrane is controlled by varying the soft segment content, soft segment polarity/hydrophilicity and soft segment molecular weight.
2. Description of the Background
In general, polyetherurethane block or segmented copolymers exhibit good biocompatibility along with high strength and elastomeric properties. This unique combination of properties is due in part to the two-phase morphology of the polyurethane molecule. In a typical polyurethane, aggregated aromatic or aliphatic urethane or urea segments constitute a hard glassy or semicrystalline phase, while low glass transition temperature (Tg) oligomeric segments comprise the liquid-like, rubbery soft phase or segment. The morphology of a polyurethane depends on many factors, including hard and soft segment chemistry, segment polarity differences, hard segment content, and hard and soft segment molecular weights.
In both polyurethaneureas and polyurethanes, the chemistry of the soft segment affects the degree of phase separation in the polymer, which in turn affects its bulk and surface properties and subsequent biocompatibility. Polyurethaneureas, similar to the ones disclosed in this patent only as to their hard segment compositions, have been shown to be resistant to degradation in several applications (Paynter, et al., "The Hydrolytic Stability of Mitrathane, a Polyurethaneurea--An X-ray Photoelectron Spectroscopy Study", J. Biomed. Mater. Res. 22:687-698 (1988); Szycher, et al. "Blood Compatible Polyurethane Elastomers", J. Biomater. Appl. 2:290-313 (1987)).
The application of natural and synthetic polymer membranes to the separation of gaseous and liquid mixtures of low molecular weight has been reported in a number of reviews. Many studies of membrane permeability to simple low molecular weight (MW) permeants have been reported in which the composition of glassy-rubbery or crystalline-rubbery copolymers are varied. A polyurethane multipolymer membrane different from the one disclosed herewith has been shown to be water and salt permeable. In thermoplastic segmented block copolymers where one block or segment is glassy or crystalline (hard segment) and another is rubbery or liquid-like (soft segment), the permeation of molecules occurs primarily through the soft segment. The relatively impermeable hard segment, provides physical integrity to the polymer by virtue of its strong intermolecular interactions with like segments on adjacent molecules, even under conditions which may cause swelling of the soft segment.
Okkema, et al. discloses a series of polyether polyurethanes based on polyethylene oxide (PEO), polytetramethylene oxide (PTMO) and mixed PEO/PTMO soft segments suitable as blood contacting surfaces, but with a hard segment content of 55 wt %, too high to be useful in the present invention. (Okkema et al., "Bulk Surface and Blood-Contacting Properties of Polyurethanes Modified with Polyethylene Oxide", J. Biomater. Sci. Polymer. Edn.1(1):43-62 (1989)).
Takahara, et al. discloses the preparation of Segmented Poly (etherurethaneureas) (SPUU) with hydrophilic and hydrophobic polyether components. (Takahara et al., "Surface Molecular Mobility and Platelet Reactivity of (SPUUS) with Hydrophilic and Hydrophobic Soft Segment Components", J. Biomater. Sci. Polymer. Edn. 1(1):17-29 (1989)). Platelet adhesion and dynamic contact angle measured after adsorption of bovine serum albumin revealed that the SPUUs with hydrophilic soft segments had a non-adhesive surface.
Chen, et al. examines the relationship between structure and properties of polyether based polyurethanes. (Chen et al., "Synthesis, Characterization and Permeation Properties of Polyether Based Polyurethanes", J. Appl. Polym. Sci. 16: 2105-2114 (1972)). Of particular interest is the testing of the transport of water and low molecular weight salt through polymeric membranes made of elastomers that are block copolymers consisting of hard and soft segments, with the former acting as physical crosslinks.
U.S. Pat. No. 3,804,786 to Sekmakas discloses water-dispersible cationic resins, particularly polyurethane resins prepared by reaction of a resinous polyepoxide with a polyisocyanate to provide an hydroxy-functional polyurethane with tertiary amine functionality. These resins are useful for electrode position at the cathode.
U.S. Pat. No. 3,826,768 to Suzuki and Osonol discloses a process for preparing polyurethane compositions by dispersion of polyurethane-containing isocyanates made from polyols and organic isocyanates in water under specified conditions.
U.S. Pat. No. 3,852,090 to Leonard et al. discloses the utilization of a urethane film for waterproofing a breathable textile substrate.
U.S. Pat. No. 4,124,572 to Mao relates to thermoplastic polyurethanes prepared by a specified method. The thus produced elastomers are useful for automotive products, applications such as cattle ear tags, coatings and coated fabrics.
U.S. Pat. No. 4,183,836 to Wolfe, Jr. discloses a water-based polyurethane dispersion and its preparation by reacting an aliphatic diisocyanate with three critical active hydrogen compounds to form a pre-polymer containing carboxyl and free isocyanate groups, and then dispersing the pre-polymer in an aqueous medium with a tertiary amine and a diamine. These dispersions are useful in coating applications such as textile materials.
U.S. Pat. No. 4,190,566 to Noll et al. relates to non-ionic, water dispersible polyurethanes with substantially linear molecular structure and lateral polyalkylene oxide polyether chains containing ethylene oxide units of specified content.
U.S. Pat. No. 4,202,880 to Fildes et al., discloses sustained release delivery means comprising a biologically active agent, i.e., a drug, a linear hydrophilic block polyoxyalkylene-polyurethane copolymer, and optionally a buffer. A single hydrophilic soft segment is used. Only the hard segment is hydrophobic.
U.S. Pat. No. 4,202,957 to Bunk, et al. discloses polyurethane polyether-based elastomers which are thermoplastic and recyclable, and have increased high temperature resistance that makes them suitable for injection molding.
U.S. Pat. No. 4,224,432 to Pechhold et al. discloses a polyurethane comprising a reaction product of a polymerizate of tetrahydrofuran and an alkylene oxide, an organic polyisocyanate and a chain extender which is an aliphatic polyol or a polyamine. 2001.
U.S. Pat. No. 4,367,327 to Holker et al. relates to a breathable polyurethane film for coating fabrics to make them waterproof. The polyurethane film comprises in stoichiometric amounts a hard segment made of a low molecular weight diisocyanate with a difunctional compound, and a soft segment comprising polyethylene glycol. The mechanical properties of the film are improved by crosslinking with a triisocyanate.
U.S. Pat. No. 4,849,458 to Reed et al. discloses a hydrophilic, segmented polyether polyurethane-urea exhibiting increased tensile strength and elongation when wet with water. The polymers form clear films that are permeable to water vapor.
Many of these materials are segmented polyurethane elastomers. Some of them, moreover, have found biomedical applications virtually without being modified. However, despite their widespread use, many biomaterials were originally developed for nonmedical uses. In fact, most polyurethane materials were developed to satisfy high volume, industrial needs. A most notable example is DuPont's LYCRA® Spandex, a polyurethane utilized in the fabrication of circulatory support device components. This material was later sold under the trade name BIOMER® Segmented Polyurethane.
AVCOTHANE-51® resulted from the combination of two commercially available polymers, a silicone and a polyurethane, both of which are widely used as fabric coatings. AVCOTHANE-51® is utilized in biomedical devices such as an intra-aortic balloon. The sole improvements introduced for its biomedical applications were the use of highly purified starting materials, the filtration of the product solution and clean conditions for the fabrication of blood-contacting surfaces. Another biomedical polyurethane, AVCOTHANE-610®, also called CARDIOMAT-610®, and ANGIOFLEX® are presently being used in blood pumps and trileaflet heart valves.
The thermoplastic material PELLETHANE® was first applied to the manufacture of cannulae for blood vessels, and later of catheters. This material had originally been developed as an extrusion molding resin exhibiting superior hydrolytic stability than their polyester-based counterparts. Table 1 below lists some of the biomedical polyurethanes available in the U.S. market.
The known materials listed in Table 1 below may be essentially divided into two groups, where for each group one material is derived from the previous one, and so on.
TABLE 1 ______________________________________ Biomedical Polyurethanes ______________________________________ AVCOTHANE-51/CARDIOTHANE-51 (10% silicone) AVCOTHANE-610/CARDIOTHANE-610/ANGIOFLEX Biothane BIOMER/LYCRA Spandex/Mitrathane BPS-215 Estane 5714 Extrudable BIOMER PELLETHANE 2363/Renathane Superthane Tecoflex Texin Tygothane Vialon ______________________________________
If the polyesterurethanes, which exhibit low hydrolytic stability, are eliminated from the list, two classes of polyetherurethanes remain. These are the polyurethanes containing solely urethane groups, and polyurethaneureas, which also contain urea groups. Table 2 below lists some of the common reactants used in polyurethane synthesis.
TABLE 2 ______________________________________ Reactants of Biomedical Polyurethanes ______________________________________ POLYETHER H(O--CH.sub.2 --CH.sub.2 --CH.sub.2 --CH.sub.2 --).sub.n OH polytetramethylene oxide (PTMO) polytetramethylenetherglycol (PTMEG) polytetrahydrofuran (poly(THF)) DIISOCYANATE OCN--Ph--CH.sub.2 --Ph--NCO 4,4-diphenylmethane diisocyanate (MDI) CHAIN EXTENDERS HO--CH.sub.2 --CH.sub.2 --CH.sub.2 --CH.sub.2 --OH Polyurethanes: Butane Diol (BD) H.sub.2 N--CH.sub.2 --CH.sub.2 --NH.sub.2 Polyurethaneureas: Ethylene Diamine (ED) ______________________________________
The majority of useful biomedical elastomers are those prepared from polyether glycols. A most commonly-used polyether glycol is a product of the ring-opening polymerization of tetrahydrofuran (THF). This polyether is known mostly as polytetramethylenetherglycol (PTMEG), polytetramethyleneoxide (PTMO) and polytetrahydrofuran (poly(THF)). The present inventors have found that polyurethanes containing only soft segments of PTMO are impermeable to permeants as low as 180 daltons MW (glucose) and are, therefore, unsuitable for use in the present invention.
The most commonly used diisocyanate is 4,4-diphenylmethanediisocyanate (MDI). MDI-based polyurethane elastomers generally have physical and mechanical properties that are superior to polymers prepared from tolylene diisocyanate (TDI), or the aliphatic diisocyanates such as hexamethylene diisocyanate (HDI) and dicyclohexanediisocyanate (HMDI), a hydrogenated MDI analogue. Aliphatic diisocyanates produce non-yellowing polymers upon exposure to ultraviolet radiation and are thus extremely desirable for industrial and apparel coating applications. HMDI hard segments are often too miscible with the polyether segments to provide the degree of phase separation required to achieve optimal mechanical properties. This is particularly true at elevated temperatures, such as 37° C., which significantly decrease the physical strength of a polymer. Phase separation is, therefore, important for attaining good physical properties in polyurethane elastomers. This relationship is discussed further below.
The reaction of isocyanate groups with low molecular weight difunctional reagents leads to chain extension, and to the formation of hard segments connecting the polyether soft segments through urethane groups. If the chain extender is a diol, the hard segment has repeat units connected by urethane groups, whereas if it is a diamine, the hard segment comprises urea groups. In the later case, the resulting polymer is referred to as a polyurethaneurea, although in common useage, both groups are often referred to as polyurethanes. Some of the properties of these elastomers are shown in Table 3 below.
TABLE 3 ______________________________________ Biomedical Polyurethane Properties POLYURETHANES POLYURETHANEUREAS e.g, PELLETHANE 2363.sup.1 e.g., BIOMER.sup.2 ______________________________________ moderate phase separation good phase separation thermoplastic solvent cast (unless H.sub.2 O extended) >70A shore hardness low hardness/modulus possible moderate toughness extreme toughness moderate hysteresis/creep low hysteresis/creep good flex fife excellent flex life severe distortion in autoclavable autoclave ______________________________________ .sup.1 MDI/PTMO/BD .sup.2 MDI/PTMO/ED
The chemical composition of the permeable, rubbery phase of a block copolymer may be varied in this invention without resulting in a significant variation in its total volume fraction or glass transition temperature. Polyurethanes like the PELLETHANE 2363® series are moderately phase-separated thermoplastics generally having a shore hardness of 70A or higher. These polymers are reasonably tough and resistant to fatigue, but exhibit a high level of hysteresis or creep under load. These polyurethanes are usually unable to withstand autoclaving without distortion and molecular weight reduction. Polyurethaneureas like BIOMER® are more highly phase-separated elastomers which are generally manufactured in solution unless the diamine chain extender is completely replaced by water, as it is in the extrudable BIOMER® polymer. When the total content of hard segment is lowered, useful urea-containing urethanes are obtained. These are elastomers approaching natural rubber characteristics. Both BIOMER® and the polyether PELLETHANES® have pure PTMO soft segments and are unsuitable for use in the present invention.
A combination of high elongation at break and high ultimate tensile strength make the polyurethaneureas tougher than the corresponding polyurethanes. Their low hysteresis or creep properties, however, are probably their most outstanding feature. Polyurethaneureas exhibit excellent flex life when subjected to biaxial strain, such as in a blood pump. Finally, polyurethaneureas can withstand one or two autoclave cycles without evidencing a significant decrease in molecular weight or physical properties. This is indicative of a superior ability to retain their properties at elevated temperatures relative to their polyurethane analogues.
Although many polyurethanes and polyurethaneureas are available commercially, some of which were discussed above, none forms membranes of permeability, strength, flexibility and biocompatiblity required for growing cells by permitting the passage of nutrients, cell products and cell waste materials while preventing the passage of immunological or microbiological substances that might be detrimental to cell growth and the manufacture of cell products.
This invention relates to a biocompatible, hydrophilic, segmented block polyurethane copolymer, comprising
about 5-45 wt % of at least one hard segment;
about 95-55 wt % of at least one soft segment, comprising at least one hydrophilic, hydrophobic or amphipathic oligomer selected from the group consisting of aliphatic polyols, aliphatic or aromatic polyamines and mixtures thereof; the copolymer being capable of forming a substantially non-porous, semi-permeable film having a tensile strength greater than about 350 psi and up to about 10,000 psi, an ultimate elongation greater than about 300% and up to about 1,500% and a water absorption such that the sum of the hydrophilic volume fraction of the soft segment and the absorbed water volume fraction is greater than about 100% and up to about 2,000% of the dry polymer volume and greater than about 50% and up to about 95% of the wet polymer volume and being permeable to molecules of molecular weight up to about 6,000 to 600,000 daltons and substantially impermeable to cells and particulate matter.
This invention also relates to a non-porous, semi-permeable, biocompatible film formed from the block copolymer described above.
Also encompassed herein is a method of permeating molecules of a predetermined molecular weight range while substantially preventing the passage of cells and particulate matter between two fluids, the method comprising interposing between the two fluids a non-porous, semi-permeable, biocompatible film formed from the copolymer of the invention.
A more complete appreciation of the invention and many of the attendant advantages thereof will be readily perceived as the same becomes better understood by reference to the following brief description of the drawings.
FIG. 1 depicts the variation in glucose permeability vs. time through dense membranes of the inventor with varying hydrophilicity. The wt % hydrophilic content or hydrophilicity is as follows: A (85%); B (66%); C (50%); D (40%); E (30%); F (20%); G (10%); H (0%).
FIG. 2 shows the correlation of membrane tensile strength vs. hydrophilic content of the polymers of the present invention. In every case the tensile strength of the hydrated membrane is lower than that of the dry membrane. The difference is small, however, and useful polymers may be obtained even at high hydrophilic contents.
FIG. 3 is a representation of the variation of the capacity for water absorption of the membrane of this invention with increasing hydrophilicity.
Other objects, advantages and features of the present invention will become apparent to those skilled in the art from the following discussion.
This invention arose from a desire by the inventors to improve on existing polymer technology to regulate, by varying certain parameters of the polymer composition, the permeability of the membranes obtained therefrom. Thus, by keeping the hard segment structure fixed, for example, the inventors have provided a co-polymer composition where they can vary the soft segment compostition, soft segment molecular weight and proportion thereof to the hard segment. The variation of these parameters provides a plurality of membranes of specifically tailored permeabilities.
This invention provides strong, biocompatible, hydrophilic segmented block polyurethane copolymers comprising a minor volume fraction of short hard segments and amphipathic or hydrophilic soft segments. Soft segment molecular weight, soft segment chemistry, and soft segment concentration may be chosen so that the resulting block copolymer absorbs sufficient water and the sum of the volume fraction of water and the volume fraction of hydrophilic soft segment exceed about 50% of the total volume of the water-swollen polymer. More preferable, the volume of absorbed water alone equals or exceeds about 50% of the total volume of the water-swollen polymer. In both cases the water-swollen polymer has an apparent continuous phase of hydrated soft segment and/or water which permits the permeation of macromolecules into, and through, the copolymer. This is particularly true when the copolymer is prepared in the form of a membrane, film or coating.
Although many of the copolymers disclosed herein possess hard segments which are polyurethanes or polyureas, the nature of the hard segment is a relatively unimportant determinant of the permeability of the resulting copolymers. Since the hard segments are essentially impermeable, their major function is to provide physical strength to the copolymer while existing as a separate molecular phase from the soft segment(s). In all cases maximum permeability to proteins and other macromolecules is achieved at minimum hard segment content. Therefore, when maximum permeability is required of the copolymer, its total hard segment is chosen to be no higher than required to provide sufficient strength for use in the intended application. Since hard segments other than polyurethanes and polyureas can often provide the required strength, it is within the scope of the present invention to employ copolymers with hard segments other than polyurethanes or polyureas.
Examples of suitable hard segments include those which when prepared as homopolymers have melting points (Tm) or glass transition temperatures (Tg) above 37° C. and preferably above about 60° C. in the dry state and which have melting points or glass transition temperatures above 37° C. in the fully hydrated state when initially hydrated at 20° to about 37° C.
Suitable hard segments have the optional requirement that, if present at sufficiently-high molecular weight and total concentration in the copolymer, they form a separate molecular phase from the soft segment(s) such that a distinct Tg or Tm is measurable in the copolymer, which must be within the above-specified range and which is also greater than the major Tg or Tm of the soft segments when the copolymer is fully hydrated. It should be noted that if the hard segment content is low and/or if the hard segment molecular weight is low, available instruments may be unable to detect the dominant thermal transition of the hard segment, hence the statement that detectability of Tg or Tm is an optional requirement.
Based on these requirements it can be seen that possible hard segments with the specified thermal transitions and water resistance which can be used in the present invention include a wide variety of chemical compositions. This is further illustrated by the following list of examples which is not intended to be all-inclusive or to limit the scope of the invention: aromatic and cycloaliphatic polyethers, polyesters, preferably aromatic polyesters, polyamides, polyimides, polycarbonates, polyolefins, polyacrylates, polydienes, polyacetals and other homopolymers, copolymers or multipolymers which have Tg or Tm greater than 37° C. in the hydrated state and preferably greater than about 60° C. in the hydrated state.
Furthermore, although essentially linear polyurethane(urea) copolymers are presented as exemplary copolymers, it is possible to achieve the required strength for certain applications by replacing some or all of the high-cohesive-energy hard segments with covalent crosslinks. Suitable crosslinks may be obtained through the use of multi-functional reagents employed in the synthesis or membrane casting steps and/or crosslinking may be achieved by a variety of methods known in the art which involve the use of various kinds of radiation to crosslink the polymer during or after it is converted to a configured shape, often through the inclusion of suitable reagents which become reactive when exposed to radiation. In polymers which derive significant strength from covalent crosslinks and posses little or no hard segment content, it is expected that hard segment Tg or Tm will be absent or unmeasurable by currently-available instrumental methods.
Furthermore, although essentially linear polyurethane(urea) copolymers are presented as exemplary copolymers, it is possible to achieve the required permeability and strength by incorporating branching or grafting along the backbone of the polymers of the present invention. One method of introducing branch points is through a combination of reactants having functionality greater than two together with monofunctional reactants. For example, a monofunctional polyalkyleneoxide may be reacted with a trifunctional isocyanate to produce a difunctional isocyanate with a pendant polyalkyleneoxide chain. The modified diisocyanate may then be used in the synthesis of a copolymer with branched or graft structure. Other methods of achieving branching and grafting are well known to those skilled in the art and are considered to be within the scope of the current invention.
Regardless of the hard segment chemistry or the presence or absence of covalent crosslinks, branch points or grafted side chains, the resulting polymer must retain sufficient water absorptivity and molecular weight between crosslinks (or molecular weight between hard segments defined later as "spacer length") to possess an apparent continuous aqueous phase in the fully-hydrated state. The exact hard segment content or crosslink density that is required to maintain a water-rich phase greater than about 50 vol % will vary for each specific polymer, but is easily measured gravimetrically by hydrating essentially dry polymer and noting the weight change if polymer density is known, or volume change upon hydration by displacement of a fluid of known specific gravity or direct measurement with, e.g., calipers. Polymers suitable for the practice of this invention will absorb sufficient water such that the total of the volume fraction of absorbed water and the volume fraction of the water-absorbing hydrophilic soft segments, which may be calculated from the density and weight fraction of hydrophilic soft segment present, exceeds about 50 vol % of the total volume of the fully-hydrated polymer. More preferable are copolymers which absorb sufficient water so that the volume fraction of absorbed water alone exceeds about 50 vol % and up to about 95 vol % of the total volume of the fully-hydrated polymer.
In the practice of the present invention the hard segment can also include a linkage between polyols or polyamines formed by a single diisocyanate without the use of chain-extending reagents.
While it is often desirable to use the polymers of the present invention in the form of films and membranes in unsupported form, it may also be useful to apply the polymers as coatings, laminations or impregnations to reinforcing substrates. Suitable substrates may be woven or knitted fabrics, microporous polymer structures, including integral microporous structures made of the polymers of the present invention, glass or carbon fiber mats and the like. These are known in the art and need not be further described herein. Particularly desirable substrates are expanded polytetrafluoroethylene, expanded polypropylene, expanded polyethylene, sintered ultra-high molecular weight polyolefins, carbon fiber fabrics, sintered carbon, woven dacron, knitted dacron, dacron velour and the polymers of this invention either as a separate substrate or as an integral part of the membrane. However, others are suitable as well.
Also provided herein is a non-porous, semi-permeable, optically-clear biocompatible film, membrane or coating formed from the block copolymer of this invention.
The optically-clear, non-porous, semi-permeable, film, membrane or coating formed from the block copolymer of this invention allows direct visual observation through the film or membrane. Also provided herein is a method of permeating molecules of molecular weights of up to about 6,000 to 600,000 daltons, and sometimes higher, while preventing the passage of condensed matter, and cells between two fluids, the method comprising interposing between the two fluids the non-porous polymer membrane, film or coating of this invention.
Chemistry, molecular structure and macroscopic structure affect the permeability and selectivity of a polymer membrane. Macroscopic structure, particularly the presence or absence of permanent pores, also determines the mechanism by which permeation will occur.
Two different mechanisms of permeation through membranes are discussed in the following paragraphs. These are the ones associated with non-porous or dense membranes and in microporous membranes.
In a microporous membrane, the passage of gases, vapors and solutes occurs through small capillary-like pores that inhibit the passage of larger molecules and cells, but which may eventually become clogged with oversized permeants restricting the passage of desirable permeants. Since microporous membranes have pores that are larger than the wavelength of visible light, they are invariably opaque or translucent in color, precluding the possibility of direct or microscopic observation of the contents of membrane containers. A non-porous or dense membrane acts in general as an absolute barrier to cells and other condensed phases of matter, but may be made selectively permeable to predetermined gases, vapors and/or solutes. Since dense membranes have no permanent pores that are larger than the wavelength of visible light, they can be water-clear or transparent in color. This is a very significant improvement over opaque microporous membranes, particularly in in vitro cell culture applications.
The mechanisms which provide selective permeability in microporous and non-porous dense membranes are quite different. As a result, the characteristics of these two types of membranes differ. For the purpose of this discussion, water-swollen membranes are considered to be dense if they are dense in their dry state. The inventors have found that permeation through pre-hydrated, water-absorbing membranes appears to follow simple Fickian diffusion kinetics as discussed below, even when a protein is the permeating species.
It has generally been accepted that high molecular weight molecules could not pass through dense membranes due to their large size and/or low solubility in the membrane polymer. The following description of the phenomenon of permeation through dense membranes will explain the mechanism the inventors believe is responsible for permeation through the membranes of the present invention that are non-porous or dense membranes, and will clearly differentiate the membranes of the present invention from conventional micorporous membranes.
In pinhole-free, dense polymeric membranes, it is known that the transmission of low molecular weight solutes, such as vapors and incondensible gases, occurs generally by activated diffusion. The driving force in activated diffusion is a concentration gradient within the membrane. The permeant first dissolves in the surface of the membrane on the side of highest concentration, and then diffuses across the film. Upon arrival at the opposite surface, the permeant desorbs and may then enter the surrounding space as a gas or vapor, or enter a liquid stream adjacent to the membrane's desorption surface.
The development of a concentration gradient within the membrane arises from a concentration difference in the phases that are in direct contact with each face of the membrane. The driving force for diffusion is the difference between the concentrations of permeant dissolved in the two faces of the membrane. For simplicity's sake, this is often reported as the concentration difference between the two adjacent phases. A linear relationship between the concentration of permeant in the phase in equilibrium with the film and the actual equilibrium concentration of permeant dissolved in the film, is assumed by Henry's Law, which holds for many polymers, to be represented by the mathematical equation
c=sp (I)
wherein
c is the concentration of permeant in the polymer film,
p is the concentration of permeant in equilibrium with the film, and
S is the solubility coefficient for the polymer.
In the simple case of the permeation of water through a dense membrane, made from nonpolar membrane polymers which absorb very little water, [e.g., polyethylene and polypropylene], SH20 is independent of p. For polymers which absorb larger amounts of water, S may change with p. In general, the solubility of the permeant in a dense membrane is an important determinant of permeability, because it establishes a maximum driving force that can exist within the film. Since solubility generally decreases as molecular weight of the solute increases, the solubility of proteins in any polymer membrane designed to permit their permeation is of particular importance. Fick's Law governs the rate of transport of the permeant through the thin film under the existing concentration gradient in accordance with the following mathematical equation
q=-D dc/dx, (II)
wherein
q is the amount of permeant diffusing through a unit area of the film per unit time,
dc/dx is the concentration gradient across a thickness dx, and
D is the diffusion constant for the specific polymer/permeant system.
If D is unaffected by the local concentration, c, then integration across the film thickness, l results in the following equation
q=D(c.sub.1 -c.sub.2)/l, (III)
wherein
c1 and c2 are the concentrations in the two surfaces of the film.
If c1 and c2 are related by Henry's law to the concentration of permeant in equilibrium with the two film surfaces, then equation (III) results in the equation (IV) below
q=DS(p.sub.1 -p.sub.2)/l, (IV)
wherein
the product of the diffusion constant D and Henry's Law constant or solubility coefficient, S, is known as the permeability constant p. Thus, equation (IV) is equivalent to equation (V) below.
p=DS=q1/(p.sub.1 -p.sub.2), (V)
wherein p has units of volume times thickness divided by area, driving force and time. It can be clearly seen from equation (V) that the rate of permeation depends on both the diffusivity D and solubilty S of the permeant in the membrane polymer.
The p values for many polymer/permeant pairs may be found in the literature, but only for cases in which the permeant is a relatively low molecular weight gas, vapor or solute. No such values are available for the permeation of proteins through dense polymer membranes.
A simple inspection of equation (IV) reveals that the permeation rate of a specific non-porous film is directly proportional to the concentration difference and film area, and is inversely proportional to the film thickness.
In the design of a membrane polymer for use in the present invention the permeability coefficient, p, may be maximized through changes in polymer chemistry or structure which maximize D and S for the desired permeant. These changes will increase both the water uptake and the segmental mobility of the polymer.
Our finding that a dense membrane in which water or a water-swollen hydrophilic soft segment phase comprises a major component, e.g., greater than about 50 vol %, protein diffusion rates may be comparable to, although lower than their diffusion rates in water is an important aspect of the present invention. High equilibrium water content may significantly increase protein solubility in the hydrated membrane relative to the membrane's dry state. Since dense-membrane permeability depends on both the diffusivity and the solubility of the permeant in the membrane phase, a membrane polymer with high water content may be permeable to high molecular weight, water-soluble permeants by presenting a water-like continuous phase through which the permeant may easily pass (diffusivity enhancement) and an aqueous environment in which the permeant may easily dissolve (solubility enhancement).
Some polymer properties influencing the permeability constant are discussed below.
Crystalline polymers are generally considered to be completely impermeable. In semicrystalline polymers, an increase in crystallinity produces a decrease in permeability. This effect can be quite significant at the phase inversion point when the continuous phase, which is usually the phase present at >50% volume fraction, changes from amorphous to crystalline. Certain membrane polymers of the present invention may also form impermeable crystalline regions within the soft segments when the membrane polymer is in the dry state. On hydrating, however, we have found that these crystalline regions become amorphous and readily permit the passage of relatively high molecular weight permeants.
An amorphous polymer will be more permeable as a rubbery material at a temperature above its glass transition temperature (Tg) than in its glassy state below Tg. Silicone rubber, for example, has a Tg of -120° C. When at room temperature, it is 140° C. above its Tg, and it is, therefore, extremely permeable to a number of gases and vapors. Silicone is virtually impermeable to water-soluble permeants of high MW, however, since its hydrophobicity results in very low solubilites of permeant in the polymer, which absorbs little or no water. In segmented polymers, such as polyurethaneureas, where the hard segment is glassy or crystalline and the soft segment is rubbery, permeation occurs primarily through the rubbery phase. If the content of hard segment is increased to a point where it becomes the continuous phase, the permeability coefficient, p, drops significantly. An important aspect of the polymers of the present invention is that the soft segment Tg is relatively low due to the choice of reactants and due to the placticizing effect of absorbed water and that the impermeable hard segments comprise a minor volume fraction of the water-swollen polymer.
The greater the solubility of a permeant in the hydrated polymer, the greater the concentration gradient of permeant that may exist within the polymer. The difference between the solubility parameters of the permeant and the polymer is one way of expressing this property. However, specific interactions normally exist between the polymer and the permeant which make any predictions based solely on the solubility parameter less than accurate. One such specific interaction involves hydrogen bonding between (water-swollen) polymer and permeant. More specifically, reversible hydrogen bonding among water molecules, chemical groups on the polymer, and chemical groups on the permeant molecules may play an important role in facilitating permeability of proteins through dense membranes of the present invention.
As indicated above, the chemical structure of a polymer may be varied, and this variation may be used to maximize the permeability of a dense film made from that polymer to a specific permeant. However, at the present time, an understanding of the exact relationship between the structure of the polymer and the permeant selectivity obtained by a membrane during solute separation is lacking. Any a priori prediction of permeability, thus, remains difficult.
Crosslinking generally decreases the permeability of a membrane, particularly to large molecules, such as proteins. At low crosslink density, however, the permeability of low molecular weight solutes may be only slightly affected. The crosslinking of polyurethanes, for example, may be the result of certain side reactions during polymer synthesis which form allophanate and/or biuret groups, the reaction of polyfunctional reagents to form urethane or urea groups, or because of exposure to radiation. For any of these cases, high levels of crosslinking may have a significant negative effect on the permeation coefficient of proteins and other macromolecules, although low to medium levels may be useful in enhancing the strength of the membranes, particularly in the hydrated state. It is an important feature of the present invention that the amount of crosslinking in membranes, films and coatings be kept low enough so that the previously-stated water absorption requirements are met.
Stretching and orienting a film generally reduces its permeability constant p, primarily because of denser molecular packing or increased crystallinity, which occur as a result of the orientation.
A substantial sorption of water by a polymer film increases the diffusion constant D due to swelling and plasticization. Thus, water absorption by the membrane polymers of the present invention can increase permeability by both Tg-lowering plasticization, and by a reduction in crystallinity of the hydrophilic domains relative to their crystallinity in the dry state. The affinity, or solubility, S, of the water-swollen polymer to water-soluble permeants such as proteins is also related to polymer water absorption, since a water-swollen soft segment capable of hydrogen bonding with sorbed water, will appear to the permeant to be more water-like than the dry polymer.
The present inventors have found that by carefully choosing the soft segment chemistry to enhance water absorption, and by limiting the (impermeable) hard segment content such that it comprises a minor volume fraction of the water-swollen polymer membrane, protein permeability may be achieved. The present inventors have also found that an additional structural variable is important in determining the upper molecular weight of solutes which will permeate through the polymer membrane (i.e. selectivity): segment molecular weight or, more precisely, segment molecular length.
As previously mentioned, the soft segment comprises the permeable, but weak phase of the membrane polymer. The hard segment comprises the strong, impermeable phase of the membrane polymer. The much higher cohesive energy density of the hard segment gives it the ability to add strength to the overall polymer, but contributes essentially no permeability to the polymer (membrane). Thus it may be assumed that all permeation occurs through the soft segment. It has also been mentioned that the most effective hard segments are those with the best phase separation from the soft segment. That is, on a molecular scale, the most desirable hard segments are those that separate into domains containing like hard segments on adjacent polymer chains, while the soft segments comprise a separate phase. In an aqueous environment, the soft segment will also contain an amount of absorbed water which can vary from nearly zero to very high levels, depending on the inherent hydrophilicity of the soft segment oligomers.
Since the soft segment oligomers are, on average, covalently bonded at each end to a hard segment, it is clear that the maximum spacing possible between the impermeable hard segments is related to the length of the soft segment oligomer. Thus a critical molecular dimension for permeation of large molecules is set by the average soft segment molecular length. For essentially linear soft segment oligomers, molecular length is directly proportional to molecular weight. It follows then that increasing soft segment oligomer molecular weight should increase the maximum molecular weight of solutes which may permeate through the polymer. This effect may be applied to tailoring membrane permeability by choosing soft segment oligomer molecular weight. A typical commercially-available polyether oligomer, for example, may be obtained in molecular weights ranging from a few hundred to a few thousand daltons. To achieve molecular weight cutoffs higher than those obtainable with commercially-available soft segment oligomers, another approach is possible. Available soft segment oligomers may be coupled together prior to the reaction used to synthesize the final membrane polymer.
In polyurethane synthesis, a so-called three-step reaction can be employed in which the first step involves covalently bonding two or more oligomers together while optionally retaining the oligomer's original end-groups by appropriate control of the stoichiometry of the coupling reaction. For example, three moles of hydroxyl-terminated polyether oligomer might be reacted with two moles of a diisocyanate chosen to be different from the isocyanate used in the hard segment of the final polymer. Using a different diisocyanate to couple soft segment oligomers is optional but preferable since it minimizes the association of the coupling segment with the hard segment of the polymer. This is the desired situation for maximum permeability. In this example, if the original polyol molecular weight was 2,000 daltons, the coupled oligomer would have an average molecular of 6,000 plus the molecular weight of the two diisocyanates used in the urethane-forming coupling reaction. When this coupled oligomer is subsequently reacted to form the final membrane polymer, the maximum end-to-end distance between hard segments would be increased more than three times, relative to the original 2,000 molecular weight oligomer before coupling.
The maximum end-to-end distance of the optionally-coupled soft segment oligomer is referred to herein as a "spacer length". In the inventors' theoretical model of the membrane polymer, the spacer length is a determinant of the upper molecular weight cut-off of the membrane polymer. The relationship between the maximum permeant molecular weight which can pass through a membrane may not be a linear function of the spacer length. A permeant which assumes a roughly spherical conformation might increase its spherical diameter in proportion to the cube root of its molecular weight. A rod-like permeant, on the other hand, might increase its major dimension in direct proportion to its molecular weight. Furthermore, there is additional uncertainty associated with the relationship between average distance between impermeable hard segments and the molecular weight/length of the soft segment oligomer "spacers". It is likely that in the dry membrane polymer the soft segment oligomers assume a somewhat random coil conformation, or they may be folded into crystalline domains. Upon water immersion and absorption, if there is significant water uptake and optional vitrification of the soft segment crystalline regions, a volume increase will result. As the polymer membrane increases in volume, the now amorphous, coiled oligomers may assume a more linear conformation, making average spacer length closer to the soft segment oligmer end-to-end distance. An additional effect of increased soft segment molecular length may be that longer chain length between hard segments permits the formation of a smaller number of hard segment domains, albeit of larger size. This effect could be caused by increased mobility of hard segments tethered through covalent bonds to very long soft segment spacers. For a spherical hard segment domain, domain volume increases with the cube of the diameter. A small increase in domain diameter may result in a large decrease in the number of hard segment domains impeding the transport of high molecular weight solutes, resulting in an increase in permeability to high MW permeants.
Short hard segment length enhances permeation of high MW solutes for the same reason that long soft segment length does. It is therefore desirable to minimize hard segment length. This must be done without decreasing total hard segment content, e.g., weight fraction of hard segment, below a critical minimum, since the strength of the polymer decreases with total hard segment content. For a given hard segment content and soft segment molecular weight, the hard segment length is minimized at maximum membrane polymer molecular weight. Too high a molecular weight, however, causes fabrication difficulties due to excessively-high melt or solution viscosities. In the present invention, membrane polymer molecular weight is controlled by chain-stopping through the addition of monofunctional reagents to the reaction mixture, or through the use of a stoichiometric imbalance of one of the reactants. Furthermore, by selecting certain hydrophilic monofunctional chain-stoppers the permeability of the polymers of the present invention can be enhanced. This may be attained by adding to the total hydrophilic content of the polymer while also limiting molecular weight to a desired range.
The polymers of the present invention may be synthesized to have a specific permeability to a given permeant and/or to have a specific molecular weight cutoff, by implementing an empirical, yet systematic approach. The empirical nature of the method is mandated by the nature of the phenomenon of permeability through dense membranes, the properties of specific permeants or non-permeants, including their solubility properties, molecular size and conformation. The inventors provide herein a systematic approach to the production of membrane polymers in accordance with the present invention, which may be used to tailor membrane properties for specific applications. This is described briefly in the following paragraphs.
The permeation of solutes through dense polymeric membranes is determined for the most part by the diffusivity and solubility of the permeants in the membrane polymer. If the membrane polymer absorbs a significant amount of the solvent, then the permeation of the solutes will be determined by the diffusivity and solubility of the permeants in the solvent-swollen membrane polymer.
The absorption of a solvent, e.g., water, by the membrane polymer requires that the polymer have some affinity for the solvent. In addition, by definition, the solvent must be capable of dissolving the solute/permeant. It follows, thus, that the absorption of the solvent by the membrane may increase contribution of the solubility factor to the permeability coefficient by making the environment within the membrane polymer more like the pure solvent than it was in the dry state.
In general, in addition to enhancing the solubility of the permeant in the membrane polymer, a low molecular weight solvent will often act as a plasticizer for the membrane polymer. Plasticization involves a degree of dissolution of the polymer by the plasticizer. Furthermore, as the level of plasticizer/solvent increases, the glass transition temperature of the mixture will generally decrease. A decreased glass transition temperature suggests that the plasticizer may facilitate the relative movement of macromolecular chains by inserting themselves between adjacent chains to increase the intermolecular spacing there between. In addition to the above, plasticizer/solvents may reduce the degree of possible polymer-polymer interactions through specific interactions between the polymer and the plasticizer/solvent. A reduction in the soft segment crystallinity upon hydration, which occurs with certain membrane polymers of the present invention, is an example of the latter mechanism.
In the case of an isotropic polymer membrane, significant solvent absorption/swelling will produce a measurable increase in the physical dimensions of the membrane, e.g., along each of the x, y and z axes, by an amount approximately equal to the cube root of the volume fraction of the solvent absorbed therein. This provides direct evidence that the polymer chains have increased intermolecular distance in the swollen state since the same number of polymer molecules are now contained in a larger total volume. This increased spacing and facilitated movement of polymer chains may increase permeability by increasing the diffusivity contribution to the permeability coefficient.
Thus, the absorption of a solvent by a membrane polymer may enhance the membranes permeability by increasing both the diffusivity and the solubility of a particular permeant. One method of tailoring the membrane of the present invention to obtain a specific permeability rate and/or molecular weight cutoff, is to vary the composition and morphology of the membrane. This will effect an enhancement of the amount of solvent absorbed, and of the extent of solubility and diffusivity that results from greater solvent absorption.
Although in some instances it may not always be possible to make exact quantitative predictions of the permeation characteristics of the resulting membrane, the inventors have found that certain qualitative and quantitative relationships exist which guide the process. Furthermore, the permeability of candidate membranes may be performed with the methods described by the inventors herein. The structure vs. property relationships provided herein may be used to adjust the permeability properties of the membrane through an iterative process of synthesis, membrane casting and permeability measurement, until the desired values for the intended use are attained.
In the examples provided in Table 4 below it is assumed that the permeant is a water-soluble macromolecule and that the solvent is water or an aqueous fluid. Those skilled in the art will know that similar approaches may be applied that are suited for other solvent/permeant systems by modifying the soft segment to facilitate the absorption of a non aqueous solvent, for example.
TABLE 4 __________________________________________________________________________ Membrane Polymer Structure Versus Property Relationships Variable Effect __________________________________________________________________________ Increasing Soft Segment Increases water absorption at constant soft segment hydrophilicity Molecular Weight and constant soft segment content (++) Increases permeability rate (+++) Increases molecular weight cutoff (++) Increases (dry) soft segment crystallinity (++) Decreases (dry) tensile modulus unless soft segment crystallizes (-) Increases ultimate tensile elongation unless soft segment crystallizes (+) Increasing Soft Segment Increases water absorption at constant soft segment molecular Hydrophilicity weight and constant soft segment content (+++) May increase soft segment crystallinity if hydrophilic segments crystallize (++) Increasing Hard Segment Decreases permeability rate (---) Content Increases tensile strength (++) Increases tensile modulus (+++) Increases wet strength (++) Increased Hard Segment Increases permeability rate at constant hard segment content (+) Domain Size Mixing Two or More Soft Increases permeability rate when it decreases soft segment Segments crystallinity (++) Can be used to increase solubility of permeant in polymer (by adding groups which have an affinity for permeant) and therefore increases permeability (++) Crosslinking At Low Crosslink Increases permeability if used to obtain strength by significantly Density reducing hard segment content. (++) Can decrease permeability rate and molecular weight cutoff at higher crosslink density (---) __________________________________________________________________________ (+) and (-) refer to the nature of the effect and its intensity: (+++) = Strong positive effect. (-) = Weak negative effect, etc.
When permeation occurs by transport through "large" pores, e.g., greater than about 0.1 micron, the transmission rate through a microporous membrane is generally directly proportional to the film area and the concentration driving force. However, the transmission rate is affected far less by the thickness of the film than it is in monolithic films. On the other hand, the porosity of a microporous membrane is a major determinant of the permeability rate. A microporous membrane made from polyethylene, polycarbonate, polyvinylchloride or other polymers and copolymers which are glassy or crystalline at the use temperature, e.g., 37° C., will transport polar permeants primarily through its pores. For that type of membrane, therefore, permeability increases and strength decreases with total porosity or void volume fraction.
The application of microporous membranes to the concentration-driven transport of large molecules, such as proteins present in a medium, poses several problems. Since only the pores of the membrane are available for the mass transfer of large molecules, the fraction of the total area of the membrane available for permeation is limited. This slows the rate of transfer of molecules across the membrane. Porous membranes which work well in pressure-driven separation such as ultrafiltration, exhibit much lower permeation rates when used in concentration-driven processes in which pressure is not or can not be applied to the upstream side of the membrane. Usually, highly porous membranes also lack strength and present a rough surface to blood and tissue alike. Furthermore, the pores become easily clogged by the adsorption of a protein or, in blood-contacting applications of the membrane, a build-up of a thrombus or fibrin mat. All these effects dramatically reduce transport rates. A reduced transport rate is likely to slow the response of cells placed on the other side of the membrane and may even produce an undesirable out-of-phase/positive-feedback of, e.g., insulin release, at low glucose levels, in the case of glucose-sensitive insulin-producing cells. As the transport of nutrients and other necessary molecules is further reduced, the cell viability will become threatened. Dense membranes lacking pores, having therefore microscopically smooth surfaces, in accordance to this invention, reduce or eliminate these problems.
The careful consideration of the known properties of various types of biocompatible polymers, and the inventors' experience with urethanes in particular, led to the utilization of polyurethanes for the preparation of copolymers that are flexible, strong, biocompatible, non-porous, and inexpensive and which at the same time have specific permeability characteristics. By practicing the present invention, the quality, safety and efficacy of the product is assured. The development of the present polyurethane was undertaken to ensure the attainment of desirable strength and elastomeric properties along with high quality, safety and efficacy of any films and membranes produced therefrom.
The following paragraphs will mostly refer to a copolymer of 4,4'-diphenylmethane diisocyanate (MDI), polytetramethylene oxide (PTMO), and ethylene diamine (ED). The copolymer will serve to exemplify the invention which is not limited to it. The chemical structure often used to represent a polyurethaneurea obtained by a reaction of MDI, PTMO, and ED, a copolymer of this invention, is structure (2) in Table 5 below. However, the information provided herein by means of example is applicable in general to all copolymers in accordance to this invention. This, therefore, applies to hard segments other than the ones exemplified.
TABLE 5 __________________________________________________________________________ Structure of Four Exemplary Polyurethanes of Increasing __________________________________________________________________________ Hydrophilicity ##STR1## ##STR2## ##STR3## ##STR4## ##STR5## ##STR6## __________________________________________________________________________ PSX = polydimethylsiloxane (i.e. silicone), PTMO = polytetramethyleneoxide PEO = polyethyleneoxide
In the last three structures of the series ((2), (3), and (4)), the hydrophilicity increases as concentration of ether oxygens in the soft segment increases. Ether oxygens are the preferred hydrophilic group for the practice of the present invention, especially the ether oxygens present on the polyethyleneoxide (PEO) and PEO-containing copolymers, multipolymers and blends.
When PEO homopolymers are used as the sole soft segment, it is particularly preferred to use high molecular weight oligomers, preferably above about 1,000 daltons, and most preferably above 3,000 daltons, for the reasons already stated. PEO ether oxygens readily absorb and hydrogen bond with water, without giving rise to a permanent adsorption of the permeants, which would otherwise retard or prevent permeation through the membranes of the present invention. On the other hand, it is possible to utilize other hydrophilic groups in the soft-segment for practicing of the present invention, including hydroxyl, carboxyl and/or other ionic groups alone, or in various combinations, to achieve a desired water absortivity.
The copolymers of the invention may be prepared by one-step, two-step or three-step synthetic methods depending on the complexity of the chemical structure desired. Examples of polymers prepared by all three methods are provided below. The one-step method is exemplified in Table 6 below.
TABLE 6 __________________________________________________________________________ Polymer Obtained From a MDI/BD/PEO One-Step Synthesis __________________________________________________________________________ ##STR7## ##STR8## wherein A is about 4 to 23000, preferably about 4 to 180; X is about 1 to 25, preferably about 1 to 15; Y is about 1 to 20, preferably about 1 to 10; Z is about 1 to 20, preferably about 1 to 10; and the end groups may vary. __________________________________________________________________________
In the one step synthesis, all the reactants are added to the reaction chamber at the same time. In the example cited above, the end groups on the polymer may vary depending upon which polyol reacts with the isocyanate e.g., (MDI) and the exact stoichiometry of the reaction mixture. The end group could be butanediol (--OH), polyethylene oxide (--OH), or isocyanate (--NCO) residues.
The two-step method is exemplified in Table 7 below.
TABLE 7 __________________________________________________________________________ A MDI/ED/DBA/PEO/PPOPEO Polymer Prepared by Two-Step Synthesis __________________________________________________________________________ ##STR9## ##STR10## ##STR11## wherein A is about 1 to 23000, preferably about 4 to 180; B is about 4 to 400, preferably about 4 to 200; C is about 1 to 100, preferably about 4 to 75; W is about 1 to 25, preferably about 1 to 15; X is about 1 to 25, preferably about 1 to 15; Y is about 1 to 20, preferably about 1 to 10; and Z is about 1 to 20, preferably about 1 to 10. __________________________________________________________________________ The PPOPEO polyol may be either a block or random copolymer.
The three-step method is exemplified in Table 8 below.
TABLE 8 __________________________________________________________________________ A TDI/PEO/MDI/ED/DBA Polymer Prepared by Three-Step Synthesis __________________________________________________________________________ ##STR12## ##STR13## ##STR14## wherein A is about 4 to 23000, preferably about 4 to 180; X is about 1 to 25, preferably about 4 to 15; Y is about 1 to 25, preferably about 4 to 15; and Z is about 1 to 20, preferably about 4 to 10. __________________________________________________________________________
As already indicated, the synthetic pathways of these methods will be generally discussed by reference to the particular examples provided. However, an artisan would know how to extend the knowledge acquired herein to the synthesis of other copolymers in accordance with this invention. The exemplified prepolymer, for example, may be made using a combination of different polyols or polyamines or mixtures thereof.
By means of example, in a two-stage reaction, the DBA, PTMO and the MDI may be first reacted to form an isocyanate-terminated prepolymer. Preferred conditions for this step are as follows. The prepolymer may then be chain extended with ethylene diamine (ED) at low temperatures, such as about 0° to 70° C., and preferably about 5° to 10° C., to give a high molecular weight, segmented polymer. In a typical solution polymerization, e.g., using urethane-grade reactants and reagent grade solvents, enough water may be present as an impurity to consume a significant portion of the isocyanate groups present. This reaction will generate carbon dioxide and a urea group, that will couple two MDI residues with no methylene groups there between. These structures will be present in proportion to the amount of water present in the reactants and solvent. The hard segments produced in each reaction may be expected to contribute differently to the properties of the polymer, e.g., by changing the degree of phase separation from the soft segment. Many other reactions, such as side reactions, further complicate the structure of the polymer of the invention, thus making any simple representation of the copolymer approximate. The side reactions may create difficulties for any prediction of structure vs. property relationships as well as increase the likelihood of batch-to-batch variations in the characteristics of the copolymer of the invention. The use of pure, dry reactants and anhydrous reaction conditions, and the use of chain-terminating reagents aids in the control of the overall polymer molecular weight minimizes side reactions and gives polymer structures more closely approximating the ideal or theoretical structure.
In the development of the polyurethane copolymers of the invention, the elastomers are designed to have excellent physical characteristics, such as toughness and elongation. In addition, the copolymers of this invention are designed as a family of materials with a broad range of modulus and hardness that may be tailored for many particular applications. Although tailoring of permeability properties of the copolymer of this invention is often of primary importance, within the structural constraints of the required permeability, it is also possible to tailor physical properties as well. In most cases the polymers of the present invention will have the desired protein and/or macromolecular permeability and also possess excellent physical properties as well. The fact that excellent physical properties can be obtained is of particular importance in maintaining barrier properties of the membranes, i.e., exclusion of unwanted cells and high molecular weight permeants. A high level of toughness when compared to certain gels and hydrocolloids permits the copolymers of the present invention to be fabricated into many useful shapes while still maintaining physical integrity of the membrane. Of particular importance is the ability to fabricate very thin, unsupported membranes, often less than 30 μM in thickness. The importance of thickness in determining necessary permeation rate has been described above. Some typical physical properties of membranes of the present invention are listed in Table 9 below.
TABLE 9 ______________________________________ Characteristics of Copolymers of Invention (Measured Dry) Characteristic Value ______________________________________ Tensile Strength ≧≈350 psi Elongation at Break ≧≈300% Initial Modulus ≈75 to 20,000 psi ______________________________________
Because of an interest in preparing polyurethanes of different moduli, the relationship between modulus and total hard segment content is sometimes important. For the polyurethanes of the present invention, the hard segment content is defined herein as the weight of diisocyanate plus chain extender, and hydrophobic chain terminator, if present, divided by total polymer weight. A linear proportion is found between initial, i.e., measured at less than 10% strain, modulus and hard segment over a range of about 9 to 30% hard segment content. Linear, not crosslinked, elastomers of about 9% hard segment and below have properties similar to unvulcanized rubber and are, therefore, not of particular interest for the present use as unsupported films or membranes. They may be used, however, as coatings or impregnations on porous reinforcing substrates.
At high elongations, the pure soft segment may undergo reversible crystallization, giving an increased modulus and a somewhat reduced ultimate elongation. The thus resulting polymer also possesses excellent strength and certain other desirable properties.
TABLE 10 ______________________________________ Copolymer Characteristics Characteristics Range ______________________________________ Tensile strength > about 350 and up to about 10,000 psi Elongation at Break > about 300% and up to about 1,500% Water Absorption + > about 100% and up to Hydrophilic Soft Segment > about 2,000% dry wt > about 50% and up to about 95% wet weight or more preferably: Water absorption only 100% and up to > about 2,000% dry wt about > about 50% and up to about 95% wet weight ______________________________________
The diisocyanate and all reactants which contribute an active hydrogen, i.e., polyols, diamine, amines, may be added in a proportion of about 0.9 to 1.2 and more preferably about 0.95 to 1.1. The reactants may be added to a solvent of the following characteristics.
Suitable solvents are organic solvents that partially or completely stabilize or suspend the various reagents utilized in the preparation of the polymer. Preferred solvents are generally polar liquids and may include, but are not limited to, dimethylacetamide, dimethylformamide, dimethylsulfoxide, 2-methyoxyethanol, n-methylpyrrolidone, pyridine, and tetrahydrofuran. Combinations of these solvents may also be used.
The solution of diisocyanate and polyalkylene oxide in a solvent is preferably about 40 to 85 wt % solids, more preferably about 50 to 80 wt % solids, and still more preferably about 75 wt % solids. However, it may be varied within a broader range.
The polyalkylene oxide reagent typically has a molecular weight of about 200 to 9,000, although other ones may be utilized.
The diisocyanate may be an aromatic or an aliphatic polyisocyanate. The diisocyanates may be selected from the group consisting of alkyl diisocyanates, arylalkyl diisocyanates, cycloalkylalkyl diisocyanates, alkylaryl diisocyanates, cycloalkyl diisocyanates, aryl diisocyanates, and cycloalkylaryl diisocyanates, which may be further substituted with oxygen, and mixtures thereof. However, others are also suitable.
The reaction may be conducted at a temperature of about 50° to 130° C., and more preferably about 55° to 60° C. for aromatic isocyanates and about 100° to 110° C. for aliphatic isocyanates, and a pressure of about 0.1 to 100 atm, and more preferably about 0.1 to 10 atm. Preferred are atmospheric pressure and an atmosphere free of moisture and oxygen.
The reaction will in general go to completion in about 3 hours, and it may be conducted with agitation.
The thus obtained polymer or prepolymer will, in general, have a molecular weight of about 300 to 1,000,000, and more preferably, about 5,000 to 60,000.
The reagents and solvents should preferably be of high purity if the best results are desired. However, other grade reagents and solvents may also be utilized.
In general, as indicated above, the synthesis of polyurethanes is affected by moisture. Accordingly, all equipment utilized for synthesizing the copolymers of the invention should be thoroughly dried before use. All steps of the preparation thus should, in general, be maintained substantially water-free. Caution, in addition, should be exercised not to expose any reactants or solvents to atmospheric moisture. Moreover, some of the substances utilized for the synthesis of the copolymers of the invention, such as diphenyl methane diisocyanate (MDI), are highly toxic. Accordingly, the use of a respirator and gloves and adequate mechanical ventilation is recommended when handling them. Combustible solvents, such as dimethylformamide, which are suitable for use herein, are absorbed through the skin. Accordingly, any vapor breathing and skin contact with these compounds must be avoided.
One general procedure for preparing the copolymer of the invention is as follows. The polyols may be blended together under essentially anhydrous conditions, preferably under vacuum and a nitrogen atmosphere at a temperature of about 100°-110 ° C. until their water content is, e.g., less or equal to about 250 ppm. This value is usually attained in about 1 to 1.5 hours. A clean, dry nitrogen-purged reactor may then be filled with the dry polyol blend. A polyol or polyamine, such as dibutyl amine may then be accurately weighed and added to the reactor, and a solvent, such as dimethylformamide (DMF), may be added to a concentration of about 40 to 85% solids, and more preferably about 75% solids to form a pre-polymer, and the mixture may then be stirred, e.g., at about 30 to 40 rpm. A diisocyanate, such as 4,4'-diphenylmethane diisocyanate (MDI), may be added at this point. The content of the reactor may then be heated to about 60° C. with a variation of about 2° C. The reaction is then allowed to continue for, generally, about 3 hours at this temperature, noting the temperature at regular intervals throughout. At the end of the 3 hours, the reaction is stopped by cooling, e.g., in an ice bath. The temperature of the solution at this point should be about 15° C. with a margin of 2° C. for starting the chain extension reaction. The thus obtained pre-polymer may be diluted to about 25% in an organic solvent, such as DMF, with a margin of error of about 2%. Samples may be removed from the reactor at different times for titration to determine the amount of isocyanate in order to assess readiness for ethylene diamine addition according to the following protocol. The figures provided are exemplary, but similar calculations may be conducted for different volumes and amounts of substrate to be titrated.
The percent of solids of the prepolymer in the reaction vessel is calculated from the recorded additions. A derivatizing solution may be prepared by adding 7.5 grams of dibutylamine to a dry 250 ml volumetric flask and diluting to the mark on the flask with the same organic solvent used in the synthesis. Three 5 gram (nominal) samples of the prepolymer may be accurately weighed, and each placed into a separate Erlenmeyer flask with a dry magnetic stir bar. 20 ml of the derivatizing solution may be added to each sample using a 20 ml volumetric pipet. The flask may then be covered with aluminum foil and stirred for 20 minutes at room temperature. 50 ml of isopropyl alcohol (IPA) and six drops of bromophenol blue indicator may be added. A buret may be filled with 1.0N aqueous HCl. The solution may then be stirred and titrated with 1.0N aqueous HCl to a yellow end point, and the amount of titrant used recorded. Two blanks may then be prepared by repeating the previously described procedure without adding the prepolymer sample to the flask. The amount of ethylene diamine (ED) required for chain extension may then be calculated by using the equations shown below. ##EQU1##
In addition, the following two steps may be performed simultaneously with the titration.
Chain extension may be attained by adding a solution containing about 40 to 60 wt %, and preferably about 50 wt %, of the theoretical amount of ethylene diamine (ED) in a solvent such as dimethyl formamide (DMF), in a proportion of ED:DMF of about 1:5. The ED solution may be added to the mixture over a period of, e.g., about 30-45 minutes. In general, about 20 minutes is sufficient to permit complete reaction. Half the remaining ED, as calculated below, may be added at this point.
Remaining ED (%)=Titrated ED %-ED % added
After the addition of the ED, e.g., the reaction may go to completion in about 20 minutes. The above-described titration/calculation may then be repeated until the presence of isocyanate is no longer detected by titration. If isocyanate is still present after all the ED/DMF solution is added and reacted, the reaction may be aborted and discarded. If no isocyanate is detected, the mixture may be further stirred for, e.g., about 30 minutes, at about 15° C. with a variance of about 2° C. The polymer may then be stabilized by the addition of about 0.5% to 5% Tinuvin 328 and 0.5% to 5% Tinuvin 770, and preferably 0.5 to 1% of each, based on total solids of the polyurethane polymer formed. This may be attained with about 25 wt % solution of Tinuvin 328 and Tinuvin 770 in THF.
Tinuvin 770 is a commercially available product comprising bis(2,2,6,6-tetramenthyl-4 -piperidyl)sebacate or bis(2,2,6,6-tetramethyl-4-piperidinyl)decanedioate. Similarly, Tinuvin 328 is one of a family of substituted benzotriazoles. Other families of compounds may also be used in their stead. Examples of stabilizers are antioxidants, thermal stabilizers and ultraviolet (UV) light absorbers include, but are not limited to, hindered amine light stabilizers, sterically hindered phenol compounds, compounds with sterically hindered phenolic hydroxyl groups, compounds from the hydroxyphenyl-benzotriazole family, and light stabilizers of the benzophenone-type. Combinations of any or all of the compounds listed above may also be used as well as other stabilizers known in the field.
The reaction mixture may then be further stirred for, e.g., about 30 minutes at about 15° C. with a variance of about 2° C., and the thus attained polyurethane filtered through, e.g., a woven stainless steel 10 micron filter into, e.g., clean, dry glass containers.
Of particular importance are the temperature ranges and the ratio or proportion of the reactants in the different reaction steps. The optimal reaction temperature for the reaction of aromatic diisocyanates with polyols is about 50° to 60° C. The optimal reaction temperature for the reaction of aliphatic diisocyanates with polyols is about 100° to 110° C. The optimal reaction temperature for amine terminated reactants is about 0° C. and 25° C. This reaction temperature applies to amines used as chain extenders and amines used in the soft segment. The diisocyanate and all reactants which contribute an active hydrogen, i.e., polyols, diamines, amines, may be added in a proportion of about 0.9 to 1.2 and more preferably about 0.95 to 1.1. The reactants may be added to a solvent as described above.
These reactions are typically conducted at atmospheric pressure, but it may also be undertaken at other pressures such as in the range of about 0.1 to 100 atm.
Although the copolymer of the invention may be prepared in a wide range of molecular weights, for some applications preferred is a molecular weight of about 5,000 to 1,000,000, and more preferable about 6,000 to 60,000. Still another range of preferred copolymer molecular weight is about 2,000 to 10,000, and more preferable about 3,000 to 6,000. Some of these may be used as pre-polymers capable of further reaction during fabrication, whereas higher molecular weight homologues are utilized as the final polymers for preparation of the films such as membranes, sheets or hollow fibers.
The soft segment used in the preparation of the polyurethane of the invention may be a polyfunctional aliphatic polyol, or a polyfunctional aliphatic or aromatic amine such as are commonly used for the preparation of polyurethanes or mixtures thereof. The molecular weight of the soft segment is typically about 200 to 1,000,000, and preferably about 400 to 9,000.
The aliphatic polyols of the soft segment may be selected from the group consisting of linear and branched polyalkylene and polyalkenyl oxides, random and block copolymers thereof, polycarbonate polyols, hydroxyl-terminated silicones, random and block copolymers thereof with polyalkylene oxides, linear and branched polyalkenyl and polyalkylene polyols, and mixtures thereof. However, other polyols may also be utilized if the resultant polymer posses the required water absorptivity.
Examples of polyols that are suitable for use in the present invention are polyethylene oxides, polypropyleneoxides, polytetramethylene oxides, random or block polypropylene oxide-polyethylene oxide copolymers, various ethyleneoxide-terminated polyols, random or block polytetramethylene oxide-polyethylene oxide copolymers, polycarbonate diols and triols, multifunctional hydroxyalkyl- or amine-terminated silicones, random or block silicone-polyethyleneoxide copolymers, polybutadiene diols and triols, polyisobutylene diols and triols, and mixtures thereof.
The amines of the soft segment may be selected from the group consisting of amine-terminated homologues of the exemplary polyols, including but not limited to polyamine-terminated alkylene oxides and random and block copolymers thereof, polyamine-terminated silicones, random and block copolymers thereof with polyalkylene oxides and mixtures thereof.
Examples of the amines that are suitable for use in the present invention are multifunctional amine-terminated polytetramethylene oxides, multifunctional amine terminated polyethylene oxides, random or block multifunctional amine terminated polypropylene oxide-polyethylene oxide copolymers, random or block multifunctional amine-terminated polytetramethylene oxide-polyethylene oxide copolymers, multifunctional amine-terminated silicones, random or block amine-terminated silicon polyethylene oxide copolymers and mixtures thereof.
Suitable polyisocyanates for the preparation of the hard segment of the copolymer of the invention are aromatic or aliphatic polyisocyanates.
The organic diisocyanates may be selected from the group consisting of alkyl diisocyanates, arylalkyl diisocyanates, cycloalkylalkyl diisocyanates, alkylaryl diisocyanates, cycloalkyl diisocyanates, aryl diisocyanates, cycloalkylaryl diisocyanates, all of which may be further substituted with oxygen, and mixtures thereof.
Examples of polyisocyanates are 4,4'-diphenylmethane diisocyanate, hexamethylene diisocyanate, dicyclohexylmethane diisocyanate, 2,4-toluene diisocyanate, 2,6-toluene diisocyanate, hexamethylene-1,6-diisocyanate, tetramethylene-1,4-diisocyanate, cyclohexane-1,4-diisocyanate, naphthalene-1,5-diisocyanate, diphenylmethane-4,4'-diisocyanate, xylylene diisocyanate, dicyclohexylmethane-4,4'-diisocyanate, 1,4-benzene diisocyanate, 3,3'-dimethoxy-4,4'-diphenyl diisocyanate, m-phenylene diisocyanate, isophorone diisocyanate, polymethylene polyphenyl diisocyanate, 4,4'-biphenylene diisocyanate, 4-isocyanatocyclohexyl-4'-isocyanatate, and mixtures thereof. Preferred are diphenylmethane diisocyanate, dicyclohexylmethane diisocyanate and mixtures thereof.
The chain extender of the hard segment used in the preparation of the copolymers of the invention may be an aliphatic polyol or an aliphatic or aromatic polyamine such as those known for preparing polyurethanes.
The polyol for the hard segment may be preferably selected from the group consisting of alkylene, cycloalkylene and arylene diols, triols, tetraalcohols, and pentaalcohols, and mixtures thereof.
Examples of polyols suitable for the preparation of the hard segment are 1,4-butanediol, ethylene glycol, 1,6-hexanediol, glycerine, trimethylolpropane, pentaerythritol, 1,4-cyclohexane dimethanol, phenyl diethanolamine, and mixtures thereof, among others. However, other polyols are also suitable.
The polyamine of the hard segment may be selected from the group consisting of alkyl, cycloalkyl and aryl amines which may be further substituted with N, O, or halogen, complexes thereof with alkali metal salts, and mixtures thereof.
Suitable polyamines for preparing the hard segment are p,p'-methylene dianiline and complexes thereof with alkali metal chlorides, bromides, iodides, nitrites and nitrates, 4,4'-methylene-bis(2-chloroaniline), piperazine, 2-methylpiperazine, oxydianiline, hydrazine, ethylenediamine, hexamethylenediamine, xylylenediamine, bis(p-aminocyclohexyl)methane, dimethyl ester of 4,4'-methylenedianthranilic acid, p-phenylenediamine, m-phenylenediamine, 4,4'-methylene bis(2-methoxyaniline), 4,4'-methylene bis(N-methylaniline), 2,4-toluenediamine, 2,6-toluenediamine, benzidine, dichlorobenzidine, 3,3'-dimethylbenzidine, 3,3'-dimethoxybenzidine, diansidine, 1,3-propanediol bis(p-aminobenzoate), isophorone diamine, and mixtures thereof.
In another embodiment, the hard segment of the copolymer may further comprise an end group selected from the group consisting of monofunctional aliphatic alcohols, polyols, aliphatic or aromatic amines and mixtures thereof. Preferred monofunctional aliphatic polyols for the end group are monofunctional polyalkylene oxides, siloxanes, and mixtures or copolymers thereof. Examples of aliphatic polyols are monofunctional polyethylene oxides, monofunctional polytetramethylene oxides, monofunctional polypropylene oxides, monofunctional siloxanes, and mixtures and/or copolymers thereof. However, others are also suitable.
The monofunctional amines of the end group may be selected from the group consisting of dialkylamines, amine-functional siloxanes, amine-terminated polyalkylene oxides and mixtures and copolymers thereof.
The hard segment of the copolymer of the invention may preferably have a molecular weight of about 160 to 10,000, and more preferably about 200 to 2,000. Its components also have preferred molecular weights as shown in Table 11 below.
TABLE 11 ______________________________________ Preferred Molecular Weights for Hard Segment Component Hard Segment Component Most Preferred MW Preferred MW ______________________________________ Aromatic Diisocyanates 150-270 100-500 Aliphatic Diisocyanates 150-270 100-500 Chain Extenders 60-200 18-500 ______________________________________
Although both the hard and soft segments may be utilized in a broad range of molecular weights, Table 12 below shows typical useful molecular weight ranges and preferred molecular weight ranges for some exemplary components of the soft segment.
TABLE 12 ______________________________________ Preferred Molecular Weights for Soft Segment Components Most Pre- Soft Segment Component ferred MW Preferred MW ______________________________________ Polyethylene oxide 1000-9,000 200-1,000,000 Polytetramethylene oxide 1000-9,000 500-50,000 Polypropylene oxide-polyethylene 1000-5,000 500-50,000 oxides Polytetramethylene 1000-2,000 500-50,000 oxide-polyethylene oxides Amine-capped 600-6,000 200-1,000,000 polypropylene-polyethylene oxides Polycarbonates 300-3,000 200-50,000 Amine-capped 500-2,000 200-50,000 polytetramethylene oxides Hydroxyl-alkyl and amine-capped 200-5,000 100-20,000 silicones Silicone-polyethylene oxides 500-5,000 200-1,000,000 Polybutadienes 500-3,000 200-50,000 Polyisobutylenes 1,000-5,000 500-10,000 ______________________________________
The content of hard segment of the copolymer is typically about 5 to 45 wt %, the remainder of the polymer consisting of soft segment, which may be a combination of hydrophilic, hydrophobic and amphipathic oligomers.
In one preferred embodiment, the copolymer comprises about 9 to 30 wt % of the hard segment, and more preferably 10 to 28 wt % thereof. Similarly, a typical content of the soft segment is about 91 to 70 wt %, and more preferably about 90 to 72 wt %. However, other proportions of hard and soft segments are also suitable for practicing this invention.
A polymer made from this composition will have the properties described in Table 13 below.
TABLE 13 __________________________________________________________________________ Characteristics of Film of the Invention Characteristics Range __________________________________________________________________________ Tensile strength > about 350 and up to about 10,000 psi Elongation at Break > about 300% and up to about 1,500% Water Absorption + Hydrophilic > about 100% and up to about 2,000% dry wt Soft Segment > about 50% and up to about 95% wet wt or more preferably Water absorption only > about 100% and up to about 2000% dry weight > about 50% and up about 95% wet wt Thickness (when unsupported) about 5 to 100 microns Thickness (when supported or about 1 to 100 microns reinforced) __________________________________________________________________________
This invention also provides a non-porous, semi-permeable, biocompatible film that comprises the block copolymer of the invention. In a preferred embodiment, the film is formed from the copolymer of this invention. In another preferred embodiment the film is coated onto a support. In still another preferred embodiment, the film is an integrated part of the substrate and is made of the same or similar polymer.
In particularly preferred embodiments, the non-porous film of the invention is provided in the form of a flexible sheet and a hollow membrane or fiber. Typically, the flexible sheet may be prepared as a long rollable sheet of about 10 to 15 inches width and 1 to 6 feet length. However, other dimensions may also be selected. Of particular importance is the thickness of the sheet which may be about 5 to 100 microns, and more preferably about 19 to 25 microns when it is to be used without support or reinforcement.
The flexible sheet is prepared from the block copolymer of the invention by methods known in the art, typically, by casting, and more preferably by casting on a web or release liner. As already indicated, the composition may be coated as a film onto a substrate. Where permanently supported on a reinforcing web, e.g., a fabric, the film or membrane may be thinner, e.g., as thin as about 1 micron, whereas when used unsupported the thickness may only be as low as about 5 to 10 microns.
When membranes are fabricated from the polymer of the invention by knife-over-roll casting onto a release paper, web or liner in the form of dry films, they may have an about 1 to 100 micron nominal thicknesses on a continuous coating line. A 20-foot-long continuous web coater may be utilized having, e.g., a maximum web width of 15 inches equipped with two forced-air ovens. In one particular embodiment, the coater may be modified for clean operation by fitting the air inlet ducts with High Efficiency Particulate Air (HEPA) filters. A nitrogen-purged coater box may be used to hold and dispense filtered polymer solutions or reactive prepolymer liquids. However, other set-ups are also suitable.
All but trace amounts of a casting solvent, e.g., dimenthylformamide may be removed by coater's hot air ovens fitted with HEPA filters. After membrane casting, membrane and substrate may be further dried to reduce residual solvent content to less than about 100 ppm, as determined by liquid chromatography. The thickness of the fully-dried cast films may be measured by, e.g., using a spring micrometer sensitive to 0.0001 inch (2.5 μM) or visually by using a microscope.
The membrane of this invention may have any shape resulting from a process utilizing a liquid which is subsequently converted to a solid during or after fabrication, e.g., solutions, dispersions, 100% solids prepolymer liquids, polymer melts, etc. Converted shapes may also be further modified using methods such as die cutting, heat sealing, solvent or adhesive bonding or any of a variety of other commonly-used fabrication methods. For example, when in the form of a hollow tube, the membrane is generally prepared with a diameter of about 0.5 to 10 mm , and more preferably about 1 to 3 mm, and a thickness of about 1 to 100 microns, and more preferably about 19 to 25 microns. The hollow membrane may easily be prepared in long rollable form, and be cut to a length of about 0.75 to 31 inches, and more preferably about 0.5 to 6 inches.
Hollow fibers may be fabricated from the polymer solutions by dipping clean, dry, mandrels, e.g., a 1 mm diameter stainless steel mandrel into the polymer solution. The mandrel may be suspended in a baffled chamber maintained at above normal room temperature, e.g., about 27° to 50° C., in a Class 1,000 Cleanroom. The mandrel may be attached to a motor driven cable and dipped into the polymer solution and withdrawn at an even speed and the solvent may be allowed to evaporate. The mandrel may then be inverted, hung and dipped again. This procedure may be repeated, e.g., three times, to yield a tube with a single wall thickness of, e.g., 19 microns. Multiple dippings may be performed to reduce the chances of pinholes occurring in the polymer hollow fibers. The mandrels may then be left in the heated chamber for at least 16 hours to allow the solvent to evaporate. To aid in the removal of the hollow fibers from the mandrel, the coated mandrel may be soaked in distilled water for, e.g., one hour. The removal of any remaining residual solvent may be achieved by water extracting the hollow fibers in distilled water for, e.g., 24 hours. The hollow fibers may then be flushed three times with distilled water and packaged in distilled water in clean glass tubes. Prior to filling the hollow fibers they may be leak-tested. One end of the hollow fiber may be heat-sealed, the fiber filled with distilled water and the remaining end heat-sealed. The filled hollow fiber may then be pressurized and the tube examined for water leakage under pressure.
The fabrication methods just described employ liquid solutions or reactive liquid prepolymers of the membrane polymers. In the case of essentially linear polymers of the present invention, thermoplastic fabrication methods may also be employed. Membrane polymers made by the bulk or solvent-free polymerization method described above may be cast into, e.g., a teflon-lined pan during the polymerization reaction. As the reaction proceeds and the polymerizing liquid becomes a rubbery solid, the pan may be postcured in an oven at, e.g., 100°-120° C. for about 1 hour. Upon cooling, the rubbery mass may be chopped into pellets and dried in a dehumidifying hopper dryer for, e.g., about 16 hours. The dry pellets may then be compression molded, e.g., at about 175° C. to form a flat membrane which, when cool, will leave a thickness of about 50 μM. Extrusion, injection molding, calendering and other conversion methods that are well-known in the art may also be used to form membranes, films and coatings of the polymers of the present invention, including hollow fibers.
As already indicated above, the non-porous film of the invention is substantially permeable to molecules of molecular weight of up to about 6,000 to 600,000, and more preferably of up to about 6,000 to 60,000, and is substantially impermeable to molecules of molecular weight greater than about 6,000 to 600,000 daltons, and more preferably greater than about 100,000. The utility of a specific membrane is based on its ability to allow the permeation of desired permeants while preventing the permeation of other permeants, including all condensed phases of matter. It is within the scope of the present invention to provide membranes with permeability to permeants of up to about 600,000 daltons and higher, while simultaneously excluding permeants of higher molecular weight and/or lower solubility. To control the permeability rate and/or MW cut-off based on permeant solubility in the water-swollen membrane polymer, the soft segment composition, content and molecular weight may be varied during polymer synthesis.
Commercially-available polyether oligomer, for example, may be obtained in molecular weights ranging from a few hundred to a few thousand. To achieve molecular weight cutoffs higher than those obtainable with commercially-available soft segment oligomers, available soft segment oligomers may be coupled together prior to the synthetic reaction to obtain the final membrane polymer.
In polyurethane synthesis, a so-called three-step reaction may be employed, in which the first step involves covalently bonding two or more oligomers together, while optionally retaining the oligomer's original end-groups by appropriate control of the stoichiometry of the coupling reaction. For example, three moles of hydroxyl-terminated polyether oligomer might be reacted with two moles of a diisocyanate optionally chosen to be different from the isocyanate used in the hard segment of the final polymer. Using a different diisocyanate to couple soft segment oligomers minimizes the association of the coupling segment with the hard segment of the polymer, which is desireable for maximum permeability. For instance, if the original polyol molecular weight were about 2,000, the coupled oligomer would have an average molecular weight of about 6,000 plus the molecular weight of the two diisocyanates used in the urethane-forming coupling reaction. When this coupled oligomer is subsequently reacted to form the final membrane polymer, the maximum end-to-end distance between hard segments is increased more than three times, relative to the original 2,000 molecular weight oligomer before coupling. When an organic diisocyanate is used to couple soft segments, and that diisocyante is chosen to be different from the diisocyanate used in the hard segment, the coupling diisocyanate is considered to be part of the soft segment.
Preferred are low hard segment lengths of molecular weights, e.g., about 160 to 1,000, and a proportion of hard to soft segment of about 1 to 11, and more preferably about 1 to 6.
The above disclosure sets forth a number of embodiments of the present invention. Other arrangements or embodiments, not necessarily set forth in detail herein, may be practiced under the general teachings of the present invention, and as set forth in the following examples, which are not intended to be limiting in nature.
One Step Synthesis
64 grams of a polyethylene oxide, molecular weight about 3,350, were mixed with 8 g butanediol in a disposable beaker at 60° C. To this were added, with vigorous stirring, 28 g diphenylmethane diisocyanate (MDI). When all reactants were homogeneous a drop of catalyst, stannous octoate or dibutyltin dilaurate, was added. The mixture was poured into a pan and postcured for 45 to 60 minutes in a 100° C. oven. This reaction may also be performed in an extruder to yield a product in pelletized form. The results are summarized in Table 14 below.
TABLE 14 ______________________________________ Hydrophilic Urethane: One-Step Synthesis With Stoichiometric Imbalance For MW Control mole solid polymer equivalents Hydrophilic PU (wt %) (100 g batch) ______________________________________ MDI 28.00 0.2238 Butanediol 8.00 0.1776 Carbowax 3350 64.00 0.0382 Total 100.00 % HS 36.00 % SS 64.00 Mole NCO 0.2238 Mole Active H 0.2158 Ratio NCO:H 1.04 ______________________________________
Two-Step Synthesis
72.15 g of a blend of 15 wt % polyethylene oxide, molecular weight about 1,450, and 85 wt % polypropylene oxide-polyethylene oxide copolymer, molecular weight about 2,000, were blended with 1.25 g dibutylamine at 500° C. in a glass reaction vessel. This blend was dissolved in 80.0 g dimethylformamide and 24.0 g diphenylmethane diisocyanate were then added with vigorous stirring. The reaction was continued for about 3 hours at 50°±5° C. The thus obtained product was dissolved in 220 g of dimethylformamide, and the resulting solution cooled to 10° C. in an ice bath. 2.6 g ethylenediamine dissolved in 100 g of dimethylformamide were added to the cold solution with vigorous stirring, and the stirring was continued for about 30 minutes. The polyurethaneurea solution was then removed from the reaction vessel and filtered through an 8-9 micron stainless steel filter. The results obtained from three separate experiments are summarized in Tables 15, 16, and 17 below.
TABLE 15 ______________________________________ Hydrophilic Urethane Preparation: Two-Step Synthesis Mono- functional Amine-Terminated PEO End Group For MW Control mole solid polymer equivalents Hydrophilic PU (wt %) (100 g batch) ______________________________________ MDI 24.14 0.1929 ED 2.85 0.0948 Witco EPD-56 11.50 0.0117 Carbowax 1450 61.51 0.0865 Total 100 % HS 26.99 % SS 73.01 Mole NCO 0.1929 Mole Active H 0.1930 Ratio NCO:H 0.9998 ______________________________________
TABLE 16 ______________________________________ Hydrophilic Urethane Preparation: Two-Step Synthesis mole solid polymer equivalents Hydrophilic PU (wt %) (100 g batch) ______________________________________ MDI 18.90 0.1510 ED 1.35 0.0449 Witco EPD-56 10.00 0.0101 BASF ER1250/25 14.75 0.0227 Carbowax 1450 51.30 0.0721 Jeffamine M-2070 3.70 0.0019 % HS 23.95 % SS 76.05 Mole NCO 0.1510 Mole Active H 0.1517 Ratio NCO:H 0.9958 ______________________________________
TABLE 17 ______________________________________ Hydrophilic Urethane Preparation: Two-Step Synthesis With Dialkylamine End Group for MW Control mole solid polymer equivalents Hydrophilic PU (wt %) (100 g batch) ______________________________________ MDI 24.00 0.1918 ED 2.60 0.0865 Witco EPD-56 10.95 0.0111 Carbowax 1450 61.20 0.0860 Dibutylamine 1.25 0.0097 % HS 27.85 % SS 72.15 Mole NCO 0.1918 Mole Active H 0.1933 Ratio NCO:H 0.9922 ______________________________________
Three-Step Synthesis
69.89 g polyethylene oxide, molecular weight about 1,450, were reacted for 3-4 hours with 8.18 g dicyclohexylmethane diisocyanate at 100° C. in a glass reaction vessel. The product was cooled to 50° C. and 80 g dimethylformamide and 1.24 g dibutylamine were added. 18.47 g diphenylmethane diisocyanate were added to this with vigorous stirring, and the reaction continued for 3 hours at 50°±5° C., with stirring. The thus obtained product was dissolved in 220 g dimethylformamide, and the resulting solution cooled to 10° C. in an ice bath. 3.21 g ethylenediamine dissolved in 100 g of dimethylformamide was added to the cold solution, with vigorous stirring, and the stirring continued for 30 minutes. The polyurethaneurea solution was then removed from the reaction vessel and filtered through an 8-9 micron stainless steel filter. The results are shown in Table 18 below.
TABLE 18 ______________________________________ Hydrophilic Urethane Preparation: Three-Step Synthesis mole solid polymer equivalents Hydrophilic PU (wt %) (100 g batch) ______________________________________ Prepolymer Step HMDI 10.76 0.0763 Carbowax 1450 89.24 0.1117 Polymer Formation MDI 18.47 0.1476 ED 3.21 0.1068 1st step prepolymer 77.08 0.0312 Dibutylamine 1.24 0.0096 Total 100 % HS 22.92 % SS 77.08 Mole NCO 0.1476 Mole Active H 0.1486 Ratio NCO:H 0.9931 ______________________________________
Two-Step Polymer Synthesis
The purity, molecular weight and water content of the starting materials were determined by titration. The polyurethanes were synthesized in glass batch reactors with glass-distilled solvents using a two-step prepolymer/chain extension method as described in Example 2.
The film forming polymer used was a polyurethaneurea with a diphenylmethanediisocyanate/ethylene diamine hard segment and a hydrophobic and hydrophilic mixed polyalkyleneoxides soft segment. A series of five elastomers with nominal hydrophilic contents of 0, 10, 20, 30, 40 and 50 wt % were synthesized by the two step, prepolymer/chain extension method described in Example 2 in dimethylformamide (DMF) solvent. The optimum molecular weight of each polyol was determined to be about 1,400 and 2,000 and then fixed for the whole series of polymers, subject to availability from commercial suppliers. Infrared spectrophotometry and/or titration were used to monitor the disappearance of isocyanate to assure the completion of the reaction. The content of the hard segment was held constant at about 20 wt % for a series of polymers. The membrane casting solution of each polymer was filtered through a 10 micron 316 woven stainless steel filter and outgassed under mild vacuum prior to film casting.
Preparation of Membranes by Knife Over Roll Casting
Membranes were fabricated from the polymers of the above examples by knife-over-roll casting onto a release paper, web or liner in the form of dry films of 1 to 100 micron nominal thicknesses on a coating line. A 20-foot-long continuous web coater was utilized, that had a maximum web width of 15 inches and was equipped with two forced-air ovens. A nitrogen-purged coater box was used to hold and dispense filtered polyurethane solutions.
All but trace amounts of a casting solvent, such as dimenthylformamide, were removed by the coater's hot air ovens which were fitted with HEPA filters. After membrane casting, membrane and substrate were further dried to reduce residual solvent content to about 100 ppm, as determined by liquid chromatography. The thickness of the fully-dried cast films were measured using either a spring micrometer sensitive to 2.5 microns or visually using a microscope.
Selective Permeation of Glucose
A 1 wt % glucose solution was prepared in phosphate buffered saline (PBS). In the glucose experiments for all of the polymer films, eight permeation chambers with similar membranes were used. The experiment was repeated utilizing membranes of increasing hydrophilicity, between 0% and 85%. As the hydrophilicity is increased, the permeability of the membrane increases while the permeation time decreases. The glucose concentration on the downstream side of each chamber was determined using a quantitative glucose oxidase enzymatic assay. The test sample was added to a mixture containing glucose oxidase, peroxidase and o-dianisidine. The reaction was allowed to proceed to completion, for approximately 45 minutes at 23° C. The final color intensity was measured at 450 nm on a Milton Roy Visible Spectrophotometer, Model Spectronic 20D, and found to be proportional to the glucose concentration. A calibration curve was generated by plotting the glucose concentrations from 0 to 3000 μg/ml (0 to 3 mg/ml) vs. the absorbance at 450 nm. The data were analyzed using linear regression to generate the line with the best fit. This correlation was used to calculate the glucose concentration in the unknown samples.
A model was developed using Mathematica® to calculate the permeability coefficient, p, for each cell. The permeabilities were then averaged. The % equilibrium for each cell was calculated. FIG. 1 of this patent contains these data for membranes of increasing hydrophilicity. The curves of FIG. 1 were generated using the averaged data from two chambers for each point. The first seven polymers in this series (i.e., 0 to 66% hydrophilicity inclusive) comprised a nominal soft segment molecular weight of 1,700 daltons. The polymer with 85% hydrophilicity had an 8,000 dalton soft segment molecular weight and a glucose permeability of 29,000. After correcting for its higher hydrophilicity using a linear extrapolation, its glucose permeability is 240% higher than the homologous polymer with a nominal 1,750 soft segment molecular weight. This demonstrates the ability to increase permeability by increasing soft segment molecular weight of the polymers of the present invention. Using the mathematical model developed, a best fit regression curve was generated. The p calculated from the regression analysis is reported herein. Thus, the fast permeability of the membranes for the glucose molecule was demonstrated to be increased at increasing degrees of hydrophilicity.
Tensile Properties of the Membranes of the Invention
The mechanical properties in tension of the polymers prepared in Example 4 were determined according to ASTM procedure D1708. A Lloyd Universal Testing Machine, Model 500N, and a 112 pound load cell was used to evaluate the polymers. The initial modulus, tensile strength at break, and the ultimate elongation were calculated for water-extracted, solvent-cast films. The films were equilibrated at 23° C. and 50% relative humidity for 24 hours prior to testing. Microdogbone samples of both dry and hydrated films were used to determine the tensile properties at 23° C. for each polyurethaneurea. The hydrated samples were prepared by placing the films in water for 24 hours, die cutting the samples and returning them to the water. Die cutting the samples after they were hydrated insured that the width of all the microdogbones was the same regardless of the amount of swelling that occurred for each polymer. The samples were removed from the water, the thickness was measured and they were tested. Five test specimens of each polymer, dry and hydrated, were analyzed. The instrument is interfaced to an IBM compatible computer which programs the machine and performs the appropriate calculations and the statistical data reduction. The tensile porperties of membranes according to this invention having increasing hydrophilicity are provided in Table 19 below.
TABLE 19 ______________________________________ Tensile Properties of Dry and Hydrated Polyurethaneureas as a Function of Membrane Hydrophilicity Initial Tensile Ultimate Hydrophilic Modulus Strength Elongation Content (psi) (psi) (%) ______________________________________ 0% dry 827 ± 46 6025 ± 304 945 ± 41 hydrated 1059 ± 87 5076 ± 236 936 ± 24 10% dry 722 ± 32 5783 ± 514 994 ± 44 hydrated 955 ± 25 3942 ± 132 945 ± 22 20% dry 737 ± 75 4428 ± 405 1039 ± 67 hydrated 895 ± 25 3171 ± 237 1026 ± 61 30% dry 681 ± 89 3409 ± 324 1110 ± 59 hydrated 677 ± 104 2560 ± 190 994 ± 68 40% dry 740 ± 69 1325 ± 85 774 ± 18 hydrated 555 ± 96 1075 ± 45 630 ± 23 50% dry 598 ± 63 1100 ± 98 830 ± 29 hydrated 456 ± 79 817 ± 44 593 ± 30 ______________________________________
Water Absorption and Extractables
Since the equilibrium water uptake is an important determinant of the moisture vapor transmission rate and the protein permeability of a polymer, the amount of water absorbed and the amount of material extracted from the polyurethaneureas were determined as well. An A&D analytical balance, Model FR-200, was used to accurately weigh samples to 0.1 mg which had been equilibrated for 24 hours at equilibrated at 23° C. and 50% relative humidity prior to testing. Three test specimens of each polymer were placed in distilled water at 23° C. and 37° C. After twenty four hours of water immersion the samples were removed, blotted dry and weighed. They were then dried for 24 hours at 23° C. and 50% relative humidity and reweighed. The weight percent of water in the polymer, or water absorption on a wet basis, which is always ≦100, was calculated with the following equation. ##EQU2##
Swelling related to the dry state is usually referred to as hydration or water absorption on a dry basis. Thus, the percent hydration or water regain, which may be greater than 100, was calculated from the following mathematical equation. ##EQU3##
The degree of swelling, which is greater than or equal to about 1.0, was calculated as the following ratio. ##EQU4##
Similarly, the percentage of extractables was calculated as follows. ##EQU5##
For all the above formulas, the variables used represent the following parameters.
Ow=original dry weight (grams)
Sw=swollen wet weight (grams)
Fw=final dry weight (grams)
The results obtained for membranes of increasing hydrophilities are shown in Table 20 below.
TABLE 20 ______________________________________ Water Absorption and Extractables at 23° C. and 37° C. as a Function of Membrane Hydrophilicity Hydrophilic Dry Basis Weight Basis Content H.sub.2 O Absorbed H.sub.2 O Absorbed Extractables (%) (%) (%) (%) ______________________________________ 23° C. 37° C. 23° C. 37° C. 23° C. 37° C. 0 1.3 1.6 1.3 1.6 0.1 0.3 10 8.0 6.9 7.4 6.5 0.1 0.3 20 21.7 16.2 17.9 14.0 0.1 0.3 30 36.1 31.2 26.5 23.8 0.3 0.5 40 63.2 48.4 38.7 32.6 0.6 0.7 50 78.4 65.3 43.9 39.5 0.7 0.9 ______________________________________
Permeation of Molecules of Varying Molecular Weights
Diffusion experiments were conducted in which the heat-sealed, hollow-fiber membranes of this invention prepared as in Example 11 below were filled with permeant solutions containing an 125 I-labeled tracer molecules of various molecular weights and placed in a test tube filled with permeant-free solution and incubated at 37° C. Aliquots were withdrawn from the test tube and measured in a well counter. Using as the membrane thickness 19 microns, and as an area of the membrane 0.016 cm2, the measured volumes of the hollow fiber and test tube, and the starting concentrations inside and outside the hollow fiber, the permeability coefficient, p, was calculated from each sample.
Regression analysis was used to calculate the best fit value for p, in this and in the diffusion cell experiments. The permeability coefficient P may be expressed in different units by applying suitable conversion factors. Data obtained for various proteins are shown in Table 21 below.
TABLE 21 ______________________________________ Permeability Coefficients for Proteins of Varying MWs Protein Molecular Weight p (μg · cm/cm.sup.2 · day · g/cm.sup.3) ______________________________________ Glucose 180 9620 Angiotensin I 1440 90 Glucagon 3550 400Insulin 6000 2300 Aprotinin 6500 25 Albumin 68000 10 IgG 158000 0 ______________________________________
Thus, it was shown that while glucose has a high p, molecules of increasing MW have lower p's. Since the dense membranes of the present invention have permeabilities which are determined by the solubility of the permeants as well as their diffusivity, the permeability coefficients do not vary strictly with molecular weight (size) of the permeants.
Oxygen Permeability of the Membranes of this Invention
The oxygen permeability was determined for various membranes prepared with the polymers of this invention using a Createch 201 T Permeometer and a Rehder flat polargraphic cell in a 100% humidity chamber at 35°±0.2° C. For each material reading four 13 mm circles of material were stacked together on the electrode. All materials were fully hydrated in 0.9% saline and incubated at 35° C. prior to readings being taken. The readings for three different samples of each material were averaged to produce the average reading in micro amps. The central thickness of each sample was measured with a micrometer. The central thickness of each material were averaged to produce the average thickness in cm. The results of the experiment are shown in Table 22 below.
TABLE 22 __________________________________________________________________________ Oxygen Permeability Through Hydrophilic and Hydrophobic Polymers Example Water Abs. Water Abs. Dk/L Dk (Hydrophilic (%) Dry (%) Dry (10.sup.-9 cc/cm.sup.2 (10.sup.-11 cc cm/cm.sup.2 Content %) Basis Basis sec mm Hg) sec mm Hg) __________________________________________________________________________ A (0) 0 0 1.85 32.8 B (9) 4 4 5.4 12.4 C (24) 20 17 5.90 10.5 D (28) 22 18 5.37 14.0 E (34) 35 26 5.48 15.4 F (58) 100 50 8.80 44.7 G (66) 92 48 9.25 12.0 __________________________________________________________________________
Example A is a polymer made from the reaction of MDI with and amine-terminated siloxane. Examples B through F are polymers made from reacting MDI with a hydrophilic/hydrophobic soft segment and then chain extending with ED. The ratio of hydrophilic to hydrophobic content in the soft segment was varied, with Example B being the most hydrophobic and Example F the most hydrophilic. Example G has a MDI/ED hard segment, a mixed hydrophobic/hydrophilic soft segment and was chain terminated with dibutylamine.
Preparation of Hollow Fibers
Hollow fibers of 1 mm nominal diameter and 19 micron thickness assessed by diffusion studies were dip cast on stainless steel mandrels, dried and water extracted from a 8% solids solution of the copolymer in dimethylformamide prepared as described in Example 2.
Hollow fibers were fabricated from the polymer solutions by dipping clean, dry 1 mm diameter stainless steel mandrels into the polymer solution. The mandrels were suspended in a baffled chamber maintained at 37° C. in a Class 1000 Cleanroom. The mandrel was attached to a motor driven cable and dipped into the polymer solution and withdrawn at an even speed. Time was allowed for the solvent to evaporate. The mandrel was inverted, hung and dipped again. This procedure was repeated three times to yield a tube with a single wall thickness of 0.75 mil. Multiple dippings were performed to reduce the chances of pinholes in the polymer hollow fibers. The mandrels were left in the heated chamber for at least 16 hours to allow the solvent to evaporate. To aid in the removal of the hollow fibers from the mandrel, the coated mandrel was soaked in distilled water for one hour. The removal of any remaining residual solvent was achieved by water extracting the hollow fibers in distilled water for 24 hours. The hollow fibers were then flushed three times with distilled water and packaged in distilled water in clean glass tubes. Prior to filling the hollow fiber with islet cells the hollow fibers were leak tested. One end of the hollow fibers was heat-sealed, the tube was filled with distilled water and the remaining end was heat-sealed. The filled hollow fiber was pressurized and the tube was examined for water leakage.
The extracted hollow fibers were then sterilized by "liquid cycle" autoclave sterilization and stored in a sterile environment until they are used.
Maintenance of Cell Distribution within Membrane.
Optimal diffusion of intracellular products out of a membrane implant is achieved, in part, by maintaining an even distribution of the cells within the membrane. It has been known to use hydrophilic natural polymers to encapsulate mammalian cells. Generally, mammalian cells have been microencapsulated through crosslinking using, for example, alginate and polylysine. One drawback to microencapsulation using certain crosslinked hydrophilic polymers is the tendency of crosslinked polymers to biodegrade.
It is also known that alginates and some vegetable gums are capable of forming high water content gels suitable as encapsulating agents. Gels where the water content is higher than 99.5% have been produced. The high water content of these gels provides these gels with high permeability to the various permeants important to hybrid artificial organs. Even at very high water contents, these gels are very viscous and thus capable of immobilizing cells dispersed within the gel. However, one drawback to the use of some of these acrylic hydrogels is their biodegradability, particularly when the gels are implanted as microcapsules directly into tissue.
By placing these high water content hydrogels within the membranes of the instant invention, it has been found that the hydrogel compositions do not rapidly biodegrade once implanted. Thus a preferred embodiment of the instant invention is the use of a hydrophilic gel with a water content≧of about 35% water but preferably ≧90% water inside of a dense, semi-permeable polymer membrane. The dense membranes of the instant invention provide immunoisolation and necessary selective permeability while also providing an absolute barrier to cells. The water swollen gel fixes the position of the cells within the dense membrane (e.g. in the shape of a hollow fiber) to prevent bunching. In addition, the high water content of the water swollen gel provides low resistance to the permeability of species leaving or arriving at the contained cells.
The dense membrane may also provide a biostable protective layer to the water-swollen gel, thus preventing or reducing biodegradation of the gel.
Suitable dense membranes include but are not limited to hydrophilic or amphipathic polyurethanes having≧about 20% water but preferably ≧50% water but less equilibrium water content than the water-swollen gel. Water content is measured in water @ 37° C. and expressed as a percentage of the wet weight of the sample after maximum weight gain has occurred. This value is determined by weighing the polymer wet and again after the polymer has been dried to equilibration at standard laboratory conditions, e.g. ˜23° C. and 50% relative humidity.
Suitable hydrogels are alginates (e.g. sodium alginate, ammonia alginates, potassium alginates, propylene glycol alginates, algins), guar gum, gum tragacanth, locust bean gum, methocel, xanthan gum, polyethylene oxide, polypropylene oxide, dextrans, acrylates, methacrylates, polyvinyl alcohol, polyvinyl pyrolidone and combinations of the above.
Those gums or resins capable of "crosslinking" may be used crosslinked or linear. For example, sodium alginate may be used "as is" or converted to its insoluble calcium form.
The most preferred hydrogel is calcium alginate wherein the water content is greater than about 90%.
With regard to all of the above-described devices, it is preferred that the devices further comprise a hydrogel, that comprises greater than about 35% water, within the cavity of the device. The hydrogel serves to immobilize the cells within the device, thus insuring an even cell distribution within the device.
The most preferred embodiment of the instant invention comprises the implantation of a dense membrane in the form of hollow fibers where the hollow fiber is filled with calcium alginate with a water content greater than about 90%. However, it is understood that the geometry of the dense membrane can be in any form including sheets, larger diameter tubes, etc.
A further description of the preparation and use of hydrogels is provided by co-file, co-pending U.S. Patent Application entitle METHOD OF CULTURING VIABLE CELLS AND METHOD OF REGULATING BLOOD GLUCOSE LEVELS BY IMPLANTATION OF VIABLE CELLS IN NON-POROUS, SEMI-PERMEABLE POLYMERIC MEMBRANES by Robert S. Ward, John Monahan and Robert Kuhn (Attorney Docket No. SOMA-20111, the text of which relating to the use of hydrogels is incorporated herein by reference.
Measurement of Permeability and Mathematical Model
The most widely used method for comparing polymers according to their moisture vapor transmission rates (MVTR) is the ASTM E96 method. The results are most often expressed as grams of water transmitted per day per square meter of film area, rather than in typical units of p, referred to above. The driving force associated with the permeation of a substance is determined by the conditions of the experiment, but is not always reported in convenient units. In order for the data to be meaningful, these factors must be taken into consideration as well as reporting the data in reference to the thickness of the membrane. The normalization to a unit thickness, such as mils, may be done by multiplying the MVTR by the film thickness in the same units.
Two variations of the ASTM E96-80 method are presently popular. The first, called the Upright-Cup method, is known as E-96-80 Procedure B. In this procedure, standard cups are filled with water to a prescribed depth and sealed with the sample. The cups are accurately weighed and placed upright in an environment maintained at 23° C. and 50% relative humidity (RH) with an air velocity of 500 to 600 ft/minute parallel to the sample. The sample is in contact with the vapor space within the cup, which is also at 23° C. and 100% RH. Following a transient time lag period at the beginning of the experiment, weight loss versus time at steady state is measured and used to calculate MVTR from the area of the sample. The vapor pressure driving force (ΔV.P.) in the ASTM E-96 Procedure B is a constant 10.5 mm Hg.
The other is the Inverted-Cup method, Procedure BW. The conditions for this procedure are in general similar to those used in the upright cup method, except that the cup is inverted so that water contacts the sample.
At the present time, there are few published tabulations of polymer MVTR values available. One mil film values may be calculated from their published water vapor permeability constants as described above. The MVTR value, as determined by the Upright Cup method, may vary over nearly four orders of magnitude, from <0.1 for polyvinylidenechloride to >800 g/M2 /day for the present hydrophilic polyurethanes. Although part of the variation is due to the varying levels of crystallinity within the range of polymers cited, the wide range of values illustrates that very significant changes in permeability may be obtained through changes in membrane chemistry.
Using the computer software program MATHEMATICA®, for doing mathematical calculations, the inventors developed an analytical model for the non-steady-state diffusion of solutes in a closed diffusion cell, which is well suited for conducting protein permeability studies utilizing two-chamber dialysis/diffusion cells. The use of these simple cells allows several experiments to proceed in parallel due to the small size and simplicity of the apparatus. The membranes are hydrated and the diffusion cells are assembled and leak-tested, then completely filled with, e.g., solute-free phosphate-buffered saline (PBS) in one chamber, chamber 2, and solute-containing PBS in a second chamber, chamber 1. No air interface is allowed between the two chambers. To avoid concentration polarization, the cells may be placed on a gentle mechanical shaker, e.g., in an incubator with temperature control for maintaining the temperature at, e.g., 37° C. The permeant concentration in chamber 2 may be measured by sensitive calorimetric methods using a visible light spectrophotometer and appropriate reagent kits. (Bradforn, M. M., "A Refined and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding", Anal Biochem, 72:248 (1976); Sedmark, J. J. and Grossberg, S. E., "A Rapid, Sensitive and Versatile Assay for Protein Using Commassie Brillant Blue G250, Anal Biochem, 79:544 (1977), Keilin D. and Hartree EF, "Properties of Glucose Oxidase [notatin]", Biochem J 42:221, (1948), and Keilin D. and Hartree EF, "Specificity of glucose oxidase[notatin]. Biochem J 50:331, (1952)).
Side 1, the side of the membrane facing chamber 1, is charged with a permeant solution with 0.03% sodium azide to retard bacterial contamination in solution at concentration, c1o, and the concentration of the solution is monitored on side two, c2, as a function of time, t, while controlling temperature and agitation to determine the permeability coefficient, p, of the membrane. It is also of interest to determine the time, t, at which concentration, c2, will reach a specific value under conditions of known p, c1o, c2o, a, v1, v2, and 1.
According to Fick's Law, the flux of permeant through a membrane is proportional to the concentration driving force across the membrane, c1-c2, and the membrane area, a, and inversely proportional to the membrane thickness, 1. The permeability coefficient, p, is the proportionality constant linking the solubility and diffusivity coefficients and the liquid film resistance together.
In this model it is assumed that p is independent of the driving force in the water-swollen membrane. It is also assumed that the flux is proportional to the area and inversely proportional to the thickness.
At equilibrium, the net flux across the membrane stops. If v1=v2, equilibrium will be reached at
c1=c2=c1o/2
For unequal cell compartment volumes, i.e., v1≠v2, the equilibrium may be calculated as if v1 at c1o and v2 at c2o were simply mixed together, i.e.,
ceq=(c1o v1+c2o v2)/(v1+v2),
wherein ceq is the equilibrium concentration in both chambers.
The driving force in membrane permeation is the difference between the upstream concentration, c1, and the downstream concentration, c2, of the permeant. The quantity (c1-c2) changes continuously during the course of a non-steady-state experiment. After an initial transient period, only a single chamber-2 concentration measurement is needed to calculate the permeability constant p according to the following equations. ##EQU6## wherein c1o=initial permeant concentration in chamber 1 (g/cc),
v1=volume of chamber 1 (cc),
c2o=initial permeant concentration in chamber 2 (g/cc),
v2=volume of chamber 2 (cc),
a=membrane area (cm2)'
l=membrane thickness (cm),
t=time (days), and
p=permeability coefficient (ugcm/daycm2 g/mL).
Thus, ##EQU7##
If an experiment is performed in a diffusion cell with equal chamber volumes, i.e., v1=v2=v, and c2o is equal to zero, the equation is reduced to the following equation.
p=-(lv Log [1-((2 c2/c1o)]/(2 a t))*10.sup.6
The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the invention as set forth herein.
Claims (57)
1. A biocompatible, hydrophilic, segmented block polyurethane copolymer having a number average molecular weight of about 5,000 to 150,000,
comprising about 5 to 45 wt % of at least one hard segment; and
about 95 to 55 wt % of at least one soft segments comprising at least one hydrophilic, hydrophobic or amphipatic oligomer selected from the group consisting of aliphatic polyols, aliphatic and aromatic polyamines and mixtures thereof; the copolymer being capable of forming a substantially non-porous semi-permeable film having a tensile strength greater than about 350 psi and up to about 10,000 psi, an ultimate elongation greater than about 300% and up to about 1,500 t and a water absorption such that the sum of the volume fraction of absorbed water and the hydrophilic volume fraction of the soft segment exceeds about 100% and up to about 2,000% of the dry polymer volume and exceeds about 50% and up to about 95% of the wet polymer volume and being permeable to monodisperse molecules of up to about 6,000 to 600,000 molecular weight and substantially impermeable to particulate matter.
2. The copolymer of claim 1, wherein the volume fraction of absorbed water is about 50% or greater than the total volume of the water swollen polymer.
3. The copolymer of claim 1, wherein the aliphatic polyols of the soft segment are selected from the group consisting of linear, branched and graft polyarylene, polyalylene and polyalkenyline oxides, random and block copolymers thereof, polycarbonate polyols, hydroxyl-terminated silicones, random and block copolymers thereof with polyalkylene oxides, linear and branched polyalkenyl, and polyalkylene polyols, and mixtures thereof.
4. The copolymer of claim 1, wherein the soft segment is selected from the group consisting of amine-terminated polyalkylene oxides and random, block and graft copolymers thereof, amine-terminated polydialkylsiloxanes, random and block copolymers thereof with polyalkylene oxides and mixtures thereof.
5. The copolymer of claim 1, further comprising an end group selected from the group consisting of monofunctional aliphatic polyols, aliphatic or aromatic amines and mixtures thereof.
6. The copolymer of claim 5, wherein
(a) the monofunctional aliphatic polyols of the end group are selected from the group consisting of monofunctional polyalkylene oxides, siloxanes and mixtures thereof; and
(b) the monofunctional amines of the end group are selected from the group consisting of dialkylamines, amine functionalized siloxanes, amine terminated polyakylene oxides and mixtures thereof.
7. The copolymer of claim 1, wherein the soft segment is selected from the group consisting of reaction products of an organic diisocyanate with a polyamine and a polyol.
8. The copolymer of claim 7, wherein the organic diisocyanate of the hard segment is selected from the group consisting of alkyl diisocyanates, arylalkyldiisocyanates, alkyl-cycloalkyl diisocyanates, alkylaryl diisocyanates, cycloalkyl diisocyanates, aryl diisocyanates, and cycloalkylaryl diisocyanates, which may be further substituted with oxygen, and mixtures thereof.
9. The copolymer of claim 7, wherein the polyol of the hard segment is selected from the group consisting of alkylene, cycloalkylene and arylene diols, triols, tetraalcohols, pentaalcohols and mixtures thereof.
10. The copolymer of claim 7, wherein the polyamine of the hard segment is selected from the group consisting of alkyl, cycloalkyl, and aryl amines, which may be further substituted with N, O or halogen, complexes thereof with alkali metal salts, and mixtures thereof.
11. The copolymer of claim 1, wherein the soft segment comprises a polyethyleneoxide of molecular weight greater than about 3,000 daltons.
12. The copolymer of claim 11, wherein the polyethyleneoxide has a molecular weight of about 8,000 or greater.
13. The copolymer of claim 6, wherein the soft segment comprises a blend of polyols selected from the group consisting of a polyethyleneoxide of molecular weight greater than about 3,000 daltons, a polyethyleneoxide-polytetramethyleneoxide copolymer and a polyethyleneoxide homopolymer, a polyethyleneoxide-polytetramethyleneoxide copolymer and an ethyleneoxide-capped polyethyleneoxide copolymer, a polyethyleneoxide-polypropyleneoxide copolymer and a polyethyleneoxide homopolymer, a polyethyleneoxide-polypropyleneoxide copolymer and a polypropyleneoxide homopolymer, a polyethyleneoxide homoploymer and a polytetramethyleneoxide homopolymer, a polyethyleneoxide copolymer and a polycarbonate homopolymer, a polyethyleneoxide copolymer and a polybutadiene homolymer, and a polyethyleneoxide copolymer and a polyisobutylene homopolymer.
14. The copolymer of claim 13, wherein the soft segment comprises a blend of a polyethyleneoxide-polytetramethyleneoxide copolymer and polyethyleneoxide homopolymer.
15. The copolymer of claim 13, wherein the soft segment is a blend of a polyethyleneoxide-polytetramethyleneoxide copolymer and a polyethyleneoxide-polypropyleneoxide copolymer.
16. The copolymer of claim 13, wherein the soft segment is a blend of a polyethyleneoxide-polytetramethyleneoxide copolymer and an ethyleneoxide-capped polypropyleneoxide polymer.
17. The copolymer of claim 13, wherein the soft segment is a blend of a polyethyleneoxide-polypropyleneoxide copolymer and a polyethyleneoxide homopolymer.
18. The copolymer of claim 13, wherein the soft segment is a blend of a polyethyleneoxide-polypropyleneoxide copolymer and a polypropyleneoxide homopolymer.
19. The copolymer of claim 13, wherein the soft segment is a blend of a polyethyleneoxide homopolymer and a polytetramethyleneoxide homopolymer providing the copolymer having a lesser tensile strength and elongation in the wet state than in its dry state.
20. The copolymer of claim 13, wherein the soft segment is a blend of a polyethyleneoxide-containing copolymer and a polycarbonate homopolymer.
21. The copolymer of claim 13, wherein the soft segment is a blend of a polyethyleneoxide-containing copolymer and a polybutadiene homopolymer.
22. The copolymer of claim 13, wherein the soft segment is a blend of a polyethyleneoxide-containing copolymer and a polyisobutylene homopolymer.
23. A non-porous, semi-permeable, biocompatible film formed from the block copolymer of claim 1.
24. The non-porous film of claim 23, in the form of a flexible sheet or a hollow membrane.
25. The non-porous film of claim 23, being attached to a substrate.
26. The non-porous film of claim 25, in the form of a coating deposited onto a substrate.
27. The non-porous film of claim 26, wherein the substrate is a woven or knitted substrate or a porous polymer.
28. The non-porous film of claim 25, having a thickness of about 1 to 150 microns.
29. The non-porous film of claim 23, having a thickness of about 5 to 150 microns.
30. A method of permeating molecules of a predetermined molecular weight range while substantially preventing the passage of cells and particulate matter between two fluids comprising interposing between the two fluids the nonporous film of claim 23.
31. A biocompatible, hydrophilic, segmented or block polyurethane copolymer having a number average molecular weight of about 5,000 to 150,000, comprising
about 5 to 45% of at least one hard segment selected from the group consisting of reaction products of an organic diisocyanate and a polyamine and a polyol; and
about 95 to 55 wt % of a hydrophilic soft segment comprising a blend of a polyethyleneoxide-polytetramethyleneoxide copolymer and a polyethyleneoxide homopolymer.
32. The block polyurethane copolymer of claim 31, wherein the organic dissocyanate comprises 4,4'-diphenylmethane diisocyanate.
33. The block polyurethane copolymer of claim 31, wherein the organic diisocyanate comprises hydrogenated diphenylmethane diisocyante.
34. The block polyurethane copolymer of claim 31, wherein the hard segment polyol comprises an alkylenediol.
35. The block polyurethane copolymer of claim 34, wherein the hard segment polyol comprises butanediol.
36. The block polyurethane copolymer of claim 31, wherein the hard segment polyamine comprises an alkylenediamine.
37. The block polyurethane copolymer of claim 36, wherein the hard segment polyamine comprises ethylenediamine.
38. A non-porous film made from the polymer of claim 31.
39. The film of claim 31, being attached to a substrate.
40. A biocompatible, hydrophilic, segmented or block polyurethane copolymer having a number average molecular weight of about 5,000 to 150,000, comprising
about 5 to 45 wt % of a least one hard segment selected from the group consisting of reaction products of an organic diisocyanate and a polyamine and a polyol; and
about 95 to 55 wt % of a hydrophilic soft segment comprising a blend of polyethyleneoxide-polytetramethyleneoxide copolymer and a polyethyleneoxide-polypropylene oxide copolymer.
41. The block polyurethane copolymer of claim 40, wherein the organic diiisocyanate comprises 4,4'-diphenylmethane diisocyanate (MDI).
42. The block polyurethane copolymer of claim 40, wherein the organic diisocyanate comprises hydrogenated diphenylmethane diisocyanate (HMDI).
43. The block polyurethane copolymer of claim 40, wherein the hard segment polyol comprises an alkylenediol.
44. The block polyurethane copolymer of claim 43, wherein the hard segment polyol comprises butanediol.
45. The block polyurethane copolymer of claim 40, wherein the hard segment polyamine comprises an alkylenediamine.
46. The block polyurethane copolymer of claim 40, wherein
the hard segment polyamine is ethylene diamine.
47. A non-porous film made from the polymer of claim 40.
48. The non-porous film of claim 47, being attached to a substrate.
49. A biocompatible, hydrophilic, segmented or block polyurethane copolymer having a number average molecular weight of about 5,000 to 150,000, comprising
about 5 to 45 wt % of at least one hard segment selected from the group consisting of reaction products of an organic diisocyanate and a polyamine and a polyol; and
about 95 to 55 wt % of a soft segment comprising a blend of a polyethyleneoxide-homopolymer and a polyethyleneoxide-polypropylene oxide copolymer.
50. The block polyurethane copolymer of claim 49, wherein the organic diisocyanate comprises 4,4'-diphenylmethane diisocyanate (MDI).
51. The block polyurethane copolymer of claim 49, wherein the organic diisocyanate comprises hydrogenated diphenylmethane diisocyanate (HMDI).
52. The block polyurethane copolymer of claim 49, wherein the hard segment polyol comprises an alkylenediol.
53. The block polyurethane copolymer of claim 52, wherein the hard segment polyol comprises butanediol.
54. The block polyurethane copolymer of claim 49, wherein the hard segment polyamine comprises an alkylenediamine.
55. The block polyurethane copolymer of claim 54, wherein the hard segment polyamine comprises ethylenediamine.
56. A nonporous film, made from the polymer of claim 49.
57. The non-porous film of claim 56, being attached to a substrate.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/052,361 US5428123A (en) | 1992-04-24 | 1993-04-23 | Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range |
US08/221,666 US5589563A (en) | 1992-04-24 | 1994-04-01 | Surface-modifying endgroups for biomedical polymers |
US08/460,701 US5756632A (en) | 1992-04-24 | 1995-06-02 | Systems for premeating molecules of predetermined molecular weight range |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87433692A | 1992-04-24 | 1992-04-24 | |
US08/052,361 US5428123A (en) | 1992-04-24 | 1993-04-23 | Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US87433692A Continuation-In-Part | 1992-04-24 | 1992-04-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/221,666 Continuation-In-Part US5589563A (en) | 1992-04-24 | 1994-04-01 | Surface-modifying endgroups for biomedical polymers |
US08/460,701 Division US5756632A (en) | 1992-04-24 | 1995-06-02 | Systems for premeating molecules of predetermined molecular weight range |
Publications (1)
Publication Number | Publication Date |
---|---|
US5428123A true US5428123A (en) | 1995-06-27 |
Family
ID=25363534
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/052,361 Expired - Lifetime US5428123A (en) | 1992-04-24 | 1993-04-23 | Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range |
US08/460,701 Expired - Lifetime US5756632A (en) | 1992-04-24 | 1995-06-02 | Systems for premeating molecules of predetermined molecular weight range |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/460,701 Expired - Lifetime US5756632A (en) | 1992-04-24 | 1995-06-02 | Systems for premeating molecules of predetermined molecular weight range |
Country Status (9)
Country | Link |
---|---|
US (2) | US5428123A (en) |
EP (1) | EP0637323B1 (en) |
JP (1) | JP3857306B2 (en) |
AT (1) | ATE169941T1 (en) |
AU (1) | AU4033893A (en) |
CA (1) | CA2134087C (en) |
DE (1) | DE69320470T2 (en) |
DK (1) | DK0637323T3 (en) |
WO (1) | WO1993022360A1 (en) |
Cited By (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723769A (en) * | 1993-11-19 | 1998-03-03 | Commonwealth Scientific And Industrial Research Organisation | Diffusion cell |
US6060534A (en) * | 1996-07-11 | 2000-05-09 | Scimed Life Systems, Inc. | Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties |
US6112908A (en) * | 1998-02-11 | 2000-09-05 | Rentiers Machinery Pty, Ltd. | Membrane laminates and methods for their preparation |
US6313254B1 (en) | 1996-09-23 | 2001-11-06 | Cardiac Crc Nominees Pty Ltd | Polysiloxane-containing polyurethane elastomeric compositions |
WO2002038197A2 (en) * | 2000-11-09 | 2002-05-16 | The Polymer Technology Group, Inc. | Devices that change size/shape via osmotic pressure |
US20020156434A1 (en) * | 1998-03-13 | 2002-10-24 | Minimed Inc. | Stabilizing catheter for protein drug delivery |
US20030078343A1 (en) * | 2001-10-22 | 2003-04-24 | Harris Kevin M. | Golf balls with segmented polyurethane |
US20030078341A1 (en) * | 2001-10-22 | 2003-04-24 | Harris Kevin M. | Golf balls with thermoplastic polycarbonate-urethane copolymers |
US20030078342A1 (en) * | 2001-10-22 | 2003-04-24 | Harris Kevin M. | Golf ball cover with segmented polyurethane |
WO2003037223A1 (en) | 2001-11-01 | 2003-05-08 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US20030114605A1 (en) * | 2001-10-22 | 2003-06-19 | Harris Kevin M. | Golf balls with thermoplastic silicone-urethane copolymers |
US20030114624A1 (en) * | 2001-10-22 | 2003-06-19 | Harris Kevin M. | Golf balls with silicone-urea copolymers |
US6615078B1 (en) | 1999-04-22 | 2003-09-02 | Cygnus, Inc. | Methods and devices for removing interfering species |
US20030216630A1 (en) * | 2002-01-25 | 2003-11-20 | Inotech Medical Systems, Inc. | Conductivity reconstruction based on inverse finite element measurements in a tissue monitoring system |
US20030218274A1 (en) * | 2002-03-15 | 2003-11-27 | The Procter & Gamble Company | Elements for embossing and adhesive application |
US6673596B1 (en) | 1997-11-25 | 2004-01-06 | Ut-Battelle, Llc | In vivo biosensor apparatus and method of use |
US20040062759A1 (en) * | 1995-07-12 | 2004-04-01 | Cygnus, Inc. | Hydrogel formulations for use in electroosmotic extraction and detection of glucose |
US20040087671A1 (en) * | 2002-08-19 | 2004-05-06 | Tamada Janet A. | Compositions and methods for enhancement of transdermal analyte flux |
US20040199059A1 (en) * | 2003-04-04 | 2004-10-07 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
WO2004104070A1 (en) | 2003-05-21 | 2004-12-02 | The Polymer Technology Group | Permselective structurally robust membrane material |
US20050054909A1 (en) * | 2003-07-25 | 2005-03-10 | James Petisce | Oxygen enhancing membrane systems for implantable devices |
US20050115832A1 (en) * | 2003-07-25 | 2005-06-02 | Simpson Peter C. | Electrode systems for electrochemical sensors |
US20050148955A1 (en) * | 2003-12-26 | 2005-07-07 | Medtronic Minimed, Inc. | Modular catheter system |
US20050148928A1 (en) * | 2003-12-31 | 2005-07-07 | Medtronic Minimed, Inc. | Multiple layer tubing and method of making same |
US20050147861A1 (en) * | 2003-12-11 | 2005-07-07 | Samsung Sdi Co., Ltd. | Proton conducting electrolyte and fuel cell using the same |
US20050161346A1 (en) * | 2003-12-08 | 2005-07-28 | Peter Simpson | Systems and methods for improving electrochemical analyte sensors |
EP1559685A2 (en) * | 2000-11-09 | 2005-08-03 | The Polymer Technology Group, Inc. | Devices that change size/shape via osmotic pressure |
US20050176136A1 (en) * | 2003-11-19 | 2005-08-11 | Dexcom, Inc. | Afinity domain for analyte sensor |
US20050282997A1 (en) * | 2002-11-12 | 2005-12-22 | The Polymer Technology Group, Inc. | Control of polymer surface molecular architecture via amphipathic endgroups |
US20060030933A1 (en) * | 2004-08-04 | 2006-02-09 | Delegge Rebecca | Thermal transition methods and devices |
US20060100411A1 (en) * | 2002-12-20 | 2006-05-11 | Meltzer A D | Organometallic-free polyurethanes having low extractables |
US20060173139A1 (en) * | 2001-10-22 | 2006-08-03 | Shawn Ricci | Golf equipment formed from amine-adduct modified polyurea compositions |
US20060178233A1 (en) * | 2001-10-22 | 2006-08-10 | Shawn Ricci | Golf equipment formed from amine-adduct modified polyurea compositions |
US20060183871A1 (en) * | 2003-05-21 | 2006-08-17 | Ward Robert S | Biosensor membrane material |
US7110803B2 (en) | 1997-03-04 | 2006-09-19 | Dexcom, Inc. | Device and method for determining analyte levels |
US20060257996A1 (en) * | 2005-04-15 | 2006-11-16 | Simpson Peter C | Analyte sensing biointerface |
US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US20070117656A1 (en) * | 2001-10-22 | 2007-05-24 | Murali Rajagopalan | Golf ball compositions having in-situ or reactive impact modified silicone-urea or silicone urethane |
US20070113471A1 (en) * | 2003-09-12 | 2007-05-24 | Uri Peled | Agricultural soil heating processes using aromatic thermoplastic polyurethane films |
US7225008B1 (en) | 2003-05-21 | 2007-05-29 | Isense Corporation | Multiple use analyte sensing assembly |
US7226978B2 (en) | 2002-05-22 | 2007-06-05 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US20070231192A1 (en) * | 2006-03-31 | 2007-10-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Sterilization methods and systems |
US20070231188A1 (en) * | 2006-03-31 | 2007-10-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for sterilization |
US20070231204A1 (en) * | 2006-03-31 | 2007-10-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Surveying sterilizer methods and systems |
US20070231189A1 (en) * | 2006-03-31 | 2007-10-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Sterilization methods and systems |
US20070250103A1 (en) * | 2006-04-19 | 2007-10-25 | Joshua Makower | Devices and methods for treatment of obesity |
US20070250020A1 (en) * | 2006-04-19 | 2007-10-25 | Steven Kim | Devices and methods for treatment of obesity |
US20070286398A1 (en) * | 2006-06-07 | 2007-12-13 | Venkatesan Ramamoorthy | Voice Recognition Dialing For Alphabetic Phone Numbers |
US20080050410A1 (en) * | 2005-10-11 | 2008-02-28 | Luna Innovations Incorporated | Self-Decontaminating Surface Coatings and Articles Prepared Therefrom |
US20080051823A1 (en) * | 2006-04-19 | 2008-02-28 | Joshua Makower | Devices and methods for treatment of obesity |
US20080102126A1 (en) * | 2006-10-27 | 2008-05-01 | Bayer Materialscience Ag | Novel hydrogels based on aliphatic NCO prepolymers |
US20080182286A1 (en) * | 2001-04-18 | 2008-07-31 | Diesetronic Licensing Ag | Immersion sensor for measuring the concentration of an analyte with the help of an oxide |
US20080262521A1 (en) * | 2006-04-19 | 2008-10-23 | Joshua Makower | Devices and methods for treatment of obesity |
US20090012554A1 (en) * | 2006-04-19 | 2009-01-08 | Joshua Makower | Devices and methods for treatment of obesity |
US20090054854A1 (en) * | 2007-08-24 | 2009-02-26 | Gernot Hochmuth | Microdialysis catheter and process for manufacture |
US20090112321A1 (en) * | 2005-08-04 | 2009-04-30 | Kitchen Michael S | Spinal stabilization device and method |
US20090208378A1 (en) * | 2006-03-31 | 2009-08-20 | Searete Llc | Methods and systems for monitoring sterilization status |
US20090281563A1 (en) * | 2006-04-19 | 2009-11-12 | Newell Matthew B | Devices, tools and methods for performing minimally invasive abdominal surgical procedures |
US20090281500A1 (en) * | 2006-04-19 | 2009-11-12 | Acosta Pablo G | Devices, system and methods for minimally invasive abdominal surgical procedures |
US20090281377A1 (en) * | 2006-04-19 | 2009-11-12 | Newell Matthew B | Devices, tools and methods for performing minimally invasive abdominal surgical procedures |
US20090301957A1 (en) * | 2006-09-06 | 2009-12-10 | Massimo Bertolucci | Filter for the removal of substances from blood products |
US20090318549A1 (en) * | 2008-06-24 | 2009-12-24 | Qlt Plug Delivery, Inc. | Combination treatment of glaucoma |
US20090326077A1 (en) * | 2008-06-27 | 2009-12-31 | Cardiac Pacemakers, Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
WO2010039986A1 (en) * | 2008-10-01 | 2010-04-08 | The University Of Akron | Polymers having both hard and soft segments, and process for making same |
US7711402B2 (en) | 1997-03-04 | 2010-05-04 | Dexcom, Inc. | Device and method for determining analyte levels |
US20100111775A1 (en) * | 2006-03-31 | 2010-05-06 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Surveying sterilizer methods and systems |
US20100179298A1 (en) * | 2009-01-12 | 2010-07-15 | University Of Massachusetts Lowell | Polyisobutylene-Based Polyurethanes |
WO2010080967A1 (en) * | 2009-01-09 | 2010-07-15 | Johnson Controls Technology Company | Natural fiber trim panel |
US7761130B2 (en) | 2003-07-25 | 2010-07-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US20100247594A1 (en) * | 2005-03-11 | 2010-09-30 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
US7828728B2 (en) | 2003-07-25 | 2010-11-09 | Dexcom, Inc. | Analyte sensor |
US20100285089A1 (en) * | 2000-09-29 | 2010-11-11 | Llanos Gerard H | Medical Devices, Drug Coatings And Methods For Maintaining The Drug Coatings Thereon |
US20100317579A1 (en) * | 2005-03-11 | 2010-12-16 | Endo Pharmaceuticals Solutions Inc. | Controlled release formulations of octreotide |
US7860545B2 (en) | 1997-03-04 | 2010-12-28 | Dexcom, Inc. | Analyte measuring device |
US7862519B1 (en) | 2003-05-21 | 2011-01-04 | Isense Corporation | Easy-to-use multi-use body fluid specimen collection and analyte sensing assembly |
US20110009799A1 (en) * | 2009-05-15 | 2011-01-13 | Interface Biologics, Inc. | Antithrombogenic hollow fiber membranes and filters |
US7875293B2 (en) | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
US7885697B2 (en) | 2004-07-13 | 2011-02-08 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20110033515A1 (en) * | 2009-08-04 | 2011-02-10 | Rst Implanted Cell Technology | Tissue contacting material |
US20110042315A1 (en) * | 2009-08-19 | 2011-02-24 | University Of Connecticut | Pervaporation composite membrane for aqueous solution separation and methods for using the same |
US20110045030A1 (en) * | 2009-08-21 | 2011-02-24 | Cardiac Pacemakers, Inc. | Crosslinkable polyisobutylene-based polymers and medical devices containing the same |
US20110054580A1 (en) * | 2009-09-02 | 2011-03-03 | Shrojalkumar Desai | Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same |
US20110054581A1 (en) * | 2009-09-02 | 2011-03-03 | Shrojalkumar Desai | Medical devices including polyisobutylene based polymers and derivatives thereof |
US20110144466A1 (en) * | 2004-12-08 | 2011-06-16 | Yanan Zhang | Catheter-Free Implantable Needle Biosensor |
EP2335566A1 (en) | 2004-06-16 | 2011-06-22 | iSense Corporation | Compound metal analyte sensor |
US20110152989A1 (en) * | 2009-12-23 | 2011-06-23 | Pacesetter, Inc. | Soft abrasion-resistant polyisobutylene urethane copolymers |
US7976554B2 (en) | 2006-04-19 | 2011-07-12 | Vibrynt, Inc. | Devices, tools and methods for performing minimally invasive abdominal surgical procedures |
WO2011084651A1 (en) | 2009-12-21 | 2011-07-14 | Medtronic Minimed, Inc. | Analyte sensors comprising blended membrane compositions and methods for making and using them |
US20110207897A1 (en) * | 2007-12-20 | 2011-08-25 | Dsm Ip Assets B.V. | Ionomers for improved compression set in certain copolymers |
US8064977B2 (en) | 2002-05-22 | 2011-11-22 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US20110312237A1 (en) * | 2007-01-18 | 2011-12-22 | Lubrizol Advanced Materials, Inc. | High Moisture Vapor Transmissive Polyurethanes |
WO2012071476A2 (en) | 2010-11-24 | 2012-05-31 | David Haffner | Drug eluting ocular implant |
US8192455B2 (en) | 2003-08-13 | 2012-06-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compressive device for percutaneous treatment of obesity |
US8277713B2 (en) | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
US8290559B2 (en) | 2007-12-17 | 2012-10-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
WO2012150409A1 (en) * | 2011-05-04 | 2012-11-08 | Rexam Healthcare La Verpilliere | Liquid dispensing device equipped with an air duct |
WO2013013055A1 (en) | 2011-07-21 | 2013-01-24 | Rubigo Therapeutics, Inc. | System for drug delivery and monitoring |
US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US20130041108A1 (en) * | 2011-05-19 | 2013-02-14 | Joseph P. Kennedy | Polymers having both hard and soft segments, and process for making same |
US8382775B1 (en) | 2012-01-08 | 2013-02-26 | Vibrynt, Inc. | Methods, instruments and devices for extragastric reduction of stomach volume |
US20130055583A1 (en) * | 2010-01-20 | 2013-03-07 | EREMA Engineering Recycling Maschinen und Anlagen Geselischaft m.b.H. Friedorf, | Method for producing a polymer material filled with long fibers |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8509871B2 (en) | 2001-07-27 | 2013-08-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US8556925B2 (en) | 2007-10-11 | 2013-10-15 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US8560039B2 (en) | 2008-09-19 | 2013-10-15 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US8562558B2 (en) | 2007-06-08 | 2013-10-22 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8583204B2 (en) | 2008-03-28 | 2013-11-12 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US20130331537A1 (en) * | 2012-06-08 | 2013-12-12 | Poly-Med, Inc. | Polyether urethane and polyether urea based copolymers and methods related thereto |
US8660663B2 (en) | 2010-12-20 | 2014-02-25 | Cardiac Pacemakers, Inc. | Lead having a conductive polymer conductor |
US8682408B2 (en) | 2008-03-28 | 2014-03-25 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8744546B2 (en) | 2005-05-05 | 2014-06-03 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
US8758679B2 (en) | 2006-03-31 | 2014-06-24 | The Invention Science Fund I, Llc | Surveying sterilizer methods and systems |
US8840552B2 (en) | 2001-07-27 | 2014-09-23 | Dexcom, Inc. | Membrane for use with implantable devices |
US8929968B2 (en) | 2003-12-05 | 2015-01-06 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
WO2015073571A1 (en) | 2013-11-15 | 2015-05-21 | Dose Medical Corporation | Ocular implants configured to store and release stable drug formulations |
US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9220888B2 (en) | 2012-04-02 | 2015-12-29 | Medtronic, Inc. | Medical leads |
US20160030641A1 (en) * | 2014-07-31 | 2016-02-04 | Proton Innovations, LLC | Mixed-phase biomaterials |
US20160090437A1 (en) * | 2006-11-30 | 2016-03-31 | The University Of Akron | Polyisobutylenes and process for making same |
US9314362B2 (en) | 2012-01-08 | 2016-04-19 | Vibrynt, Inc. | Methods, instruments and devices for extragastric reduction of stomach volume |
US9322103B2 (en) | 2010-08-06 | 2016-04-26 | Microchips Biotech, Inc. | Biosensor membrane composition, biosensor, and methods for making same |
US9439589B2 (en) | 1997-03-04 | 2016-09-13 | Dexcom, Inc. | Device and method for determining analyte levels |
US9451908B2 (en) | 2006-10-04 | 2016-09-27 | Dexcom, Inc. | Analyte sensor |
US20160324755A1 (en) * | 2015-05-06 | 2016-11-10 | Soongsil University Research Consortium Techno-Park | Method for preparing hydrocolloid having diverse range of hydrophobicity |
US9498155B2 (en) | 2003-12-09 | 2016-11-22 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
US20170106124A1 (en) * | 2015-10-17 | 2017-04-20 | Cardiac Pacemakers, Inc. | Production of in situ crosslinkable polyisobutylene-polyurethane nanofibers and coatings |
US9649069B2 (en) | 2003-08-22 | 2017-05-16 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US20170191955A1 (en) * | 2015-12-30 | 2017-07-06 | Dexcom, Inc. | Diffusion resistance layer for analyte sensors |
US9763609B2 (en) | 2003-07-25 | 2017-09-19 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US20170333835A1 (en) * | 2015-02-27 | 2017-11-23 | Fujifilm Corporation | Gas separation membrane, gas separation module, gas separation apparatus, gas separation method, and method for producing asymmetric gas separation membrane |
US20170333836A1 (en) * | 2015-02-27 | 2017-11-23 | Fujifilm Corporation | Gas separation asymmetric membrane, gas separation module, gas separation device, and gas separation method |
US20180021741A1 (en) * | 2015-02-27 | 2018-01-25 | Fujifilm Corporation | Gas separation membrane, gas separation module, gas separation apparatus, and gas separation method |
US9926399B2 (en) | 2012-11-21 | 2018-03-27 | University Of Massachusetts | High strength polyisobutylene polyurethanes |
US9986942B2 (en) | 2004-07-13 | 2018-06-05 | Dexcom, Inc. | Analyte sensor |
EP3366264A1 (en) | 2013-03-15 | 2018-08-29 | Dose Medical Corporation | Implants with controlled drug delivery features |
US10526429B2 (en) | 2017-03-07 | 2020-01-07 | Cardiac Pacemakers, Inc. | Hydroboration/oxidation of allyl-terminated polyisobutylene |
US10557030B2 (en) | 2016-10-18 | 2020-02-11 | Evonik Canada Inc. | Plasticized PVC admixtures with surface modifying macromolecules and articles made therefrom |
US10610136B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
EP3677229A1 (en) | 2014-05-29 | 2020-07-08 | Glaukos Corporation | Implants with controlled drug delivery features |
US10791928B2 (en) | 2007-05-18 | 2020-10-06 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US10813577B2 (en) | 2005-06-21 | 2020-10-27 | Dexcom, Inc. | Analyte sensor |
CN111893642A (en) * | 2020-08-10 | 2020-11-06 | 四川大学 | Halamine polymer antibacterial and antiviral nanofiber membrane and preparation method thereof |
US10835672B2 (en) | 2004-02-26 | 2020-11-17 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US10835638B2 (en) | 2017-08-17 | 2020-11-17 | Cardiac Pacemakers, Inc. | Photocrosslinked polymers for enhanced durability |
US10961340B2 (en) | 2017-07-14 | 2021-03-30 | Fresenius Medical Care Holdings, Inc. | Method for providing surface modifying composition with improved byproduct removal |
US10966609B2 (en) | 2004-02-26 | 2021-04-06 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US10980461B2 (en) | 2008-11-07 | 2021-04-20 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US11000215B1 (en) | 2003-12-05 | 2021-05-11 | Dexcom, Inc. | Analyte sensor |
CN113366306A (en) * | 2018-12-13 | 2021-09-07 | 哈美顿博纳图斯股份公司 | Composite electrode comprising a separator containing an aqueous gel and method for manufacturing such a composite electrode |
WO2021184843A1 (en) * | 2020-03-18 | 2021-09-23 | 微泰医疗器械(杭州)有限公司 | Triblock copolymer for implantable biosensor, application thereof, and preparation method therefor |
US11179079B2 (en) | 2012-09-28 | 2021-11-23 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
US11246990B2 (en) | 2004-02-26 | 2022-02-15 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US11350862B2 (en) | 2017-10-24 | 2022-06-07 | Dexcom, Inc. | Pre-connected analyte sensors |
US11382539B2 (en) | 2006-10-04 | 2022-07-12 | Dexcom, Inc. | Analyte sensor |
US11399745B2 (en) | 2006-10-04 | 2022-08-02 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US11432772B2 (en) | 2006-08-02 | 2022-09-06 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US11472911B2 (en) | 2018-01-17 | 2022-10-18 | Cardiac Pacemakers, Inc. | End-capped polyisobutylene polyurethane |
US11559260B2 (en) | 2003-08-22 | 2023-01-24 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US11730407B2 (en) | 2008-03-28 | 2023-08-22 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US20240076491A1 (en) * | 2022-08-16 | 2024-03-07 | Nano And Advanced Materials Institute Limited | Non-porous, breathable and waterproof transparent elastomer film and method for manufacturing the same |
US11998329B2 (en) | 2013-03-15 | 2024-06-04 | Dexcom, Inc. | Membrane for continuous analyte sensors |
US12091489B1 (en) * | 2023-06-05 | 2024-09-17 | Joseph P. Kennedy | Multiply-crosslinked polyisobutylene-based polyurethanes and their preparations and uses thereof |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5954966A (en) * | 1997-01-31 | 1999-09-21 | University Of Ottawa | Membrane composition and method of preparation |
FR2778081B1 (en) * | 1998-04-29 | 2000-08-25 | Fabrice Thevenet | REINFORCEMENT IMPLANTS FOR TISSUE SUTURES |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6723820B1 (en) * | 2000-11-13 | 2004-04-20 | Sun Chemical Corporation | Solvent soluble poly(urethane/urea) resins |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
US7041468B2 (en) | 2001-04-02 | 2006-05-09 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
WO2002094900A1 (en) * | 2001-05-21 | 2002-11-28 | Dow Global Technologies Inc. | Transparent polyurethane-hydrogel composition, method of making transparent polyurethane-hydrogel composition, and air-freshener application |
FR2834513B1 (en) * | 2002-01-08 | 2006-01-20 | Alstom Switzerland Ltd | MATERIALS PROVIDING CAVITATION EROSION RESISTANCE IN LIQUID FLOWS |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US6890592B2 (en) * | 2002-03-13 | 2005-05-10 | Appleton Papers Inc. | Uniform microcapsules |
US20060258761A1 (en) * | 2002-05-22 | 2006-11-16 | Robert Boock | Silicone based membranes for use in implantable glucose sensors |
TW580384B (en) * | 2002-07-01 | 2004-03-21 | Neochemir Inc | Carbon dioxide administrating device |
US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
WO2005012871A2 (en) * | 2003-07-25 | 2005-02-10 | Dexcom, Inc. | Increasing bias for oxygen production in an electrode system |
US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
CA2437639C (en) | 2003-08-11 | 2016-07-05 | Valera Pharmaceuticals, Inc. | Long term drug delivery devices with polyurethane based polymers and their manufacture |
US7858110B2 (en) | 2003-08-11 | 2010-12-28 | Endo Pharmaceuticals Solutions, Inc. | Long term drug delivery devices with polyurethane based polymers and their manufacture |
JP5496457B2 (en) * | 2004-03-24 | 2014-05-21 | ポリィノボ バイオマテリアルズ ピーティワイ リミテッド | Biodegradable polyurethane and polyurethaneurea |
AU2005223917B2 (en) * | 2004-03-24 | 2010-01-21 | Polynovo Biomaterials Pty Limited | Biodegradable polyurethane and polyurethane ureas |
EP1745085A2 (en) * | 2004-05-14 | 2007-01-24 | E.I.Du pont de nemours and company | Golf balls formed using compositions containing copolymers derived from polytrimethylene ether glycol |
US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US8886272B2 (en) | 2004-07-13 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7905833B2 (en) | 2004-07-13 | 2011-03-15 | Dexcom, Inc. | Transcutaneous analyte sensor |
CA2574933C (en) * | 2004-07-26 | 2015-05-19 | Synthes (U.S.A.) | Biocompatible, biodegradable polyurethane materials with controlled hydrophobic to hydrophilic ratio |
GB0500764D0 (en) * | 2005-01-14 | 2005-02-23 | Baxenden Chem | Low swell, water vapour permeable poly(urethane-urea)s |
US20060211839A1 (en) * | 2005-03-10 | 2006-09-21 | Radi Medical Systems Ab | Polyureaurethane material and method of producing a polyureaurethane material |
US20060205910A1 (en) * | 2005-03-10 | 2006-09-14 | Radi Medical Systems Ab | Polyureaurethane material and method of producing a polyureaurethane material |
EP1931265B1 (en) * | 2005-09-30 | 2011-12-07 | Cook Medical Technologies LLC | Coated vaso-occlusion device |
PL1954769T3 (en) * | 2005-11-02 | 2013-03-29 | Sun Chemical Corp | Flexographic and gravure printing inks for nonwoven substrates |
EP1991110B1 (en) | 2006-03-09 | 2018-11-07 | DexCom, Inc. | Systems and methods for processing analyte sensor data |
US8642307B2 (en) * | 2006-05-25 | 2014-02-04 | Nalge Nunc International Corporation | Cell culture surface chemistries |
US20080064937A1 (en) | 2006-06-07 | 2008-03-13 | Abbott Diabetes Care, Inc. | Analyte monitoring system and method |
ATE416526T1 (en) * | 2006-08-25 | 2008-12-15 | Alcatel Lucent | DIGITAL SIGNAL RECEIVER WITH Q-FACTOR MONITORING |
WO2008112894A1 (en) * | 2007-03-15 | 2008-09-18 | Jiayi Li | Devices, systems, kits and methods for treatment of obesity |
EP2072549A1 (en) * | 2007-12-19 | 2009-06-24 | Huntsman International Llc | Novel composition from a polyisocyanate and a polyether monoamine |
US20110160310A1 (en) * | 2008-09-04 | 2011-06-30 | Bayer Materialscience Ag | Tcb based hydrophilic polyurethane dispersions |
WO2010039722A1 (en) * | 2008-09-30 | 2010-04-08 | Endo Pharmaceuticals Solutions Inc. | Implantable device for the delivery of risperidone and methods of use thereof |
FR2952040B1 (en) * | 2009-10-29 | 2011-12-30 | Rexam Pharma La Verpilliere | DEVICE FOR DISPENSING LIQUID IN THE FORM OF DROPS |
DK2513200T3 (en) * | 2009-12-18 | 2018-06-14 | Coloplast As | A biomaterial |
US20110153027A1 (en) * | 2009-12-18 | 2011-06-23 | Vysera Biomedical Limited | Drug Delivery System |
AU2011325975B2 (en) | 2010-11-12 | 2015-11-26 | The University Of Utah Research Foundation | Intravaginal devices for controlled delivery of lubricants |
WO2012065998A1 (en) * | 2010-11-15 | 2012-05-24 | Dsm Ip Assets B.V. | Polyurethane copolymer |
EP2640354B1 (en) | 2010-11-15 | 2019-03-13 | DSM IP Assets B.V. | Intravaginal drug delivery device comprising a polyurethane copolymer |
FR3013614B1 (en) * | 2013-11-26 | 2018-03-23 | Nemera La Verpilliere | PUMP WITH AIR RETURN |
CN108042856A (en) * | 2018-02-07 | 2018-05-18 | 苏州元禾医疗器械有限公司 | A kind of preparation method of operation biomembrane |
CN108114327A (en) * | 2018-02-07 | 2018-06-05 | 苏州元禾医疗器械有限公司 | A kind of operation biomembrane |
CN110746299B (en) * | 2019-09-30 | 2021-01-26 | 南京工业大学 | High-quality vegetable oil polyol and preparation method and application thereof |
Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3804786A (en) * | 1971-07-14 | 1974-04-16 | Desoto Inc | Water-dispersible cationic polyurethane resins |
US3826768A (en) * | 1968-11-08 | 1974-07-30 | Asahi Chemical Ind | Process for preparing polyurethane compositions |
US3852090A (en) * | 1972-03-27 | 1974-12-03 | Lowenstein & Sons M | Waterproof, breathable coated textile substrate |
US4124572A (en) * | 1977-07-05 | 1978-11-07 | Uniroyal, Inc. | Thermoplastic polyurethane elastomer |
US4183836A (en) * | 1978-02-06 | 1980-01-15 | E. I. Du Pont De Nemours And Company | Aqueous polyurethane dispersions |
US4190566A (en) * | 1975-12-10 | 1980-02-26 | Bayer Aktiengesellschaft | Water-dispersible polyurethanes |
US4202957A (en) * | 1974-09-09 | 1980-05-13 | The Upjohn Company | Thermoplastic polyurethane elastomers from polyoxypropylene polyoxyethylene block copolymers |
US4202880A (en) * | 1976-12-13 | 1980-05-13 | Imperial Chemical Industries Limited | Delivery means for biologically active agents comprising hydrophilic polyurethane |
US4224432A (en) * | 1978-12-11 | 1980-09-23 | E. I. Du Pont De Nemours And Company | Polyurethanes prepared with tetrahydrofuran-alkylene oxide polymerizates having low oligomeric cyclic ether content |
GB2049544A (en) * | 1979-05-04 | 1980-12-31 | Akzo Nv | Ultrafiltration membranes comprising linear polyurethanes |
GB2073219A (en) * | 1980-02-29 | 1981-10-14 | Thoratec Lab Corp | Polymer surfaces for blood- contacting surfaces of a biomedical device, and methods for forming |
US4367327A (en) * | 1980-11-22 | 1983-01-04 | Shirley Institute | Breathable, non-porous polyurethane film prepared from a low molecular weight difunctional compound, a polyethylene glycol and a diisocyanate |
EP0069852A1 (en) * | 1981-07-11 | 1983-01-19 | Akzo GmbH | Linear segmented polyurethanes, process for their preparation and their use |
EP0107915A1 (en) * | 1982-10-02 | 1984-05-09 | Smith and Nephew Associated Companies p.l.c. | Surgical dressing |
WO1985005373A1 (en) * | 1984-05-21 | 1985-12-05 | Thoratec Laboratories Corporation | Moisture vapor permeable materials containing segmented block multipolymer |
WO1985005322A1 (en) * | 1984-05-21 | 1985-12-05 | Thoratec Laboratories Corporation | Moisture vapor permeable materials |
US4743629A (en) * | 1987-07-02 | 1988-05-10 | Becton, Dickinson And Company | Crosslinked polyetherurethane membranes useful in blood electrolyte sensors |
EP0272682A2 (en) * | 1986-12-22 | 1988-06-29 | Kimberly-Clark Corporation | Superabsorbent thermoplastic compositions |
US4849458A (en) * | 1988-06-17 | 1989-07-18 | Matrix Medica, Inc. | Segmented polyether polyurethane |
EP0333899A2 (en) * | 1988-03-23 | 1989-09-27 | Hampshire Chemical Corporation | Biocompatible polyurea-urethane hydrated polymers |
US4892538A (en) * | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5017664A (en) * | 1987-06-03 | 1991-05-21 | Wisconsin Alumni Research Foundation | Biocompatible polyurethane devices wherein polyurethane is modified with lower alkyl sulfonate and lower alkyl carboxylate |
US5047456A (en) * | 1989-04-21 | 1991-09-10 | Kimberly-Clark Corporation | Thermally reversible superabsorbent polymers |
US5079168A (en) * | 1988-08-10 | 1992-01-07 | Endotronics, Inc. | Cell culture apparatus |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4377010A (en) * | 1978-11-08 | 1983-03-22 | The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland | Biocompatible material comprising a base polymer bulk graft polymerized with an ethylenically unsaturated carboxylic acid |
US5116371A (en) * | 1990-07-06 | 1992-05-26 | Christensen James M | Prosthesis with improved biocompatibility |
-
1993
- 1993-04-23 WO PCT/US1993/003851 patent/WO1993022360A1/en active IP Right Grant
- 1993-04-23 US US08/052,361 patent/US5428123A/en not_active Expired - Lifetime
- 1993-04-23 EP EP93909616A patent/EP0637323B1/en not_active Expired - Lifetime
- 1993-04-23 CA CA002134087A patent/CA2134087C/en not_active Expired - Lifetime
- 1993-04-23 JP JP51941193A patent/JP3857306B2/en not_active Expired - Lifetime
- 1993-04-23 AT AT93909616T patent/ATE169941T1/en active
- 1993-04-23 DE DE69320470T patent/DE69320470T2/en not_active Expired - Lifetime
- 1993-04-23 DK DK93909616T patent/DK0637323T3/en active
- 1993-04-23 AU AU40338/93A patent/AU4033893A/en not_active Abandoned
-
1995
- 1995-06-02 US US08/460,701 patent/US5756632A/en not_active Expired - Lifetime
Patent Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3826768A (en) * | 1968-11-08 | 1974-07-30 | Asahi Chemical Ind | Process for preparing polyurethane compositions |
US3804786A (en) * | 1971-07-14 | 1974-04-16 | Desoto Inc | Water-dispersible cationic polyurethane resins |
US3852090A (en) * | 1972-03-27 | 1974-12-03 | Lowenstein & Sons M | Waterproof, breathable coated textile substrate |
US4202957A (en) * | 1974-09-09 | 1980-05-13 | The Upjohn Company | Thermoplastic polyurethane elastomers from polyoxypropylene polyoxyethylene block copolymers |
US4190566A (en) * | 1975-12-10 | 1980-02-26 | Bayer Aktiengesellschaft | Water-dispersible polyurethanes |
US4202880A (en) * | 1976-12-13 | 1980-05-13 | Imperial Chemical Industries Limited | Delivery means for biologically active agents comprising hydrophilic polyurethane |
US4124572A (en) * | 1977-07-05 | 1978-11-07 | Uniroyal, Inc. | Thermoplastic polyurethane elastomer |
US4183836A (en) * | 1978-02-06 | 1980-01-15 | E. I. Du Pont De Nemours And Company | Aqueous polyurethane dispersions |
US4224432A (en) * | 1978-12-11 | 1980-09-23 | E. I. Du Pont De Nemours And Company | Polyurethanes prepared with tetrahydrofuran-alkylene oxide polymerizates having low oligomeric cyclic ether content |
GB2049544A (en) * | 1979-05-04 | 1980-12-31 | Akzo Nv | Ultrafiltration membranes comprising linear polyurethanes |
GB2073219A (en) * | 1980-02-29 | 1981-10-14 | Thoratec Lab Corp | Polymer surfaces for blood- contacting surfaces of a biomedical device, and methods for forming |
US4367327A (en) * | 1980-11-22 | 1983-01-04 | Shirley Institute | Breathable, non-porous polyurethane film prepared from a low molecular weight difunctional compound, a polyethylene glycol and a diisocyanate |
EP0069852A1 (en) * | 1981-07-11 | 1983-01-19 | Akzo GmbH | Linear segmented polyurethanes, process for their preparation and their use |
EP0107915A1 (en) * | 1982-10-02 | 1984-05-09 | Smith and Nephew Associated Companies p.l.c. | Surgical dressing |
WO1985005373A1 (en) * | 1984-05-21 | 1985-12-05 | Thoratec Laboratories Corporation | Moisture vapor permeable materials containing segmented block multipolymer |
WO1985005322A1 (en) * | 1984-05-21 | 1985-12-05 | Thoratec Laboratories Corporation | Moisture vapor permeable materials |
EP0272682A2 (en) * | 1986-12-22 | 1988-06-29 | Kimberly-Clark Corporation | Superabsorbent thermoplastic compositions |
US5017664A (en) * | 1987-06-03 | 1991-05-21 | Wisconsin Alumni Research Foundation | Biocompatible polyurethane devices wherein polyurethane is modified with lower alkyl sulfonate and lower alkyl carboxylate |
US4743629A (en) * | 1987-07-02 | 1988-05-10 | Becton, Dickinson And Company | Crosslinked polyetherurethane membranes useful in blood electrolyte sensors |
US4892538A (en) * | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
EP0333899A2 (en) * | 1988-03-23 | 1989-09-27 | Hampshire Chemical Corporation | Biocompatible polyurea-urethane hydrated polymers |
US4849458A (en) * | 1988-06-17 | 1989-07-18 | Matrix Medica, Inc. | Segmented polyether polyurethane |
US5079168A (en) * | 1988-08-10 | 1992-01-07 | Endotronics, Inc. | Cell culture apparatus |
US5047456A (en) * | 1989-04-21 | 1991-09-10 | Kimberly-Clark Corporation | Thermally reversible superabsorbent polymers |
Non-Patent Citations (12)
Title |
---|
A. B. Trezvova, et al., Study of Semipermeable Membranes, Chemical Abstracts, 106:398 (1987). * |
Chen, et al., "Synthesis, Characterization and Permeation Properties of Polyether Based Polyurethanes", J. Appl. Polym. Sci. 16: 2105-2114 (1972). |
Chen, et al., Synthesis, Characterization and Permeation Properties of Polyether Based Polyurethanes , J. Appl. Polym. Sci. 16: 2105 2114 (1972). * |
Okkema et al., "Bulk Surface, and Blood-Contacting Properties of Polyurethanes Modified with Polyethylene Oxide", J. Biomater Sc. Polymer. Edn.1(1):43-62 (1989). |
Okkema et al., Bulk Surface, and Blood Contacting Properties of Polyurethanes Modified with Polyethylene Oxide , J. Biomater Sc. Polymer. Edn.1(1):43 62 (1989). * |
Paynter, et al., "The Hydrolytic Stability of Mitrathane, a Polyuretheneurea-An X-ray Photoelectron Spectroscopy Study", J. Biomed Mater. Res. 22:687-698 (1988). |
Paynter, et al., The Hydrolytic Stability of Mitrathane, a Polyuretheneurea An X ray Photoelectron Spectroscopy Study , J. Biomed Mater. Res. 22:687 698 (1988). * |
Szycher, et al. "Blood Compatible Polyurethane Elastomers", J. Biomater. Appl. 2:290-313 (1987). |
Szycher, et al. Blood Compatible Polyurethane Elastomers , J. Biomater. Appl. 2:290 313 (1987). * |
Takahara, et al., "Surface Molecular Mobility and Platelet Reactivity of (SPUUS) with Hydrophilic and Hydrophobic Soft Segment Components":, J. Biomater. Sci. Polymer. Edn. 1(1):7-29 (1989). |
Takahara, et al., Surface Molecular Mobility and Platelet Reactivity of (SPUUS) with Hydrophilic and Hydrophobic Soft Segment Components :, J. Biomater. Sci. Polymer. Edn. 1(1):7 29 (1989). * |
Text Book of Polymer Science, Billmeyer, Jr., 1962, pp. 6, 7, 13, 53 and 54. * |
Cited By (413)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723769A (en) * | 1993-11-19 | 1998-03-03 | Commonwealth Scientific And Industrial Research Organisation | Diffusion cell |
US20040062759A1 (en) * | 1995-07-12 | 2004-04-01 | Cygnus, Inc. | Hydrogel formulations for use in electroosmotic extraction and detection of glucose |
US6060534A (en) * | 1996-07-11 | 2000-05-09 | Scimed Life Systems, Inc. | Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties |
US6184266B1 (en) | 1996-07-11 | 2001-02-06 | Scimed Life Systems, Inc. | Medical devices comprising cross-linked hydrogels having improved mechanical properties |
US6387978B2 (en) | 1996-07-11 | 2002-05-14 | Boston Scientific Corporation | Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties |
US6313254B1 (en) | 1996-09-23 | 2001-11-06 | Cardiac Crc Nominees Pty Ltd | Polysiloxane-containing polyurethane elastomeric compositions |
US6627724B2 (en) | 1996-09-23 | 2003-09-30 | Aortech Biomaterials Pty Ltd | Polysiloxane-containing polyurethane elastomeric compositions |
US7860545B2 (en) | 1997-03-04 | 2010-12-28 | Dexcom, Inc. | Analyte measuring device |
US8676288B2 (en) | 1997-03-04 | 2014-03-18 | Dexcom, Inc. | Device and method for determining analyte levels |
US7835777B2 (en) | 1997-03-04 | 2010-11-16 | Dexcom, Inc. | Device and method for determining analyte levels |
US9931067B2 (en) | 1997-03-04 | 2018-04-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US7970448B2 (en) | 1997-03-04 | 2011-06-28 | Dexcom, Inc. | Device and method for determining analyte levels |
US7974672B2 (en) | 1997-03-04 | 2011-07-05 | Dexcom, Inc. | Device and method for determining analyte levels |
US8527025B1 (en) | 1997-03-04 | 2013-09-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US9439589B2 (en) | 1997-03-04 | 2016-09-13 | Dexcom, Inc. | Device and method for determining analyte levels |
US7110803B2 (en) | 1997-03-04 | 2006-09-19 | Dexcom, Inc. | Device and method for determining analyte levels |
US7792562B2 (en) | 1997-03-04 | 2010-09-07 | Dexcom, Inc. | Device and method for determining analyte levels |
US7711402B2 (en) | 1997-03-04 | 2010-05-04 | Dexcom, Inc. | Device and method for determining analyte levels |
US9339223B2 (en) | 1997-03-04 | 2016-05-17 | Dexcom, Inc. | Device and method for determining analyte levels |
US6673596B1 (en) | 1997-11-25 | 2004-01-06 | Ut-Battelle, Llc | In vivo biosensor apparatus and method of use |
US6112908A (en) * | 1998-02-11 | 2000-09-05 | Rentiers Machinery Pty, Ltd. | Membrane laminates and methods for their preparation |
US20020156434A1 (en) * | 1998-03-13 | 2002-10-24 | Minimed Inc. | Stabilizing catheter for protein drug delivery |
US7183068B2 (en) | 1999-04-22 | 2007-02-27 | Animas Technologies, Llc | Methods of manufacturing glucose measuring assemblies with hydrogels |
US6902905B2 (en) | 1999-04-22 | 2005-06-07 | Cygnus, Inc. | Glucose measuring assembly with a hydrogel |
US6615078B1 (en) | 1999-04-22 | 2003-09-02 | Cygnus, Inc. | Methods and devices for removing interfering species |
US20030199745A1 (en) * | 1999-04-22 | 2003-10-23 | Cygnus, Inc. | Methods and devices for removing interfering species |
US20050170448A1 (en) * | 1999-04-22 | 2005-08-04 | Cygnus, Inc. | Methods of manufacturing glucose measuring assemblies with hydrogels |
US20100285089A1 (en) * | 2000-09-29 | 2010-11-11 | Llanos Gerard H | Medical Devices, Drug Coatings And Methods For Maintaining The Drug Coatings Thereon |
WO2002038197A2 (en) * | 2000-11-09 | 2002-05-16 | The Polymer Technology Group, Inc. | Devices that change size/shape via osmotic pressure |
US6692528B2 (en) | 2000-11-09 | 2004-02-17 | The Polymer Technology Group Incorporated | Devices that change size/shape via osmotic pressure |
WO2002038197A3 (en) * | 2000-11-09 | 2002-10-10 | Polymer Technology Group Inc | Devices that change size/shape via osmotic pressure |
US7368056B2 (en) | 2000-11-09 | 2008-05-06 | The Polymer Technology Group, Incorporated | Production of potable liquids |
EP1559685A3 (en) * | 2000-11-09 | 2007-04-25 | The Polymer Technology Group, Inc. | Devices that change size/shape via osmotic pressure |
US20040140264A1 (en) * | 2000-11-09 | 2004-07-22 | The Polymer Technology Group, Incorporated | Production of potable liquids |
EP1559685A2 (en) * | 2000-11-09 | 2005-08-03 | The Polymer Technology Group, Inc. | Devices that change size/shape via osmotic pressure |
US7077859B2 (en) | 2000-12-22 | 2006-07-18 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US20050131532A1 (en) * | 2000-12-22 | 2005-06-16 | Avantec Vascular Corporation | Apparatus and methods for controlled substance delivery from implanted prostheses |
US20050107869A1 (en) * | 2000-12-22 | 2005-05-19 | Avantec Vascular Corporation | Apparatus and methods for controlled substance delivery from implanted prostheses |
US8017314B2 (en) | 2001-04-18 | 2011-09-13 | Roche Diagnostics International Ag | Immersion sensor for measuring the concentration of an analyte with the help of an oxidase |
US20080182286A1 (en) * | 2001-04-18 | 2008-07-31 | Diesetronic Licensing Ag | Immersion sensor for measuring the concentration of an analyte with the help of an oxide |
US8840552B2 (en) | 2001-07-27 | 2014-09-23 | Dexcom, Inc. | Membrane for use with implantable devices |
US9804114B2 (en) | 2001-07-27 | 2017-10-31 | Dexcom, Inc. | Sensor head for use with implantable devices |
US8509871B2 (en) | 2001-07-27 | 2013-08-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US9532741B2 (en) | 2001-07-27 | 2017-01-03 | Dexcom, Inc. | Membrane for use with implantable devices |
US10039480B2 (en) | 2001-07-27 | 2018-08-07 | Dexcom, Inc. | Membrane for use with implantable devices |
US9328371B2 (en) | 2001-07-27 | 2016-05-03 | Dexcom, Inc. | Sensor head for use with implantable devices |
WO2003020336A3 (en) * | 2001-09-05 | 2004-02-12 | Medtronic Minimed Inc | Stabilizing catheter for protein drug delivery |
WO2003020336A2 (en) * | 2001-09-05 | 2003-03-13 | Medtronic Minimed, Inc. | Stabilizing catheter for protein drug delivery |
US20030114624A1 (en) * | 2001-10-22 | 2003-06-19 | Harris Kevin M. | Golf balls with silicone-urea copolymers |
US20060178233A1 (en) * | 2001-10-22 | 2006-08-10 | Shawn Ricci | Golf equipment formed from amine-adduct modified polyurea compositions |
US7825208B2 (en) | 2001-10-22 | 2010-11-02 | Acushnet Company | Golf equipment formed from amine-adduct modified polyurea compositions |
US6739987B2 (en) | 2001-10-22 | 2004-05-25 | Acushnet Company | Golf balls with thermoplastic silicone-urethane copolymers |
US20040210021A1 (en) * | 2001-10-22 | 2004-10-21 | Harris Kevin M. | Golf balls with thermoplastic silicone-urethane copolymers |
US6809152B2 (en) | 2001-10-22 | 2004-10-26 | Acushnet Company | Golf ball cover with segmented polyurethane |
US7037217B2 (en) | 2001-10-22 | 2006-05-02 | Acushnet Company | Golf balls with thermoplastic silicone-urethane copolymers |
US6737498B2 (en) | 2001-10-22 | 2004-05-18 | Acushnet Company | Golf balls with segmented polyurethane |
US7705102B2 (en) | 2001-10-22 | 2010-04-27 | Acushnet Company | Golf equipment formed from amine-adduct modified polyurea compositions |
US20030078343A1 (en) * | 2001-10-22 | 2003-04-24 | Harris Kevin M. | Golf balls with segmented polyurethane |
US6855793B2 (en) | 2001-10-22 | 2005-02-15 | Acushnet Company | Golf balls with thermoplastic polycarbonate-urethane copolymers |
US6776729B2 (en) | 2001-10-22 | 2004-08-17 | Acushnet Company | Golf balls with silicone-urea copolymers |
US20060173139A1 (en) * | 2001-10-22 | 2006-08-03 | Shawn Ricci | Golf equipment formed from amine-adduct modified polyurea compositions |
US20030078342A1 (en) * | 2001-10-22 | 2003-04-24 | Harris Kevin M. | Golf ball cover with segmented polyurethane |
US7951870B2 (en) | 2001-10-22 | 2011-05-31 | Acushnet Company | Golf ball compositions having in-situ or reactive impact modified silicone-urea or silicone urethane |
US20070117656A1 (en) * | 2001-10-22 | 2007-05-24 | Murali Rajagopalan | Golf ball compositions having in-situ or reactive impact modified silicone-urea or silicone urethane |
US20030114605A1 (en) * | 2001-10-22 | 2003-06-19 | Harris Kevin M. | Golf balls with thermoplastic silicone-urethane copolymers |
US20030078341A1 (en) * | 2001-10-22 | 2003-04-24 | Harris Kevin M. | Golf balls with thermoplastic polycarbonate-urethane copolymers |
WO2003037223A1 (en) | 2001-11-01 | 2003-05-08 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US20030216630A1 (en) * | 2002-01-25 | 2003-11-20 | Inotech Medical Systems, Inc. | Conductivity reconstruction based on inverse finite element measurements in a tissue monitoring system |
US20030216662A1 (en) * | 2002-01-25 | 2003-11-20 | Inotech Medical Systems, Inc. | Film barrier dressing for intravascular tissue monitoring system |
US7169107B2 (en) | 2002-01-25 | 2007-01-30 | Karen Jersey-Willuhn | Conductivity reconstruction based on inverse finite element measurements in a tissue monitoring system |
US20030216663A1 (en) * | 2002-01-25 | 2003-11-20 | Inotech Medical Systems, Inc. | Tissue monitoring system for intravascular infusion |
US7184820B2 (en) | 2002-01-25 | 2007-02-27 | Subqiview, Inc. | Tissue monitoring system for intravascular infusion |
US6980852B2 (en) | 2002-01-25 | 2005-12-27 | Subqiview Inc. | Film barrier dressing for intravascular tissue monitoring system |
US7101437B2 (en) | 2002-03-15 | 2006-09-05 | The Procter & Gamble Company | Elements for embossing and adhesive application |
US20030218274A1 (en) * | 2002-03-15 | 2003-11-27 | The Procter & Gamble Company | Elements for embossing and adhesive application |
US10154807B2 (en) | 2002-05-22 | 2018-12-18 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US8543184B2 (en) | 2002-05-22 | 2013-09-24 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US11020026B2 (en) | 2002-05-22 | 2021-06-01 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US7226978B2 (en) | 2002-05-22 | 2007-06-05 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US8064977B2 (en) | 2002-05-22 | 2011-11-22 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US8053018B2 (en) | 2002-05-22 | 2011-11-08 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US8050731B2 (en) | 2002-05-22 | 2011-11-01 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US9179869B2 (en) | 2002-05-22 | 2015-11-10 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US10052051B2 (en) | 2002-05-22 | 2018-08-21 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US9549693B2 (en) | 2002-05-22 | 2017-01-24 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US8865249B2 (en) | 2002-05-22 | 2014-10-21 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US9801574B2 (en) | 2002-05-22 | 2017-10-31 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US7150975B2 (en) | 2002-08-19 | 2006-12-19 | Animas Technologies, Llc | Hydrogel composition for measuring glucose flux |
US20040087671A1 (en) * | 2002-08-19 | 2004-05-06 | Tamada Janet A. | Compositions and methods for enhancement of transdermal analyte flux |
US20060105420A1 (en) * | 2002-08-19 | 2006-05-18 | Tamada Janet A | Compositions and methods for enhancement of transdermal analyte flux |
US7884171B2 (en) | 2002-11-12 | 2011-02-08 | Dsm Ip Assets B.V. | Control of polymer surface molecular architecture via amphipathic endgroups |
US20050282997A1 (en) * | 2002-11-12 | 2005-12-22 | The Polymer Technology Group, Inc. | Control of polymer surface molecular architecture via amphipathic endgroups |
US20100113711A1 (en) * | 2002-11-12 | 2010-05-06 | Ward Robert S | Control of polymer surface molecular architecture via amphipathic endgroups |
US7671162B2 (en) * | 2002-11-12 | 2010-03-02 | Dsm Ip Assets B.V. | Control of polymer surface molecular architecture via amphipathic endgroups |
US20060100411A1 (en) * | 2002-12-20 | 2006-05-11 | Meltzer A D | Organometallic-free polyurethanes having low extractables |
US20040199059A1 (en) * | 2003-04-04 | 2004-10-07 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US7881763B2 (en) | 2003-04-04 | 2011-02-01 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US7134999B2 (en) | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US7875293B2 (en) | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
US7687586B2 (en) | 2003-05-21 | 2010-03-30 | Isense Corporation | Biosensor membrane material |
EP1629028A4 (en) * | 2003-05-21 | 2006-08-16 | Polymer Technology Group Inc | Permselective structurally robust membrane material |
US20140275900A1 (en) * | 2003-05-21 | 2014-09-18 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
US7862519B1 (en) | 2003-05-21 | 2011-01-04 | Isense Corporation | Easy-to-use multi-use body fluid specimen collection and analyte sensing assembly |
US7157528B2 (en) | 2003-05-21 | 2007-01-02 | The Polymer Technology Group | Permselective structurally robust membrane material |
WO2004104070A1 (en) | 2003-05-21 | 2004-12-02 | The Polymer Technology Group | Permselective structurally robust membrane material |
US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US20050004324A1 (en) * | 2003-05-21 | 2005-01-06 | Ward Robert S. | Permselective structurally robust membrane material |
US7225008B1 (en) | 2003-05-21 | 2007-05-29 | Isense Corporation | Multiple use analyte sensing assembly |
EP1629028A1 (en) * | 2003-05-21 | 2006-03-01 | The Polymer Technology Group | Permselective structurally robust membrane material |
US20060183871A1 (en) * | 2003-05-21 | 2006-08-17 | Ward Robert S | Biosensor membrane material |
US8118877B2 (en) | 2003-05-21 | 2012-02-21 | Dexcom, Inc. | Porous membranes for use with implantable devices |
CN1813020B (en) * | 2003-05-21 | 2012-07-04 | 帝斯曼知识产权资产管理有限公司 | Permselective structurally robust membrane material |
US8255030B2 (en) | 2003-07-25 | 2012-08-28 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US8909314B2 (en) | 2003-07-25 | 2014-12-09 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US7761130B2 (en) | 2003-07-25 | 2010-07-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US9993186B2 (en) | 2003-07-25 | 2018-06-12 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US8255033B2 (en) | 2003-07-25 | 2012-08-28 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US20050115832A1 (en) * | 2003-07-25 | 2005-06-02 | Simpson Peter C. | Electrode systems for electrochemical sensors |
US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US7379765B2 (en) | 2003-07-25 | 2008-05-27 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
USRE43399E1 (en) | 2003-07-25 | 2012-05-22 | Dexcom, Inc. | Electrode systems for electrochemical sensors |
US20050054909A1 (en) * | 2003-07-25 | 2005-03-10 | James Petisce | Oxygen enhancing membrane systems for implantable devices |
US9763609B2 (en) | 2003-07-25 | 2017-09-19 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US10610140B2 (en) | 2003-07-25 | 2020-04-07 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US9597027B2 (en) | 2003-07-25 | 2017-03-21 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US8255032B2 (en) | 2003-07-25 | 2012-08-28 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US7828728B2 (en) | 2003-07-25 | 2010-11-09 | Dexcom, Inc. | Analyte sensor |
US10376143B2 (en) | 2003-07-25 | 2019-08-13 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US7074307B2 (en) | 2003-07-25 | 2006-07-11 | Dexcom, Inc. | Electrode systems for electrochemical sensors |
US8192455B2 (en) | 2003-08-13 | 2012-06-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compressive device for percutaneous treatment of obesity |
US11559260B2 (en) | 2003-08-22 | 2023-01-24 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US9649069B2 (en) | 2003-08-22 | 2017-05-16 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9724045B1 (en) | 2003-08-22 | 2017-08-08 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US11589823B2 (en) | 2003-08-22 | 2023-02-28 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9750460B2 (en) | 2003-08-22 | 2017-09-05 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US20070113471A1 (en) * | 2003-09-12 | 2007-05-24 | Uri Peled | Agricultural soil heating processes using aromatic thermoplastic polyurethane films |
US20050176136A1 (en) * | 2003-11-19 | 2005-08-11 | Dexcom, Inc. | Afinity domain for analyte sensor |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US10188333B2 (en) | 2003-12-05 | 2019-01-29 | Dexcom, Inc. | Calibration techniques for a continuous analyte sensor |
US11020031B1 (en) | 2003-12-05 | 2021-06-01 | Dexcom, Inc. | Analyte sensor |
US11000215B1 (en) | 2003-12-05 | 2021-05-11 | Dexcom, Inc. | Analyte sensor |
US8929968B2 (en) | 2003-12-05 | 2015-01-06 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US20050161346A1 (en) * | 2003-12-08 | 2005-07-28 | Peter Simpson | Systems and methods for improving electrochemical analyte sensors |
US7081195B2 (en) | 2003-12-08 | 2006-07-25 | Dexcom, Inc. | Systems and methods for improving electrochemical analyte sensors |
US9750441B2 (en) | 2003-12-09 | 2017-09-05 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US9498155B2 (en) | 2003-12-09 | 2016-11-22 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US11638541B2 (en) | 2003-12-09 | 2023-05-02 | Dexconi, Inc. | Signal processing for continuous analyte sensor |
US10898113B2 (en) | 2003-12-09 | 2021-01-26 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US20050147861A1 (en) * | 2003-12-11 | 2005-07-07 | Samsung Sdi Co., Ltd. | Proton conducting electrolyte and fuel cell using the same |
US7846137B2 (en) | 2003-12-26 | 2010-12-07 | Medtronic Minimed, Inc. | Modular catheter system |
US20110034903A1 (en) * | 2003-12-26 | 2011-02-10 | Medtronic Minimed, Inc. | Modular catheter system |
US20050148955A1 (en) * | 2003-12-26 | 2005-07-07 | Medtronic Minimed, Inc. | Modular catheter system |
US8025644B2 (en) | 2003-12-26 | 2011-09-27 | Medtronic Minimed, Inc. | Modular catheter system |
US20050148928A1 (en) * | 2003-12-31 | 2005-07-07 | Medtronic Minimed, Inc. | Multiple layer tubing and method of making same |
US12102410B2 (en) | 2004-02-26 | 2024-10-01 | Dexcom, Inc | Integrated medicament delivery device for use with continuous analyte sensor |
US12115357B2 (en) | 2004-02-26 | 2024-10-15 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US11246990B2 (en) | 2004-02-26 | 2022-02-15 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US10835672B2 (en) | 2004-02-26 | 2020-11-17 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US10966609B2 (en) | 2004-02-26 | 2021-04-06 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8277713B2 (en) | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
EP2335566A1 (en) | 2004-06-16 | 2011-06-22 | iSense Corporation | Compound metal analyte sensor |
US10980452B2 (en) | 2004-07-13 | 2021-04-20 | Dexcom, Inc. | Analyte sensor |
US11064917B2 (en) | 2004-07-13 | 2021-07-20 | Dexcom, Inc. | Analyte sensor |
US10799159B2 (en) | 2004-07-13 | 2020-10-13 | Dexcom, Inc. | Analyte sensor |
US10799158B2 (en) | 2004-07-13 | 2020-10-13 | Dexcom, Inc. | Analyte sensor |
US9986942B2 (en) | 2004-07-13 | 2018-06-05 | Dexcom, Inc. | Analyte sensor |
US11883164B2 (en) | 2004-07-13 | 2024-01-30 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10722152B2 (en) | 2004-07-13 | 2020-07-28 | Dexcom, Inc. | Analyte sensor |
US9414777B2 (en) | 2004-07-13 | 2016-08-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10813576B2 (en) | 2004-07-13 | 2020-10-27 | Dexcom, Inc. | Analyte sensor |
US10827956B2 (en) | 2004-07-13 | 2020-11-10 | Dexcom, Inc. | Analyte sensor |
US8792953B2 (en) | 2004-07-13 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
US11026605B1 (en) | 2004-07-13 | 2021-06-08 | Dexcom, Inc. | Analyte sensor |
US7885697B2 (en) | 2004-07-13 | 2011-02-08 | Dexcom, Inc. | Transcutaneous analyte sensor |
US11045120B2 (en) | 2004-07-13 | 2021-06-29 | Dexcom, Inc. | Analyte sensor |
US10524703B2 (en) | 2004-07-13 | 2020-01-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10709362B2 (en) | 2004-07-13 | 2020-07-14 | Dexcom, Inc. | Analyte sensor |
US10918314B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US10709363B2 (en) | 2004-07-13 | 2020-07-14 | Dexcom, Inc. | Analyte sensor |
US10993641B2 (en) | 2004-07-13 | 2021-05-04 | Dexcom, Inc. | Analyte sensor |
US10993642B2 (en) | 2004-07-13 | 2021-05-04 | Dexcom, Inc. | Analyte sensor |
US10918313B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US10918315B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US10932700B2 (en) | 2004-07-13 | 2021-03-02 | Dexcom, Inc. | Analyte sensor |
US20060030933A1 (en) * | 2004-08-04 | 2006-02-09 | Delegge Rebecca | Thermal transition methods and devices |
US7582109B2 (en) | 2004-08-04 | 2009-09-01 | Delegge Rebecca | Thermal transition methods and devices |
US20110144466A1 (en) * | 2004-12-08 | 2011-06-16 | Yanan Zhang | Catheter-Free Implantable Needle Biosensor |
US10617336B2 (en) | 2005-03-10 | 2020-04-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610137B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10925524B2 (en) | 2005-03-10 | 2021-02-23 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918317B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10716498B2 (en) | 2005-03-10 | 2020-07-21 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10898114B2 (en) | 2005-03-10 | 2021-01-26 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918316B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11051726B2 (en) | 2005-03-10 | 2021-07-06 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11000213B2 (en) | 2005-03-10 | 2021-05-11 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610135B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10856787B2 (en) | 2005-03-10 | 2020-12-08 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610136B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10743801B2 (en) | 2005-03-10 | 2020-08-18 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918318B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10709364B2 (en) | 2005-03-10 | 2020-07-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US20110009338A1 (en) * | 2005-03-11 | 2011-01-13 | Endo Pharmaceuticals Solutions Inc. | Controlled release formulations of octreotide |
US20100317579A1 (en) * | 2005-03-11 | 2010-12-16 | Endo Pharmaceuticals Solutions Inc. | Controlled release formulations of octreotide |
US8507432B2 (en) | 2005-03-11 | 2013-08-13 | Endo Pharmaceuticals Solutions Inc. | Controlled release formulations of octreotide |
US20100247594A1 (en) * | 2005-03-11 | 2010-09-30 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
US10376188B2 (en) | 2005-04-15 | 2019-08-13 | Dexcom, Inc. | Analyte sensing biointerface |
US10667730B2 (en) | 2005-04-15 | 2020-06-02 | Dexcom, Inc. | Analyte sensing biointerface |
US10667729B2 (en) | 2005-04-15 | 2020-06-02 | Dexcom, Inc. | Analyte sensing biointerface |
US8060174B2 (en) | 2005-04-15 | 2011-11-15 | Dexcom, Inc. | Analyte sensing biointerface |
US20060257996A1 (en) * | 2005-04-15 | 2006-11-16 | Simpson Peter C | Analyte sensing biointerface |
US9788766B2 (en) | 2005-04-15 | 2017-10-17 | Dexcom, Inc. | Analyte sensing biointerface |
US10702193B2 (en) | 2005-04-15 | 2020-07-07 | Dexcom, Inc. | Analyte sensing biointerface |
US8744546B2 (en) | 2005-05-05 | 2014-06-03 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
US10300507B2 (en) | 2005-05-05 | 2019-05-28 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
US10813577B2 (en) | 2005-06-21 | 2020-10-27 | Dexcom, Inc. | Analyte sensor |
US20090112321A1 (en) * | 2005-08-04 | 2009-04-30 | Kitchen Michael S | Spinal stabilization device and method |
US20080050410A1 (en) * | 2005-10-11 | 2008-02-28 | Luna Innovations Incorporated | Self-Decontaminating Surface Coatings and Articles Prepared Therefrom |
US9241482B2 (en) * | 2005-10-11 | 2016-01-26 | The United States Of America, As Represented By The Secretary Of The Navy | Self-decontaminating surface coatings and articles prepared therefrom |
US7754156B2 (en) | 2006-03-31 | 2010-07-13 | The Invention Science Fund I, Llc | Surveying sterilizer methods and systems |
US20070231204A1 (en) * | 2006-03-31 | 2007-10-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Surveying sterilizer methods and systems |
US20070231192A1 (en) * | 2006-03-31 | 2007-10-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Sterilization methods and systems |
US8178042B2 (en) | 2006-03-31 | 2012-05-15 | The Invention Science Fund I, Llc | Methods and systems for monitoring sterilization status |
US11185604B2 (en) | 2006-03-31 | 2021-11-30 | Deep Science Llc | Methods and systems for monitoring sterilization status |
US20100086447A1 (en) * | 2006-03-31 | 2010-04-08 | Searete Llc | Methods and systems for sterilization |
US20100111775A1 (en) * | 2006-03-31 | 2010-05-06 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Surveying sterilizer methods and systems |
US8277724B2 (en) | 2006-03-31 | 2012-10-02 | The Invention Science Fund I, Llc | Sterilization methods and systems |
US20070231188A1 (en) * | 2006-03-31 | 2007-10-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for sterilization |
US7638090B2 (en) | 2006-03-31 | 2009-12-29 | Searete Llc | Surveying sterilizer methods and systems |
US8114342B2 (en) | 2006-03-31 | 2012-02-14 | The Invention Science Fund I, Llc | Methods and systems for monitoring sterilization status |
US8932535B2 (en) | 2006-03-31 | 2015-01-13 | The Invention Science Fund I, Llc | Surveying sterilizer methods and systems |
US20070237674A1 (en) * | 2006-03-31 | 2007-10-11 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for monitoring sterilization status |
US20070231191A1 (en) * | 2006-03-31 | 2007-10-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for monitoring sterilization status |
US10646602B2 (en) | 2006-03-31 | 2020-05-12 | Deep Science, Llc | Methods and systems for sterilization |
US8992837B2 (en) | 2006-03-31 | 2015-03-31 | The Invention Science Fund I, Llc | Methods and systems for monitoring sterilization status |
US8758679B2 (en) | 2006-03-31 | 2014-06-24 | The Invention Science Fund I, Llc | Surveying sterilizer methods and systems |
US20080085223A1 (en) * | 2006-03-31 | 2008-04-10 | Searete Llc | Sterilization methods and systems |
US20070231189A1 (en) * | 2006-03-31 | 2007-10-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Sterilization methods and systems |
US20090208378A1 (en) * | 2006-03-31 | 2009-08-20 | Searete Llc | Methods and systems for monitoring sterilization status |
US8360069B2 (en) | 2006-04-19 | 2013-01-29 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US20080262521A1 (en) * | 2006-04-19 | 2008-10-23 | Joshua Makower | Devices and methods for treatment of obesity |
US8001974B2 (en) | 2006-04-19 | 2011-08-23 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US20080051823A1 (en) * | 2006-04-19 | 2008-02-28 | Joshua Makower | Devices and methods for treatment of obesity |
US8342183B2 (en) | 2006-04-19 | 2013-01-01 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US8353925B2 (en) | 2006-04-19 | 2013-01-15 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US8356605B2 (en) | 2006-04-19 | 2013-01-22 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US8070768B2 (en) | 2006-04-19 | 2011-12-06 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US20090281563A1 (en) * | 2006-04-19 | 2009-11-12 | Newell Matthew B | Devices, tools and methods for performing minimally invasive abdominal surgical procedures |
US7976554B2 (en) | 2006-04-19 | 2011-07-12 | Vibrynt, Inc. | Devices, tools and methods for performing minimally invasive abdominal surgical procedures |
US20090281500A1 (en) * | 2006-04-19 | 2009-11-12 | Acosta Pablo G | Devices, system and methods for minimally invasive abdominal surgical procedures |
US8398668B2 (en) | 2006-04-19 | 2013-03-19 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US8460321B2 (en) | 2006-04-19 | 2013-06-11 | Vibrynt, Inc. | Devices, tools and methods for performing minimally invasive abdominal surgical procedures |
US20090281377A1 (en) * | 2006-04-19 | 2009-11-12 | Newell Matthew B | Devices, tools and methods for performing minimally invasive abdominal surgical procedures |
US20070250103A1 (en) * | 2006-04-19 | 2007-10-25 | Joshua Makower | Devices and methods for treatment of obesity |
US8585733B2 (en) | 2006-04-19 | 2013-11-19 | Vibrynt, Inc | Devices, tools and methods for performing minimally invasive abdominal surgical procedures |
US8187297B2 (en) | 2006-04-19 | 2012-05-29 | Vibsynt, Inc. | Devices and methods for treatment of obesity |
US20090012554A1 (en) * | 2006-04-19 | 2009-01-08 | Joshua Makower | Devices and methods for treatment of obesity |
US20070250020A1 (en) * | 2006-04-19 | 2007-10-25 | Steven Kim | Devices and methods for treatment of obesity |
US20090012547A1 (en) * | 2006-04-19 | 2009-01-08 | Joshua Makower | Devices and methods for treatment of obesity |
US20090036910A1 (en) * | 2006-04-19 | 2009-02-05 | Vibrynt, Inc. | Devices and Methods for Treatment of Obesity |
US20070286398A1 (en) * | 2006-06-07 | 2007-12-13 | Venkatesan Ramamoorthy | Voice Recognition Dialing For Alphabetic Phone Numbers |
US11432772B2 (en) | 2006-08-02 | 2022-09-06 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US20090301957A1 (en) * | 2006-09-06 | 2009-12-10 | Massimo Bertolucci | Filter for the removal of substances from blood products |
US9451908B2 (en) | 2006-10-04 | 2016-09-27 | Dexcom, Inc. | Analyte sensor |
US11382539B2 (en) | 2006-10-04 | 2022-07-12 | Dexcom, Inc. | Analyte sensor |
US11399745B2 (en) | 2006-10-04 | 2022-08-02 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US20080102126A1 (en) * | 2006-10-27 | 2008-05-01 | Bayer Materialscience Ag | Novel hydrogels based on aliphatic NCO prepolymers |
US9587067B2 (en) * | 2006-11-30 | 2017-03-07 | The University Of Akron | Polyisobutylenes and process for making same |
US9834622B2 (en) | 2006-11-30 | 2017-12-05 | The University Of Akron | Polyisobutylenes and process for making same |
CN105628897A (en) * | 2006-11-30 | 2016-06-01 | 阿克伦大学 | Polyisobutylenes and process for making same |
US20160090437A1 (en) * | 2006-11-30 | 2016-03-31 | The University Of Akron | Polyisobutylenes and process for making same |
US20110312237A1 (en) * | 2007-01-18 | 2011-12-22 | Lubrizol Advanced Materials, Inc. | High Moisture Vapor Transmissive Polyurethanes |
US8637629B2 (en) * | 2007-01-18 | 2014-01-28 | Lubrizol Advanced Materials, Inc. | High moisture vapor transmissive polyurethanes |
US10791928B2 (en) | 2007-05-18 | 2020-10-06 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US10403012B2 (en) | 2007-06-08 | 2019-09-03 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US9741139B2 (en) | 2007-06-08 | 2017-08-22 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US11373347B2 (en) | 2007-06-08 | 2022-06-28 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8562558B2 (en) | 2007-06-08 | 2013-10-22 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US20090054854A1 (en) * | 2007-08-24 | 2009-02-26 | Gernot Hochmuth | Microdialysis catheter and process for manufacture |
US11160926B1 (en) | 2007-10-09 | 2021-11-02 | Dexcom, Inc. | Pre-connected analyte sensors |
US11744943B2 (en) | 2007-10-09 | 2023-09-05 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US8556925B2 (en) | 2007-10-11 | 2013-10-15 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US11272869B2 (en) | 2007-10-25 | 2022-03-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US10182751B2 (en) | 2007-10-25 | 2019-01-22 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9717449B2 (en) | 2007-10-25 | 2017-08-01 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9339238B2 (en) | 2007-12-17 | 2016-05-17 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9149233B2 (en) | 2007-12-17 | 2015-10-06 | Dexcom, Inc. | Systems and methods for processing sensor data |
US10506982B2 (en) | 2007-12-17 | 2019-12-17 | Dexcom, Inc. | Systems and methods for processing sensor data |
US11342058B2 (en) | 2007-12-17 | 2022-05-24 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9901307B2 (en) | 2007-12-17 | 2018-02-27 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9839395B2 (en) | 2007-12-17 | 2017-12-12 | Dexcom, Inc. | Systems and methods for processing sensor data |
US10827980B2 (en) | 2007-12-17 | 2020-11-10 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8290559B2 (en) | 2007-12-17 | 2012-10-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9149234B2 (en) | 2007-12-17 | 2015-10-06 | Dexcom, Inc. | Systems and methods for processing sensor data |
US20110207897A1 (en) * | 2007-12-20 | 2011-08-25 | Dsm Ip Assets B.V. | Ionomers for improved compression set in certain copolymers |
US9566026B2 (en) | 2008-03-28 | 2017-02-14 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8583204B2 (en) | 2008-03-28 | 2013-11-12 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9549699B2 (en) | 2008-03-28 | 2017-01-24 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9572523B2 (en) | 2008-03-28 | 2017-02-21 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9173606B2 (en) | 2008-03-28 | 2015-11-03 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US10143410B2 (en) | 2008-03-28 | 2018-12-04 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US11147483B2 (en) | 2008-03-28 | 2021-10-19 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8682408B2 (en) | 2008-03-28 | 2014-03-25 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8954128B2 (en) | 2008-03-28 | 2015-02-10 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9693721B2 (en) | 2008-03-28 | 2017-07-04 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US11730407B2 (en) | 2008-03-28 | 2023-08-22 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9173607B2 (en) | 2008-03-28 | 2015-11-03 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US20090318549A1 (en) * | 2008-06-24 | 2009-12-24 | Qlt Plug Delivery, Inc. | Combination treatment of glaucoma |
US20100023104A1 (en) * | 2008-06-27 | 2010-01-28 | Cardiac Pacemakers, Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
US20090326077A1 (en) * | 2008-06-27 | 2009-12-31 | Cardiac Pacemakers, Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
US8501831B2 (en) | 2008-06-27 | 2013-08-06 | Cardiac Pacemakers, Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
US8324290B2 (en) | 2008-06-27 | 2012-12-04 | Cardiac Pacemakers, Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
US10028684B2 (en) | 2008-09-19 | 2018-07-24 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US11918354B2 (en) | 2008-09-19 | 2024-03-05 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US9339222B2 (en) | 2008-09-19 | 2016-05-17 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US8560039B2 (en) | 2008-09-19 | 2013-10-15 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US10561352B2 (en) | 2008-09-19 | 2020-02-18 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US10028683B2 (en) | 2008-09-19 | 2018-07-24 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US20110213084A1 (en) * | 2008-10-01 | 2011-09-01 | The University Of Akron | Polymers having both hard and soft segments, and process for making same |
WO2010039986A1 (en) * | 2008-10-01 | 2010-04-08 | The University Of Akron | Polymers having both hard and soft segments, and process for making same |
US10980461B2 (en) | 2008-11-07 | 2021-04-20 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
WO2010080967A1 (en) * | 2009-01-09 | 2010-07-15 | Johnson Controls Technology Company | Natural fiber trim panel |
US20100179298A1 (en) * | 2009-01-12 | 2010-07-15 | University Of Massachusetts Lowell | Polyisobutylene-Based Polyurethanes |
US20130079487A1 (en) * | 2009-01-12 | 2013-03-28 | Rudolf Faust | Polyisobutylene-based polyurethanes |
US8962785B2 (en) * | 2009-01-12 | 2015-02-24 | University Of Massachusetts Lowell | Polyisobutylene-based polyurethanes |
US11174336B2 (en) | 2009-01-12 | 2021-11-16 | University Of Massachusetts Lowell | Polyisobutylene-based polyurethanes |
US9574043B2 (en) | 2009-01-12 | 2017-02-21 | University Of Massachusetts Lowell | Polyisobutylene-based polyurethanes |
US10513576B2 (en) | 2009-01-12 | 2019-12-24 | University of Masschusetts Lowell | Polyisobutylene-based polyurethanes |
US9884146B2 (en) | 2009-05-15 | 2018-02-06 | Interface Biologics Inc. | Antithrombogenic hollow fiber membranes and filters |
US20110009799A1 (en) * | 2009-05-15 | 2011-01-13 | Interface Biologics, Inc. | Antithrombogenic hollow fiber membranes and filters |
US11766511B2 (en) | 2009-05-15 | 2023-09-26 | Interface Biologics, Inc. | Antithrombogenic hollow fiber membranes and filters |
US8877062B2 (en) * | 2009-05-15 | 2014-11-04 | Interface Biologics, Inc. | Antithrombogenic hollow fiber membranes and filters |
US9687597B2 (en) | 2009-05-15 | 2017-06-27 | Interface Biologies, Inc. | Antithrombogenic hollow fiber membranes and filters |
US20110033515A1 (en) * | 2009-08-04 | 2011-02-10 | Rst Implanted Cell Technology | Tissue contacting material |
US8597518B2 (en) * | 2009-08-19 | 2013-12-03 | The University Of Connecticut | Pervaporation composite membrane for aqueous solution separation and methods for using the same |
US20110042315A1 (en) * | 2009-08-19 | 2011-02-24 | University Of Connecticut | Pervaporation composite membrane for aqueous solution separation and methods for using the same |
US8529934B2 (en) | 2009-08-21 | 2013-09-10 | Boston Scientific Scimed, Inc. | Crosslinkable polyisobutylene-based polymers and medical devices containing the same |
US8927660B2 (en) | 2009-08-21 | 2015-01-06 | Cardiac Pacemakers Inc. | Crosslinkable polyisobutylene-based polymers and medical devices containing the same |
US20110045030A1 (en) * | 2009-08-21 | 2011-02-24 | Cardiac Pacemakers, Inc. | Crosslinkable polyisobutylene-based polymers and medical devices containing the same |
US8374704B2 (en) * | 2009-09-02 | 2013-02-12 | Cardiac Pacemakers, Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same |
US20110054580A1 (en) * | 2009-09-02 | 2011-03-03 | Shrojalkumar Desai | Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same |
US8676344B2 (en) * | 2009-09-02 | 2014-03-18 | Cardiac Pacemakers Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same |
US20140194963A1 (en) * | 2009-09-02 | 2014-07-10 | Cardiac Pacemakers, Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same |
US20110054581A1 (en) * | 2009-09-02 | 2011-03-03 | Shrojalkumar Desai | Medical devices including polyisobutylene based polymers and derivatives thereof |
US20130131767A1 (en) * | 2009-09-02 | 2013-05-23 | Cardiac Pacemakers, Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same |
US8903507B2 (en) * | 2009-09-02 | 2014-12-02 | Cardiac Pacemakers, Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same |
US8644952B2 (en) | 2009-09-02 | 2014-02-04 | Cardiac Pacemakers, Inc. | Medical devices including polyisobutylene based polymers and derivatives thereof |
US8942823B2 (en) | 2009-09-02 | 2015-01-27 | Cardiac Pacemakers, Inc. | Medical devices including polyisobutylene based polymers and derivatives thereof |
WO2011084651A1 (en) | 2009-12-21 | 2011-07-14 | Medtronic Minimed, Inc. | Analyte sensors comprising blended membrane compositions and methods for making and using them |
US20110152989A1 (en) * | 2009-12-23 | 2011-06-23 | Pacesetter, Inc. | Soft abrasion-resistant polyisobutylene urethane copolymers |
AU2011207140B2 (en) * | 2010-01-20 | 2014-08-28 | Erema Engineering Recycling Maschinen Und Anlagen Gesellschaft M.B.H. | Method for producing a polymer material filled with long fibers |
US20130055583A1 (en) * | 2010-01-20 | 2013-03-07 | EREMA Engineering Recycling Maschinen und Anlagen Geselischaft m.b.H. Friedorf, | Method for producing a polymer material filled with long fibers |
US8661705B2 (en) * | 2010-01-20 | 2014-03-04 | Erema Engineering Recycling Maschinen Und Anlagen Gesellschaft M.B.H | Method for producing a polymer material filled with long fibers |
US9322103B2 (en) | 2010-08-06 | 2016-04-26 | Microchips Biotech, Inc. | Biosensor membrane composition, biosensor, and methods for making same |
WO2012071476A2 (en) | 2010-11-24 | 2012-05-31 | David Haffner | Drug eluting ocular implant |
US8660663B2 (en) | 2010-12-20 | 2014-02-25 | Cardiac Pacemakers, Inc. | Lead having a conductive polymer conductor |
FR2974742A1 (en) * | 2011-05-04 | 2012-11-09 | Rexam Healthcare La Verpillier | LIQUID DISPENSING DEVICE WITH AIR CHANNEL CHANNEL |
CN103534036A (en) * | 2011-05-04 | 2014-01-22 | 雷盛医疗拉韦尔皮列尔公司 | Liquid dispensing device equipped with an air duct |
US9345616B2 (en) | 2011-05-04 | 2016-05-24 | Nemera La Verpillière S.A.S. | Liquid dispensing device equipped with an air duct |
WO2012150409A1 (en) * | 2011-05-04 | 2012-11-08 | Rexam Healthcare La Verpilliere | Liquid dispensing device equipped with an air duct |
US20130041108A1 (en) * | 2011-05-19 | 2013-02-14 | Joseph P. Kennedy | Polymers having both hard and soft segments, and process for making same |
WO2013013055A1 (en) | 2011-07-21 | 2013-01-24 | Rubigo Therapeutics, Inc. | System for drug delivery and monitoring |
US9314362B2 (en) | 2012-01-08 | 2016-04-19 | Vibrynt, Inc. | Methods, instruments and devices for extragastric reduction of stomach volume |
US8382775B1 (en) | 2012-01-08 | 2013-02-26 | Vibrynt, Inc. | Methods, instruments and devices for extragastric reduction of stomach volume |
US9155528B2 (en) | 2012-01-08 | 2015-10-13 | Vibrynt, Inc. | Methods, instruments and devices for extragastic reduction of stomach volume |
US9220888B2 (en) | 2012-04-02 | 2015-12-29 | Medtronic, Inc. | Medical leads |
US20130331537A1 (en) * | 2012-06-08 | 2013-12-12 | Poly-Med, Inc. | Polyether urethane and polyether urea based copolymers and methods related thereto |
US11179079B2 (en) | 2012-09-28 | 2021-11-23 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
US11864891B2 (en) | 2012-09-28 | 2024-01-09 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
US10562998B2 (en) | 2012-11-21 | 2020-02-18 | University Of Massachusetts | High strength polyisobutylene polyurethanes |
US9926399B2 (en) | 2012-11-21 | 2018-03-27 | University Of Massachusetts | High strength polyisobutylene polyurethanes |
EP3603590A1 (en) | 2013-03-15 | 2020-02-05 | Dose Medical Corporation | Implants with controlled drug delivery features |
US11998329B2 (en) | 2013-03-15 | 2024-06-04 | Dexcom, Inc. | Membrane for continuous analyte sensors |
EP3366264A1 (en) | 2013-03-15 | 2018-08-29 | Dose Medical Corporation | Implants with controlled drug delivery features |
EP4282390A2 (en) | 2013-03-15 | 2023-11-29 | Dose Medical Corporation | Implants with controlled drug delivery features |
WO2015073571A1 (en) | 2013-11-15 | 2015-05-21 | Dose Medical Corporation | Ocular implants configured to store and release stable drug formulations |
EP3677229A1 (en) | 2014-05-29 | 2020-07-08 | Glaukos Corporation | Implants with controlled drug delivery features |
US20160030641A1 (en) * | 2014-07-31 | 2016-02-04 | Proton Innovations, LLC | Mixed-phase biomaterials |
US9669135B2 (en) * | 2014-07-31 | 2017-06-06 | Proton Innovations, LLC | Mixed-phase biomaterials |
US10543455B2 (en) * | 2015-02-27 | 2020-01-28 | Fujifilm Corporation | Gas separation membrane, gas separation module, gas separation apparatus, gas separation method, and method for producing asymmetric gas separation membrane |
US10507437B2 (en) * | 2015-02-27 | 2019-12-17 | Fujifilm Corporation | Gas separation membrane, gas separation module, gas separation apparatus, and gas separation method |
US10537848B2 (en) * | 2015-02-27 | 2020-01-21 | Fujifilm Corporation | Gas separation asymmetric membrane, gas separation module, gas separation device, and gas separation method |
US20170333835A1 (en) * | 2015-02-27 | 2017-11-23 | Fujifilm Corporation | Gas separation membrane, gas separation module, gas separation apparatus, gas separation method, and method for producing asymmetric gas separation membrane |
US20180021741A1 (en) * | 2015-02-27 | 2018-01-25 | Fujifilm Corporation | Gas separation membrane, gas separation module, gas separation apparatus, and gas separation method |
US20170333836A1 (en) * | 2015-02-27 | 2017-11-23 | Fujifilm Corporation | Gas separation asymmetric membrane, gas separation module, gas separation device, and gas separation method |
US20160324755A1 (en) * | 2015-05-06 | 2016-11-10 | Soongsil University Research Consortium Techno-Park | Method for preparing hydrocolloid having diverse range of hydrophobicity |
WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
US20170106124A1 (en) * | 2015-10-17 | 2017-04-20 | Cardiac Pacemakers, Inc. | Production of in situ crosslinkable polyisobutylene-polyurethane nanofibers and coatings |
US10111986B2 (en) * | 2015-10-17 | 2018-10-30 | Cardiac Pacemakers, Inc. | Production of in situ crosslinkable polyisobutylene-polyurethane nanofibers and coatings |
CN108137783A (en) * | 2015-10-17 | 2018-06-08 | 心脏起搏器股份公司 | The production of cross-linking polyisobutene-polyurethane nanofiber and coating in situ |
US11112377B2 (en) | 2015-12-30 | 2021-09-07 | Dexcom, Inc. | Enzyme immobilized adhesive layer for analyte sensors |
US11262326B2 (en) | 2015-12-30 | 2022-03-01 | Dexcom, Inc. | Membrane layers for analyte sensors |
US20170191955A1 (en) * | 2015-12-30 | 2017-07-06 | Dexcom, Inc. | Diffusion resistance layer for analyte sensors |
US10557030B2 (en) | 2016-10-18 | 2020-02-11 | Evonik Canada Inc. | Plasticized PVC admixtures with surface modifying macromolecules and articles made therefrom |
US10526429B2 (en) | 2017-03-07 | 2020-01-07 | Cardiac Pacemakers, Inc. | Hydroboration/oxidation of allyl-terminated polyisobutylene |
US10961340B2 (en) | 2017-07-14 | 2021-03-30 | Fresenius Medical Care Holdings, Inc. | Method for providing surface modifying composition with improved byproduct removal |
US10835638B2 (en) | 2017-08-17 | 2020-11-17 | Cardiac Pacemakers, Inc. | Photocrosslinked polymers for enhanced durability |
US11350862B2 (en) | 2017-10-24 | 2022-06-07 | Dexcom, Inc. | Pre-connected analyte sensors |
US11943876B2 (en) | 2017-10-24 | 2024-03-26 | Dexcom, Inc. | Pre-connected analyte sensors |
US11706876B2 (en) | 2017-10-24 | 2023-07-18 | Dexcom, Inc. | Pre-connected analyte sensors |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US11382540B2 (en) | 2017-10-24 | 2022-07-12 | Dexcom, Inc. | Pre-connected analyte sensors |
US11851522B2 (en) | 2018-01-17 | 2023-12-26 | Cardiac Pacemakers, Inc. | End-capped polyisobutylene polyurethane |
US11472911B2 (en) | 2018-01-17 | 2022-10-18 | Cardiac Pacemakers, Inc. | End-capped polyisobutylene polyurethane |
CN113366306A (en) * | 2018-12-13 | 2021-09-07 | 哈美顿博纳图斯股份公司 | Composite electrode comprising a separator containing an aqueous gel and method for manufacturing such a composite electrode |
CN113366306B (en) * | 2018-12-13 | 2024-07-12 | 哈美顿博纳图斯股份公司 | Composite electrode comprising a separator containing an aqueous gel and method for manufacturing such a composite electrode |
US20210302353A1 (en) * | 2018-12-13 | 2021-09-30 | Hamilton Bonaduz Ag | Combination Electrode Having a Hydrogel Diaphragm |
WO2021184843A1 (en) * | 2020-03-18 | 2021-09-23 | 微泰医疗器械(杭州)有限公司 | Triblock copolymer for implantable biosensor, application thereof, and preparation method therefor |
CN111893642A (en) * | 2020-08-10 | 2020-11-06 | 四川大学 | Halamine polymer antibacterial and antiviral nanofiber membrane and preparation method thereof |
US20240076491A1 (en) * | 2022-08-16 | 2024-03-07 | Nano And Advanced Materials Institute Limited | Non-porous, breathable and waterproof transparent elastomer film and method for manufacturing the same |
US12091489B1 (en) * | 2023-06-05 | 2024-09-17 | Joseph P. Kennedy | Multiply-crosslinked polyisobutylene-based polyurethanes and their preparations and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP0637323A1 (en) | 1995-02-08 |
US5756632A (en) | 1998-05-26 |
JP3857306B2 (en) | 2006-12-13 |
ATE169941T1 (en) | 1998-09-15 |
JPH07505921A (en) | 1995-06-29 |
DK0637323T3 (en) | 1999-05-25 |
CA2134087A1 (en) | 1993-11-11 |
AU4033893A (en) | 1993-11-29 |
EP0637323B1 (en) | 1998-08-19 |
WO1993022360A1 (en) | 1993-11-11 |
DE69320470D1 (en) | 1998-09-24 |
DE69320470T2 (en) | 1999-04-29 |
CA2134087C (en) | 2007-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5428123A (en) | Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range | |
US5589563A (en) | Surface-modifying endgroups for biomedical polymers | |
AU616288B2 (en) | Segmented polyether polyurethane | |
WO1995026993A9 (en) | Surface-modifying endgroups for biomedical polymers | |
AU711425B2 (en) | Fluoroligomer surface modifiers for polymers and articles made therefrom | |
US4942214A (en) | Flexible breathable polyurethane coatings and films, and the prepolymers from which they are made | |
CA1323151C (en) | Crosslinked polyetherurethane membranes useful in blood electrolyte sensors | |
JPH01190720A (en) | Two-pack type polyurethane system | |
US20210138408A1 (en) | Flat sheet porous membrane | |
US20220226784A1 (en) | Hollow Fiber Membrane | |
JPS587254A (en) | Selective separation film having anti- coagulation property of blood and production thereof | |
WO2023152224A1 (en) | Polyurethane membrane for sensor | |
JPH01131226A (en) | Gas-permeable material having excellent compatibility with blood | |
NO900764L (en) | SEGMENTED POLYETHER POLYURETHAN. | |
JPH0160262B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: POLYMER TECHNOLOGY GROUP, THE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WARD, ROBERT S.;WHITE, KATHLEEN A.;REEL/FRAME:006587/0751 Effective date: 19930607 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |